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G protein-coupled receptors (GPCRs) are an important class of cell-surface 
transmembrane receptors that pass an activation signal to the interior of the cell 
through heterotrimeric G proteins. In this work, we study the human β2-adrenergic 
receptor (β2AR) and stimulatory G protein (Gs) as examples in order to understand 
the molecular basis of this signal transfer event. We solved a 3.2 Å crystal structure 
of β2AR and Gs in a nucleotide-free, intermediate signaling complex, revealing the 
interaction between the proteins at atomic resolution. The structure was consistent 
with previous biochemical knowledge, but also revealed several previously unknown 
features of the activation process. We used deuterium/hydrogen exchange and 
electron microscopy in order to find regions in the complex that change conformation 
during the activation process. These regions are highly conserved within the GPCR 
and G protein families, and his work shows the central role that they play in the 
process of GPCR signal transduction. The binding of drugs to the receptor in the 
fully activated state, as seen in the β2AR-Gs complex, was also characterized by 
radioligand and antibody fragment binding. A full kinetic model was developed for 
drug binding to the activated receptor which demonstrated how the ligand is held 
very tightly in the receptor binding pocket. This tight ligand binding can be relieved 
by the addition of GDP, demonstrating a direct allosteric link between the G protein 
nucleotide binding site and the receptor ligand binding site. Overall, this work 
demonstrates how the GPCR signal transduction machinery operates in high-
resolution structural, kinetic, and pharmacological detail. It advances our 








INTRODUCTION AND LITERATURE REVIEW 
 
1.1 – Introduction and importance. 
G protein coupled receptors (GPCRs) are a large and diverse group of cell-surface 
receptors which can bind a variety of ligands, including hormones, metabolites, ions, 
odorants, therapeutic drugs and even photons. These receptors share a common 
topology of seven transmembrane helices and an almost universal ability to activate 
one or more subtypes of heterotrimeric G proteins. GPCR-G protein signaling 
cascades are known to play extremely important roles in basic physiological 
functions such as sensatory perception, neuronal communication, hormone 
response, and development.1 These receptors have long been recognized to be 
highly druggable, to the extent that of drugs that act at known targets, the single 
largest group is the GPCRs, with about 27% of the total (in 2005).2 
The work contained in this dissertation concerns the molecular structure, function, 
and dynamics of how the prototypical GPCR and G protein pair, the β2-adrengeric 
receptor (β2AR) and stimulatory G protein (Gs), interact during the activation 
process. This complex of the receptor and G protein is the crucial intermediate state 
where the information contained in the chemical structure of the receptor-bound 
agonist is passed across the cellular membrane to the G protein, the first step of a 
cellular signaling event. This process is studied with modern molecular and 
structural methods as well as from a pharmacological perspective, leading to a much 
fuller understanding of the G protein activation process. 
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1.2 – Evolution of receptor theory.  
The discovery of GPCRs is deeply intertwined in the discovery of receptors in 
general and the development of the pharmacological sciences. Although many, 
many scientists contributed research pointing towards the existence of the proteins 
that we now call receptors, the idea that compounds act at specific sites of action on 
cells can be traced to the work of both Paul Ehrlich and John N. Langley in the late 
1870's. Langley did so in the context of studying the action of pilocarpine and 
atropine, now known as a muscarinic acetylcholine receptor agonist and antagonist, 
respectively, on the salivary secretion of the cat sub-maxillary gland. Langley's 
observations on the competing activities of the two drugs led him to suspect that 
they competed via the laws of mass action for sites of action on the gland.3 
Unfortunately, acceptance of Langley's idea was hampered by the difficulty of 
resolving questions related to the complexity of organ and tissue systems, such as 
whether the drugs were acting upon the nerve cells going to the gland or to these 
proposed sites of action on the gland itself. For this reason, Paul Ehrlich is usually 
credited as the first person to seriously study the binding of biologically active 
molecules to specific sites of interaction,4, 5 as his system of study ended up being 
much more amenable to isolation from the organism it came from. Around the turn of 
the century, he showed that the toxicity of diphtheria toxin could be neutralized with 
antibodies produced against the toxin, known as “anti-toxins” initially, even when the 
reaction was performed in vitro. Ehrlich followed up this observation with extensive 
research on the nature of the neutralization reaction. The work led him to propose 
the theory that the toxin molecules interacted with a specific antitoxin molecule, in 
the same manner that chemicals can bind and react with one another. In contrast, 
most other theories about how biologically active compounds worked at the time, 
including toxins, assumed that the effect of the compound was generalized across a 
tissue, and that the tissue-specific responses were due to how the compound was 
differentially distributed in the animal. Ehrlich’s work was clearly at odds with this 
distributive explanation, and in his extremely productive career he built up 
incontrovertible evidence that many different kinds of biologically active compounds 
bind to specific molecules in order to elicit their function,6 opening up the possibility 
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of studying these responsive molecules as well as the compounds themselves. It 
was not Ehrlich, but Langley that first started calling these responsive molecules a 
“receptive substance” (which Ehrlich quickly shortened to just “receptor”).4 Ehrlich 
was honored with the Nobel Prize in Physiology or Medicine in 1908 for these very 
important discoveries. 
John Langley continued research to advance receptor theory while studying both 
nicotinic and muscarinic acetylcholine systems during the same time Ehrlich was 
working with his toxins and anti-toxins. Langley carefully studied how the binding of 
one drug to a receptor could block the action of another one, establishing evidence 
that the competing effects of such drugs on a receptor was dependent on both the 
affinity of each drug for the receptor and the relative concentrations of the two 
drugs.7 His qualitative descriptions of drug saturation and competition were 
upgraded to a quantitative mathematical description by A.J. Clark and J.H. Gaddum 
in the mid 1920s. Clark applied the laws of mass action to the nicotinic receptor 
system,8, 9 showing that the occupancy of the receptor obeyed the same laws that 
Irving Langmuir determined for the binding of gas to solid surfaces.10 (Clark was 
apparently aware of A.V. Hill's work on the same nicotinic receptor system in 1909,11 
but did not either mention or notice that Hill had also derived the Langmuir equation 
to describe his response curve. His colleagues apparently didn't notice it either, so 
the credit commonly goes to Clark.) Gaddum extended Clark’s full mathematical 
treatment to the competition between drugs that bound the same site.12 Over the 
next several decades, the concept of efficacy was built when differences between 
the occupancy of receptors predicted from Clark and Gaddum’s basic description of 
drug binding and the biological response of the system were rigorously compared.4 
This effort included the work of such prominent pharmacologists as E.J. Ariëns,13 
R.P. Stephenson,14 and R.F. Furchgott.15 In this way, over the span of about half a 
century the idea of a drug receptor was developed from the basic concept of 
Erhlich’s specific anti-toxin molecules to a physical entity whose behavior could be 
quantitatively described and modeled.16 Although the researches did not know it at 
the time, GPCRs were some of the most commonly used receptors for performing 
these studies, with the α- and β-adrenergic and muscarinic acetylcholine receptors 
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being the most prominent examples, along with the non-GPCR nicotinic 
acetylcholine receptors.   
The next major advances in receptor theory were inspired from work in enzymology 
with hemoglobin. A.V. Hill had introduced an equation in 1910 (now known at the Hill 
equation) that described the binding of oxygen to hemoglobin, which showed a 
marked degree of cooperatively in binding.17 His observation and equation were 
given their modern interpretation much later by F. Jacob, J. Monod, J. Wyman, and 
J.P. Changeux in 1963 and 1965 when they described hemoglobin as a cooperative, 
allosteric protein. In their model, the individual subunits can exist in two different 
conformational states, one of which binds oxygen at a higher affinitiy.18, 19 This 
model, which is known today as the Monod-Wyman-Changeux (MWC) model of 
allostery, made the important advance of allowing the subunits to adopt both 
conformational states even in the absence of ligand. Several years before the MWC 
model was presented, J. Del Castillo and B. Katz had also described the activity of 
the nicotinic acetylcholine receptor ion channels using a two-state model, where 
acetylcholine binding allowed the channel to transition from an open to a closed 
state, but they did not allow the unligaded channel to transition to an open state.20 
That development was made by A. Karlin in 1967, who applied the full MWC model 
to the nicotinic receptor.21 This was the general state of the field when the G proteins 
were found, a discovery which also revealed the general nature of the GPCR signal 
transduction system. 
1.3 – Discovery of G proteins and GPCRs. 
The discovery of GPCRs as a distinct type of receptor was made possible by the 
earlier discovery of cyclic AMP (cAMP). In 1957, Earl Sutherland and Theodore Rall 
identified a soluble molecule that acted to stimulate glycogenolysis in dog liver 
homogenates.22 This molecule was produced when the hormones epinephrine and 
glucagon interacted with some unknown receptor the membrane portion of the 
homogenate, and was identified a year later as cAMP.23 The field started to study 
both the unknown receptor and the cAMP response, and about a decade later Martin 
Rodbell demonstrated that the cAMP generating enzyme and the receptors that 
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bound the hormones were most likely separate entities.24 Soon after, he also 
demonstrated that GTP was somehow involved in the transmission of the hormone 
signal from the receptor to the enzyme that stimulated cAMP production.25  
In the early to mid 1970's, Alfred Gilman started the search for Rodbell's GTP-
dependent transmission protein. His search was greatly aided by two new scientific 
developments. At this point, good antagonists for the β-adrenergic receptors had 
been developed, most prominently through the work of James Black.26 Gerald 
Aurbach created a radiolabeled version of one of these drugs and showed it could 
be used to directly measure the presence of the receptors.27 Also, a pair of S49 
lymphoma cell lines that died from cAMP elevation were isolated by Henry Bourne, 
Phil Coffino, and Gordon Tomkins; one cell line had an intact cAMP response to the 
β-adrenergic receptor agonist isoproterenol, and one was a mutant where the 
response was broken.28 In a collaborative effort between the labs of Gilman and 
Kenneth Melman, Paul Insel used these new tools to show that the mutant 
lymphoma cells still had perfectly functional β-adrenergic receptors.29 Soon after, 
Gilman's postdoctoral fellow Elliot Ross demonstrated that the mutant cells also 
retained functional adenylyl cyclase enzyme as well, but instead were missing a 
novel GTP binding protein that could be resupplied using non-mutant, detergent 
solubilized membrane extracts.30 At this time, Ross also described a model of 
receptor action that was to first to recognize that agonist binding to the receptor was 
negatively cooperative with binding of guanine nucleotides. This model became 
known as the "ternary complex model" of receptor function,31 and is described in 
more detail below in section 1.6. In 1980, shortly after the finding that the GTP 
binding proteins existed, Gilman's postdoctoral students John Northup and Paul 
Sternweis purified the protein,32 which today is known as the G protein Gs. Gilman 
had proven the existence of Rodbell's GTP-dependent transmission protein, 
eventually earning both him and Rodbell a Nobel Prize in 1995. 
The discovery of the G proteins and their relationship with the GPCRs happened at 
the beginning of the modern era of molecular biology. Over the 1980s, the ability to 
clone genes, sequence them, and produce recombinant proteins expanded from the 
6 
 
few specialized labs that developed the technology to biochemistry labs in general. 
By the end of the decade, most of the genes for the G proteins and the adenylyl 
cyclases were found through the work of Gilman, Mel Simon, Randy Reed, and 
other colleagues. In 1986, the β2-adrenergic receptor was also cloned by Brian 
Kobilka from Robert Lefkowitz’s lab and Richard Dixon from Merk,33 using peptide 
sequences from a receptor purification method worked out several years earlier by 
Marc Caron.34 The receptor’s sequence showed that both the photoreceptor 
rhodopsin and the β2-adrenergic receptor, the prototypical GPCR, shared the same 
7 transmembrane domain topology. This was a major surprise, as it was generally 
assumed at the time that the hormone receptors and the photoreceptors were not 
related to one another.5 Following this revelation, other 7 transmembrane receptors 
were quickly cloned, and the work that followed in the 1990s established our modern 
understanding of the GPCR family and the workings of the classical G-protein 
mediated signaling pathways.   
1.4 – Classes of GPCRs and G proteins. 
GPCRs have been classified by several different methods, but the most well 
recognized system divides the family into 6 classes: Class A (Rhodopsin-like), Class 
B (Secretin-like), Class C (Metabotropic glutamate-like), Class D (Fungal 
pheromone), Class E (cAMP), Class F (Frizzled/smoothened).35 Only classes A, B, 
C, and F are found in vertebrates, with approximately 800 different receptors in 
humans.36 It is clear from sequence homology that most of these classes are very 
old, from before nematode and chordate lineages split.37 Classes A, B, and C are all 
known to signal primarily through heterotrimeric G proteins. Class F instead is 
associated with signaling through the Wnt pathway, although evidence for some 
level of interaction with G proteins has been observed.38, 39 Class A is the largest 
class by far, including about 270 non-olfactory and 400 olfactory receptors in 
humans. This class generally binds small to medium size ligands that fully or 
partially interact with residues deep within the seven transmembrane domain core of 
the protein.40 Classes B and C are smaller, with 48 and 22 members in humans, 




Heterotrimeric G proteins are much less numerous than GPCRs. Typically, the G 
proteins are classified by the identity of the Gα subunit, of which the 16 different 
human genes are divided into 4 classes.43 The Gs class contains Gαs and Gαolf; the 
Gi/o class contains Gαo, Gαi1, Gαi2, Gαi3, Gαt1, Gαt2, Gαz, and Gαgust; the Gq/11 
class contains Gαq, Gα11, Gα14, Gα15/16; and the G12/13 class contains, not 
surprisingly, Gα12 and Gα13. There is also a fifth class of heterotrimeric G proteins, 
known as Gv (named for the Roman numeral “V”), which is not observed in humans 
but found in other animals, including other vertebrates. Gv is just as ancient as the 
other four classes, traceable back to the earliest metazoans.44 Classically, the Gs 
class is characterized by its ability to stimulate cAMP production by adenylyl 
cyclases (AC) and the Gi class by the opposite, to inhibit AC function. The Gq class 
activates phospholipase Cβ (PLCβ) enzymes and the G12/13 class is liked to 
activation of RhoGEF proteins. However, the list of known Gα effectors has grown to 
include many other signaling pathways, and classification is also complicated by the 
fact that the Gβγ subunits are able to activate effectors in their own right once they 
are released from the heterotrimeric complex with Gα.43 The analysis of the myriad 
signaling pathways associated with heterotrimeric G proteins is out of the scope of 
this dissertation, but instead we focus on the very early event common to all 
heterotrimeric G protein pathways, the activation of the G protein by a GPCR.  
There are 5 Gβ and 12 Gγ genes in humans, which are generally expressed widely 
in overlapping patterns (the exception is Gγ1, which is restricted to the brain and 
eye).45 Many, but not all combinations of Gβγ dimers can form, and there have been 
some indications that specific combinations are preferred for some receptors and/or 
Gα subunits.46 However, there are also many cases where the different 
combinations of Gβ and Gγ subunits do not seem make much of a difference for 
either receptors or the effectors they interact with.47 Likely because of this 
uncertainty in the role of Gβγ subtype specificity, no classification system exists for 
them as it does for the Gα subunits. 
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1.5 – Canonical GPCR signaling. 
In the canonical GPCR-mediated G protein activation scheme, a GPCR binds an 
agonist (or in the case of rhodopsin, absorbs a photon to create a covalently bound 
agonist) on its extracellular side, which enhances the propensity of the receptor to 
enter an activated conformation. This change is recognized from the intercellular 
side of the receptor by a heterotrimeric G protein, which binds to the activated 
receptor. Normally, a molecule of guanine diphosphate (GDP) is tightly bound to the 
Gα subunit of the G protein, but when the G protein binds to the activated receptor it 
causes the GDP to dissociate. A guanine triphosphate (GTP) molecule from the 
cytosol can then bind to the vacant site on the Gα subunit, causing the G protein to 
dissociate from the receptor and the alpha subunit to dissociate from the Gβγ 
subunit. The GTP-bound Gα and Gβγ subunits both go on to activate various other 
signaling proteins in the cell, causing a cell-specific cascade of reactions that leads 
to an appropriate behavior (or an inappropriate one, in the case of disease) in 
response to the GPCR agonist.48 This process may or may not involve full 
dissociation of the Gα and Gβγ subunits.49   
The Gα subunit contains an intrinsic GTPase activity, enabling it to convert the 
bound GTP molecule to a GDP molecule. However, this reaction is typically quite 
slow for heterotrimeric G proteins, and in a cellular context the rate of the GTPase 
reaction is usually enhanced by the interaction of the Gα subunit with a member of 
the regulator of G protein signaling (RGS) proteins.50 The GDP-bound Gα subunit is 
then able to bind the Gβγ subunit again, leading to the termination of both Gα and 




Figure 1-1. The canonical GPCR and G protein signaling cycle. Please see text for details. 
Figure reprinted from Rasmussen et al.52 
In addition to the signal termination by RGS-mediated or intrinsic GTP hydrolysis, 
GPCR signaling is often accompanied by a cellular process that pulls the activated 
receptors off of the plasma membrane and into endosomes, known as 
desensitization. In the most well established pathway, which is present for the 
majority of GPCR systems studied to date, an agonist-bound, activated receptor is 
recognized by a G protein-coupled receptor kinase (GRK). The kinase 
phosphorylates several residues on the receptor, typically on intercellular loop 3 or 
the C-terminus. This phosphorylation promotes the removal of the receptor from the 
plasma membrane into clathrin-dependent vesicles.53 The arrestin class of proteins 
is usually involved in this process, although recent research has also ascribed it a 
large number of additional roles in GPCR-mediated signaling.54  
1.6 – GPCR activation and binding theory. 
The advent of good radiolabeled antagonists for GPCRs allowed for a very important 
observation about the mechanism of G protein activation. Competition binding 
assays with unlabeled agonists demonstrated that a second, higher affinity binding 
site for agonists to their receptor appeared when their cognate G proteins were 
present in the samples. If the G protein was dissociated by the addition of the non-
hydrolyzable GTP analogue GTPγS, the high-affinity binding was lost, shown in 
figure 1-2A, below. This was evidence that not only is the G protein activated by the 
agonist-bound receptor, but it can also induce the receptor itself to adopt an 
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activated conformation, indicating a true allosteric link between the ligand and G 
protein binding sites. This observation was the basis for the “ternary complex model” 
(TCM) between receptor, G protein, and agonist, as formulated by Eliot Ross31 and 
Andre De Lean.55 The TCM and its descendents, shown in figure 1-2B and C, below, 
are the most common mathematical models for GPCR function in current use.  
 
Figure 1-2. Development of the ternary complex model of GPCR function. A) An early 
example of high-affinity agonist binding. The agonist isoproterenol binds β-adrenoreceptors 
with two different affinities, leading to a binding curve with a shallower-than-normal slope. 
Reprinted from Ross et al.31 This research was originally published in the Journal of 
Biological Chemistry, © the American Society for Biochemistry and Molecular Biology. B) An 
early formulation of the ternary complex model reprinted from De Lean et al,55 where the 
binding of the G protein (denoted as “X” in the diagram) enhances the affinity of the receptor 
(“R”) for the agonist (“H”). In the description of the model, the effector is activated by 
interaction with X after its nucleotide-catalyzed release from the high affinity complex, 
although that is not immediately apparent in the provided diagram. This research was 
originally published in the Journal of Biological Chemistry, © the American Society for 
Biochemistry and Molecular Biology. C) A modern schematic of the cubic ternary complex 
model (cTCM) which incorporates a two-state model of receptor activation into the basic 
conceptual framework of the TCM. Figure redrawn based on Christopoulos and Kenakin.56 
The TCM as originally described did not explicitly apply a two-state model to the 
receptor, although agonist and G protein binding were proposed to cause 
conformational changes to the receptor, which was represented implicitly in the 
mechanism. It was not until 1993 that Philippe Samama and colleagues applied a 
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full 2-state model to GPCRs, called the extended ternary complex model (eTCM),57 
even though similar models were applied 26 years earlier to the nicotinic receptors.21 
The application of the model was made in the context of research from Tommaso 
Costa and Albert Herz that showed high levels of basal activity from overexpression 
of receptors, and these systems facilitated the discovery of inverse agonists as a 
way that drugs could interact with GPCRs .58 A few years later, the eTCM model was 
upgraded again to the cubic ternary complex model (cTCM) by Terry Kenakin, drawn 
above in figure 1-2C, which allowed the G protein to interact with a receptor in the 
inactive conformation as well.59-61 The cTCM represents a thermodynamically 
complete two-state model that interacts with one ligand and one G protein. As 
discussed at length in section 5.8, it is unclear how prevalent the states with 
interacting inactive receptor and G protein are in reality. The cTCM also forms the 
basis for more models that describe more complex situations, such as binding of 
allosteric GPCR ligands or ligand biased signalling.56  
1.7 – GPCR and G protein structure. 
All GPCRs share a core fold that consists of 7 transmembrane α-helices (numbered 
TM1 to TM7), connected in a serpentine fashion with the N-terminus of the protein 
on the extracellular side of the membrane and the C-terminus on the intercellular 
side. A short, amphiphatic helix known as helix 8 (H8) is also found directly after 
TM7, where it lies parallel with the membrane. On most receptors, palmitoylation 
site(s) and/or a stretch of cationic residues immediately follow H8 and help keep the 
helix on the membrane. The residues of the transmembrane helices are primarily 
hydrophobic in nature, although a number of polar or charged residues are typically 
found in the center of the transmembrane bundle.62, 63 These residues form a 
network of hydrogen bonds with each other and with several water molecules that 
help hold the hydrophobic transmembrane helices together in the hydrophobic 
membrane layer, but is also flexible enough to allow the helices to move as required 
during the conformational changes involved in GPCR function.63, 64 The only class of 
GPCRs that we have high-resolution structural data in the transmembrane region is 
for class A receptors, but it is likely that class B and C have similar overall 
structures, since they interact with and activate the exact same G proteins as the 
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class A receptors. Shown below in figure 1-3 are some of the key features of the 
GPCR fold. 
 
Figure 1-3. Structural overview of GPCRs. The inactive β2-adrenergic receptor (PDB 2RH1) 
is used as an example. Numbered features are as follows: 1) Palmitoylation at the end of 
helix 8, colored in magenta. 2) Ligand binding site, ligand colored in yellow. 3) 
Transmembrane helix kicks induced by proline or glycine residues, colored in green. 4) 
(E/D)RY motif, colored in orange. 5) NPxxY motif, colored in salmon. Please see text for 
additional details.  
TM3 is the longest helix in the transmembrane region, and it is tipped by ~35° from 
the normal vector of the membrane. It makes well-conserved contacts with TM2-6, 
forming the structural core that the other helices pack and move against. In the 
extracellular loop 1 region (ECL1) between TM2 and TM3, a highly conserved 
disulfide bond is formed, which also serves to stabilize the GPCR fold. The ECL2 
region is highly variable in sequence and structure for GCPRs in general, but it tends 
to be conserved for each receptor family. Similarly, the ligand binding site is 
conserved within the receptor families but not highly in general, and is usually 
formed between TM3, TM5, TM6 and TM7.40  
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Towards the center of the receptor, most of the TM helixes have a single kink 
induced by proline and/or glycine residues. These kinks serve as fulcrums that 
amplify small movements in the extracellular side of the receptor to larger ones on 
the intracellular side, discussed more in chapter 3. On the intercellular side of the 
receptor, there are two prominent structural and sequence features. One feature, the 
(E)DRY motif, located on the intracellular side of TM3, is part of the so-called "ionic 
lock" interaction. This interaction was seen in the first GPCR structure solved, bovine 
rhodopsin, which showed a salt bridge between the TM3 DRY sequence and a 
glutamic acid on TM6 that helped to prevent the receptor from reaching its activated 
conformations.65 However, it is not obvious how important similar interactions are for 
other GPCRs, as such salt bridges are not observed in most other receptor 
structures and the effects of mutations in the motif are complex.66 The other feature 
has a consensus sequence motif of NPxxY, and is found at the end of TM7, right 
before the bend that allows Helix 8 to lie along the membrane. This sequence is 
important for stabilizing the active receptor conformations, discussed further in 
chapter 3.  
Heterotrimeric G proteins consist of 3 different polypeptide chains, the Gα, Gβ, and 
Gγ subunits. The Gβ and Gγ subunits bind very tightly together, a process that is 
typically aided by specific chaperone molecules.67, 68  The Gβ and Gγ polypeptide 
chains do not dissociate from one another, so the dimer is often treated as a single 
subunit, the Gβγ subunit. The C-terminus of Gγ is either farnesylated or 
geranylgeranylated, and serves to anchor the subunit in the membrane.47 Shown 
below in figure 1-4A, the Gβ subunit has a 7-bladed WD-repeat fold, also called a β-
propeller fold, and an N-terminal alpha helix. The Gγ is mostly alpha helical in 
structure, and it packs along the Gβ α-helix and the 5th, 6th, and 7th WD repeat. The 
Gα subunit binds to the Gβγ subunit through contacts between the 1st, 2nd, and 3rd 
WD repeat of Gβγ and the switch II and N-terminal region of Gα,69 shown below in 
figure 1-4B. The interaction with the switch II region is always broken when the Gα is 
bound to GTP,51 but for the N-terminal region there is evidence that suggests some 
G proteins can maintain the interaction even after activation with GTP, and other G 
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proteins tend to lose all interactions and physically dissociate into separate Gα and 
Gβγ subunits.70, 71 
 
Figure 1-4. Structural overview of G proteins. The GDP-bound Gt/Gi chimera heterotrimer 
structure (PDB 1GOT) is used as an example. Numbered features are as follows: 1) 
Farnesylation or geranylgeranylation of the Gγ C-terminus and palmitoylation and/or 
myristoylation of the Gα N-terminus. 2) The Gα switch II domain (shown in periwinkle blue) 
includes G-box sequence 2 and binds to Gβ when the protein is GDP bound. 3) The Gα 
switch I domain (shown in orange) includes G-box sequence 3. 4) G-box sequences 1, 4, 
and 5 (shown in magenta) form the rest of the guanine nucleotide binding site. 5) The 
catalytic arginine residue (shown in cyan) is at the c-terminal end of the α-helical domain 
and is followed by switch 1. Please see text for additional details. 
The heterotrimeric Gα subunits are part of a class of GTPase enzymes that include 
the EF-Tu and EF-G families of elongation factors and the p21ras (Ras) small 
GTPase homologs. All of these proteins contain a core fold of a twisted, 6-strand β-
sheet domain surrounded by α-helices and a highly conserved 5-loop structure that 
forms the guanine nucleotide binding site, shown above in figure 1-4C. The 
consensus sequences of the loops are called the G-box domains, and are given the 
designations G-1 through G-5. Two regions that include the G-box domain G-2 and 
G-3 change conformation due to the presence of the γ-phosphate of GTP and are 
known as switch I and switch II, respectively. The functions of these G-box domains 
are discussed in more depth in sections 3. and 5.4 where their participation in G 




























Heterotrimeric Gα subunits have an additional domain composed of a 6 α-helix 
bundle which is grafted into a loop of the core GTPase fold. This forms a protein with 
two distinct sections; the Ras-like GTPase domain and the Gα specific α-helical 
domain.51  The α-helical domain has a key residue, arginine 201 on Gαs, that is 
necessary for hydrolysis of GTP to GDP. The homologous arginine for the Ras 
family is not found on the Ras proteins themselves, but instead is supplied by a 
separate protein required for hydrolysis, known as Ras-GAP.  
1.8 – Motivation for research. 
At the beginning of my research, there was high resolution structural information for 
only two GPCRs, the human β2-adrenergic receptor and bovine rhodopsin. These 
receptors were in an inactive conformation, but it was known from biochemical and 
biophysical work that they must change conformation quite significantly during 
activation. In particular, the transmembrane helix 6 of the receptor was known to 
move outward, which would open up a binding site on the receptor that almost 
certainly seemed to be the site of interaction with the G protein α-subunit c-terminus. 
However, several major questions about the activated receptor and its interaction 
with G protein remained, which made the nucleotide-exchange step the least well-
understood part of the G protein signaling cycle. The orientation between the 
interacting receptor and the G protein was unknown, and it was unclear how the 
activated receptor actually caused the changes to the G protein that led to 
nucleotide exchange. The leading models suggested that the receptor either pulled 
the Gβγ subunit away from the Gα subunit, the “lever-arm” model, or tilted it in 
towards the Gα subunit, the “gear-shift” model. Both models suggested that the 
accompanying distortion of the Gα switch I and II regions was also responsible for 
forcing out the nucleotide. There were also several models of activation that required 
a dimer of receptors or had a single receptor bind to both Gα and Gγ subunits 
simultaneously. In addition, it was unclear if the simple act of binding to a receptor 
was enough to cause nucleotide exchange on a G protein, or if the exchange step 




I started the project with the end goal of being able to obtain a crystal structure of the   
β2AR and Gs interacting together. Brian Kobilka and his postdoc, Søren G. F. 
Rasmussen, recently crystallized the β2AR and knew how to make it in quantity.  
Roger Sunahara’s lab had also started making significant quantities of the Gs 
heterotrimer, so I was confident that if we could figure out how to make a β2AR-Gs 
complex sample, we could actually produce enough sample to complete a 
crystallography project. We hoped that seeing the interaction between the two 
proteins in high structural resolution would either solve or greatly aid in answering 
the questions mentioned in the previous paragraph about the nucleotide exchange 








G PROTEIN PRODUCTION AND RECEPTOR-G PROTEIN 
COMPLEX OPTIMIZATION 
 
2.1 – Introduction. 
This section contains work that was done in order to determine how receptor and G 
protein could be made to interact to form a molecular complex, figure out how to 
produce the large quantities of G protein needed, and how to stabilize the receptor-
G protein complex for crystallography. In most cases, the data in this section are the 
first indications of findings that were more conclusively proved in the work presented 
in the following chapter. This work represents the majority of my time invested 
throughout the project. The first experiments that devised the overall nucleotide-
depletion strategy for making receptor-G protein complex and proving it could be 
purified (given in sections 2.3 to 2.9) were performed by me using my own 
heterotrimer and receptor produced and purified by Søren G. F. Rasmussen from 
Dr. Brian Kobilka's lab. However, once we started crystallography trials, Søren 
performed the final sample preparation so it could go directly into Brian Kobilka’s 
crystallization trays, and I focused on making enough G protein to support the 
crystallography effort as well as worked together with Søren to assess the sample 
quality and find ways it could be improved. Later on in the project, many other 
collaborators joined to contribute techniques and reagents that proved to be critical 
to success, but this was only after Søren and I had worked for a couple years to 
optimize the basic receptor-G protein coupling protocol and were making high-
quality samples that still refused to crystallize into useful crystals. 
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2.2 – Overall Gs heterotrimer purification strategy. 
The overall strategy used for Gs heterotrimer expression and purification was 
pioneered by Gilman lab 20-30 years ago.72, 73 The three G protein subunits are co-
expressed in insect cells by infection with recombinant Autographa californica 
multiple nuclear polyhedrosis viruses, with a single N-terminal hexahistidine tag on 
the Gβ subunit. Membranes from the infected cells are isolated and then the intact 
heterotrimer is solubilized with detergent. This is followed by chromatographic 
purification using Ni-NTA resin, strong anion exchange, and gel filtration. The bulk of 
the purification is done on the Ni-NTA column and the following anion exchange step 
is effective at separation of the heterotrimer from excess Gβγ subunits. The gel 
filtration step serves mainly to reduce the concentration of detergent and exchange 
the sample into the final buffer.  
In the original procedure that our protocol was based on,73 the protein was initially 
solubilized in sodium cholate, exchanged into C12E10 (closely related to another 
historically used detergent Lubrol, or C12E9), and finally into CHAPS. For our 
samples, however, we knew that the final detergent in our protocol had to be 
dodecylmaltoside (DDM) because of the receptor's detergent requirements. 
Therefore, we re-worked the sequence of detergents so that the protein was 
exchanged from sodium cholate into anzergent 3-12 and then into DDM. This 
allowed us to add together purified receptors and G proteins with no fear of 
detergent mixing problems. Because directly exchanging the solubilized membranes 
into DDM was prohibitively expensive, anzergent 3-12 was used as an intermediate 
detergent. The critical micelle concentration of anzergent 3-12 (0.094 %) is in-
between between that of sodium cholate (0.41 %) and DDM (0.0087 %),74 which 
facilitates quick and complete detergent exchange.  
2.3 – Optimization of transfection and expression conditions. 
The incubation time for protein expression was determined by partially purifying G 
protein from membranes harvested from Hi5 insect cells between 27 and 76 hours 
post transfection, shown below in figure 2-1. The relative amounts of Gα and Gβ 
subunits were quantified by Coomassie blue staining of SDS-PAGE gels75 of 
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samples obtained by following the first part of the Gs purification method given in 
method 6.1 up through elution from the Ni-NTA column. The partial purification of 
samples was necessary because gels and western blots of crude membrane 
fractions showed very large amounts of G protein subunits being produced, but only 
a minor fraction could be solubilized with detergent, indicating that most of the 
protein was in an insoluble, aggregated form. From inspection of the graph, 
harvesting the sample during the window of time between 40 and 48 hours post-
infection was determined to be optimal for routine protein production.  
Ni-NTA purifiable, membrane bound
G protein subunits
























Figure 2-1. Expression of G protein subunits in Hi5 insect cell membranes. Samples were 
purified by Ni-NTA chromatography, run on a SDS-PAGE gel, and stained with Coomassie 
blue. The window between 40 and 48 hours was chosen for harvesting membranes for 
optimal protein production.  
2.4 – Optimization of G protein solubilization conditions.  
The temperature and detergent used to solubilize the Gs heterotrimer was also 
optimized. For this assay, a single preparation of membranes with 5 mg/ml 
membrane protein was incubated for 1 hour with 1% concentration of various 
detergents in Gs purification wash buffer at the specified temperature. The samples 
were centrifuged at high speed and analyzed by SDS-PAGE. The ratio of insoluble 
(pelleted) verses soluble (supernatant) G protein subunits were determined by 
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densitometry of the Coomassie-stained gel bands, shown below in figure 2-2. The 
detergents used were chosen because of their historical use in G protein or GPCR 
purifications or because of their low cost. It can be seen that in all cases, sodium 
cholate was the best performing detergent, sometimes by a wide margin. Although 
extremely inexpensive, the polyoxyethylene-based detergents and Triton X-100 both 
did not perform well in general. Anzergent 3-12, a zwitterionic detergent, and DDM, 
the required detergent for purification of the receptor, also were not able to 
outperform cholate for the initial membrane solubilization steps. It can also be seen 
from the graph that the best temperature for protein extraction was 0°C, so in the 
end the chosen conditions for Gs solubilization were the same as those determined 
by Kozasa & Gilman73 for G12, Gq, Gz, and Gi1. 














































Figure 2-2. Solubilization of Gs subunits from Hi5 insect cell membranes. A) Ratio of soluble 
to insoluble Gαs subunit. B) Ratio of soluble to insoluble Gβ1 subunit. For both proteins, the 
ratio was determined with densitometry of Coomassie-stained SDS-PAGE gels. The chosen 
solubilization condition was incubation of membranes with sodium cholate at 0°C for 1 hour.  
2.5 – Gs dephosphorylation.  
Because of data shown in section 2.10, we determined that we needed to insure that 
both our receptor and G protein were not phosphorylated in order to interact 
efficiently. While we routinely added protein phosphatases to the reaction mixture 
during incubations for forming receptor-G protein complex, we also found it 
convenient and beneficial to dephosphorylate the G protein sample during 
purification. Evidence for this is found in figure 2-3 below, where several anion 




Figure 2-3. MonoQ anion exchange chromatography of Gs heterotrimer. Shown are 280 nm 
absorbance and conductivity traces from two purification runs without any protein 
phoshatases and from two runs that had 5 units per liter original culture volume of lambda 
protein phosphatase (λPPase) added before the column. For the first run of both the λPPase 
and non- λPPase treated samples, fractions were analyzed by SDS-PAGE gels and stained 
with Coomassie blue, shown below the traces in their corresponding position.   
Although the chromatographs from individual purification runs can vary quite 
significantly from one another, the general elution patterns shown in the traces 
above were typical. Without any additional protein phosphatases added to the 
samples, the Gs eluted in a broad peak from the column around 23 millisiemens per 
centimeter (mS/cm) with sodium chloride as the eluent salt.  When similar samples 
were treated for 1 hour with 5 units per liter of cell culture volume of lambda phage 
protein phosphatase (λPPase, made and assayed in-house by methods given in 
sections 6.3 and 6.4) the Gs eluted reliably at 20.5 mS/cm.  The λPPase treated 
protein came off the column in a tighter peak, significantly improving the 
chromatography and reducing eluate volume. In addition, λPPase treatment reduced 
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by comparison of the intensity of the SDS-PAGE bands for the Gα and Gβ subunits. 
Although we never systematically determined why the λPPase treatment made such 
an improvement in the anion exchange chromatography, we assume it is because 
the removal of the phosphate groups from the proteins in the sample reduces the 
overall negative charge of the proteins as well as eliminates the charge 
heterogeneity that arises from non-uniform phosphorylation. Both these effects 
would lead to the observed elution profiles which show the protein tends to interact 
with the resin a little weaker than without λPPase treatment and that it elutes in a 
sharper and more consistent peak.  
2.6 – Receptor and G protein interact in rHDL particles.  
In order to test if the purified G protein could interact with a receptor and allow 
agonist-induced nucleotide loss of the G protein, we used a conformationally-
sensitive fluorescent receptor that had been developed in the Kobilka lab. 
Previously, the Kobilka lab together with our own lab showed that versions of the 
β2AR can be made which have 5 of the most reactive cysteines mutated into non-
reactive residues, allowing facile labeling on any other accessible cysteine residue 
with mono-bromobimane, a very small, environmentally sensitive fluorescent dye.76, 
77 It was found that the large conformational changes that the receptor experiences 
upon activation could be detected using a bimane-labeled β2AR with a unique 
reactive cysteine at residue 265, which is located towards the cytoplasmic end of 
transmembrane helix 6 (TM6). Fortunately, the bimane label also did not interfere 
with G protein binding when attached to that residue, allowing us to confirm receptor 




Figure 2-4. Conformational change of the receptor in the presence of agonist and G protein 
in rHDL discs. In figure A, bimane-labeled β2AR in rHDL particles is mixed with excess Gs 
heterotrimer without any drugs. In figure B, the labeled receptor is incubated with saturating 
amounts (100 μM) of the agonist isoproterenol (Iso) or with Iso and Gs together. Full 
experimental details given in method 6.5. Figure reprinted from Yao et al, 2009.77 
In the bimane-receptor assay shown above (described in methods section 6.5), the  
conformational changes of the fluorophore-labled TM6 domain of the receptor forces 
the flourophore into a more polar environment, detected as a generalized decrease 
in fluorescence intensity as well as a redshift in the λmax of the fluorescence 
spectrum. Both Gs (figure A) and the agonist isoproterenol (figure B) cause the 
environment of the flourophore to change to a similar extent when added to the 
receptor alone. However, when both the agonist and the G protein are added 
together, the environment of the flourophore changes to an even greater extent than 
either the drug or G protein can do so by itself (figure B). We interpret this 
phenomenon as evidence for cooperativity of receptor activation between the 
agonist and G protein. Such behavior is expected, as agonists by definition cause 
the GPCR to interact with and activate G protein. This experiment also confirmed 
that both the receptor prepared by the Kobilka lab and the Gs heterotrimer prepared 
by our lab were completely functional.  
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2.7 – Apyrase helps stabilize the receptor and G protein interaction.  
We also hypothesized that since GDP release is the consequence of G protein 
binding to the receptor, known from the cononical G protein cycle, we might be able 
to stabilize the interaction of the two proteins by removing GDP from the sample as it 
is relased upon receptor-G protein complex formation. Removal of the GDP would 
drive the equlibrium towards complex formation by preventing GDP re-association to 
already formed complexes and causing them to dissociate in the reverse reaction. 
We tested this idea using the same bimane-labeled receptor assay as in section 2.6 
above. However, this time we used samples of the receptor with Gs heterotrimer in 
rHDL discs and then added the enzyme apyrase, a non-specific nucleotide 
hydrolase, to convert the free GDP to GMP and Pi, shown below in figure 2-5.  
  
Figure 2-5. Conformational change of the receptor and G protein in rHDL discs when treated 
with apyrase to remove GDP. Shown in black is the fluorescence emission spectrum of 
samples with only receptor and G protein. When the sample was incubated with 10 μM 
GTPγS for 40 minutes in order to uncouple all the G protein from the receptor, the spectrum 
changed to the one shown in grey. When it was incubated with apyrase or apyrase plus 100 
μM of the agonist isoproterenol (ISO), the spectra changed to the ones shown in blue and 
green, respectively. Figure reprinted from Yao et al, 2009.77 
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When apyrase was added to the sample with receptor and G protein, it caused a 
small but noticeable decrease in fluorescence intensity and a slight redshift. This 
effect was also present when apyrase was added to samples with the agonist 
isoproterenol, causing the intensity of the fluorescence signal to decrease to 48% of 
the non-activated receptor signal as opposed to 55% for samples that were only 
incubated with the agonist and G protein but no apyrase (figure 2-4). More evidence 
in support of using apyrase to help drive the receptor-G protein coupling reaction to 
completion was found using radioligand binding of an antagonist to the receptor, but 
the interpretation of the data is dependent on the overall model of receptor and G 
protein allostery and so it is discussed in chapter 4, which deals at length with such 
experiments.  
2.8 – Receptor and G protein can interact in detergent. 
Initially, we were not certain if it would be possible for the Gs heterotrimer and the 
β2-adrenergic receptor to interact productively while solubilized in detergent instead 
of being in an rHDL particle or other bilayer membrane environment. In order to 
measure receptor-G protein interaction in detergent, the bimane-receptor assay 
used in section 2.6 above was adapted to use with highly concentrated, detergent 
solubilized proteins in a 384-well plate format.  Details of the assay are given in 
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Figure 2-6. Conformational change of the receptor in the presence of agonist and G protein 
in DDM detergent. A) 100 μM isoproterenol (ISO, an agonist) was added to samples of 1 μM 
bimane-labeled β2AR either with or without 5 μM Gs. The fluorescence spectra were taken 
at the specified timepoints after the addition of drug. B) 200 μM alprenolol (ALP, an 
antagonist, used at a concentration that should compete 400× more effectively than the ISO 
concentration used for binding the receptor) was added to the same samples. C) GTPγS 
was added to the same samples to force G protein to uncouple from the receptor.   
We found that we could get the two proteins to interact in DDM detergent when they 
were at micromolar concentrations. In part A of figure 2-6, one can see that upon 
addition of the agonist isoproterenol to the samples, we saw a decrease in 
fluorescence intensity and redshift of λmax that is also seen in rHDL. In the samples 
where Gs is included along with ISO, the effect is more extreme than when it is not 
included, indicative of interaction between receptor and G protein just as in figure 2-
4. The isoproterenol-induced changes in fluorescence can be fully reversed in the 
sample without G protein by addition of alprenolol, a competing antagonist, shown in 
part B. Only a fraction of the signal can be reversed with antagonist when G protein 
was included in the initial incubation with agonist, and even extended incubation up 
to 2 hours does not overcome the effect. However, addition of GTPγS, which is 
known to bind to activated G protein and cause it to dissociate from the receptor and 
into separate subunits, rapidly reversed the G protein effect. All together, the 
response of the receptor and G protein containing sample indicated that the two 
proteins were able to form a stable complex in detergent. The decrease in decrease 
in fluorescence intensity and redshift of λmax suggests that the receptor was in an 
active conformation and the quick response of the sample to guanine nucleotide 
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suggests that G protein was in a conformation that can rapidly bind guanine 
nucleotides.  
2.9 – Receptor and G protein complex is stable and purifiable in detergent.  
After confirming our basic strategy of forming the β2AR and Gs complex in detergent 
using the bimane-labeled receptor assay shown above in section 2.8, we needed to 
determine if the complex was stable enough to purify away from any remaining 
contaminating proteins and coupling reaction byproducts. To do so, we made a 
small sample of complex and purified it with anion exchange chromatography. The 
preparation of the sample was almost exactly as described in method described in 
section 6.9, except that the sample was incubated for 30 minutes at 30°. Receptor 
alone and Gs heterotrimer alone were also run on the anion exchange column under 
identical conditions to confirm the ability of the column to separate the complex from 
the excess proteins that did not form a complex. Chromatographs of the three 






Figure 2-7. Anion exchange chromatography of β2AR, Gs heterotrimer, and β2AR-Gs 
complex. Shown are absorbance traces at 280 nM for each of the indicated samples along 
with silver stained SDS-PAGE analysis of representative fractions along each 
chromatogram, lined up to correspond to the approximate position of the fractions in the 
chromatogram. In these gels, the topmost band corresponds to Gαs, the middle band to 
Gβ1, and the lowest and slightly fuzzy band to the β2AR. The extremely dark band on the 
receptor + Gs gel is due to contaminating protein and is not a feature in the chromatogram.  
Formation of a stable receptor and G protein complex was confirmed by the co-
migration of receptor with both the Gα and Gβ subunits of the G protein on the anion 
exchange column. The complexed receptor and G protein eluted at a fraction that 
neither the receptor nor the Gα subunit was found at when the proteins were run 
separately. The height of the peak and intensity of the bands also told us that the 
desired sample of the receptor and G protein complex was forming at efficiencies in 
the neighborhood of 40%, a perfectly workable starting point for further optimization. 
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exchange and can be separated from leftover unreacted receptor and G proteins. At 
this stage, we started preparing milligram quantities of this complex and attempted 
crystallization trials with the sample.  
2.10 – Protein phosphorylation inhibits complex formation. 
Relatively soon after we started to prepare large amounts of β2AR-Gs complex, we 
tested the sample for phosphorylated residues. The idea we had was that because 
the receptor is known to be phosporylated as part of normal receptor physiology 
leading to the downregulation of signaling,78 and that there were some other reports 
of Gs proteins being phosphorylated,79 perhaps we could increase the efficiency and 
stability of complex formation by removing any phosphate modifications that were 
added by the insect cell kinases during protein overexpression. We used the 
commercially available phosphoprotein stain Pro-Q Diamond (Molecular Probes, 
Invitrogen) on samples analyzed with SDS-PAGE, shown below in figure 2-8.   
 
Figure 2-8.  Pro-Q Diamond phosphoprotein staining of β2AR-Gs complex samples. On the 
left, Coomassie blue stain was used to test for total protein on an SDS-PAGE gel. On the 
right, Pro-Q Diamond phosphoprotein imagining was used to detect phosphorylation of the 
same gel. Please see text for the description of the experiment. Data was obtained by Søren 
Rasmussen with samples prepared by Søren Rasmussen and Brian DeVree. 
In the experiment, a sample containing both β2AR-Gs complex and uncomplexed 
reactants was purified using a M1-FLAG antibody affinity column for the N-terminal 











purification, but the G protein still had any phosphate modifications that were made 
to it by the insect cells that were used to overexpress it. Both the eluted sample and 
the flow-through during the loading of the column were analyzed by SDS-PAGE, 
with some of each sample pre-treated with a large excess of λ-phage protein 
phosphatase (λPPase), an enzyme that removes all phosphates from tyrosine, 
threonine, serine, and histidine residues. The gels were stained with ProQ dye 
according to the manufacturer's directions and then with Coomassie blue stain. The 
dye will often stain each protein at a certain background level, so it is important to 
confirm the presence of a phosphate group by seeing that the dye-stained band 
decreases intensity upon extensive λPPase treatment.  
In figure 2-8, one can see that the some of the Gαs protein was not successfully 
complexed with the receptor and instead remained in the flow-through. This non-
reactive Gα subunit stained well with the ProQ dye, but the band completely 
disappeared after λPPase treatment, indicating that the subunit was probably 
phosphorylated. In contrast, the Gα subunit that co-purified with the receptor as a 
complex stained relatively poorly with the phosphoprotein dye (compare dye 
intensity with coomassie blue stain intensity), and the intensity of the band did not 
change after λPPase treatment. These data suggested to us that the phosphorylated 
G protein probably does not efficiently interact with the receptor. For this reason and 
because of the chromatography improvements outlined in section 2.5, we routinely 
treated the G protein with λPPase during purification. As a precaution against the 
possibility that the dephosphorylation of the receptor or G protein was not fully 
completed during the purification process, we also added the phosphatase into the 
complexing reaction mixture to ensure the removal of any remaining phosphates on 
either the receptor or G protein.   
2.11 – Receptor and G protein complex has 1:1 stoichiometry. 
Another question we needed answered about our β2AR-Gs complex samples was 
the overall stoichiometry of the different subunits. In some of the lab’s previous work 
it was shown that a single receptor was all that was required to activate the G 
protein,80, 81 but at the time there were also many papers suggesting that normally a 
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dimer of receptors was responsible for activation in physiological contexts.82, 83 We 
could not use Coomassie blue staining to test the ratio of β2AR to Gs because the 
receptor stained poorly, so instead we used two other techniques to estimate the 
stoichiometry of the complex; SDS-PAGE analysis of fluorescamine labeled proteins 
and total amino acid analysis.  
Fluorescamine is a non-fluorescent spiro compound that will quickly react with 
primary amines, such as those found on lysine residues or non-capped peptide N-
termini, to form a fluorophore that is covalently attached through the amine. It 
absorbs photons from the UVA region and emits blue light, allowing detection of 
proteins in gel using standard UV transilluminators. We labeled and purified an SDS-
denatured sample of β2AR-Gs complex with fluorescamine and ran the sample on 
an SDS-PAGE gel. The ratio of the intensities of the bands is compared with the 
theoretical predictions based on the number of lysine residues in each protein and a 
stoichiometry of receptor to G protein of either 1:1 or 2:1. In figure 2-9 below, it can 
be seen that the predicted signal ratio is much closer to the experimentally derived 
ratio if only a single receptor is assumed to be included in the β2AR-Gs complex. 
 
Figure 2-9. Fluorescamine labeling of β2AR-Gs complex. A sample of purified β2AR-Gs 
complex was labeled using the method given in section 6.10 and analyzed by SDS-PAGE. 
Quantification of the signal shows much better agreement with a 1:1 ratio of receptor to G 
protein that the alternate model of a 2:1 ratio. Data was obtained by Søren Rasmussen 
according to the method derived by both Brian DeVree and Søren Rasmussen. 
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In addition to fluorescamine labeling, we also tested the ratio of receptor to G protein 
in our samples by amino acid analysis. The sample was hydrolyzed in hot HCl and 
analyzed by HPLC by the University of Michigan Protein Structure Facility. 
Tryptophan and cysteine cannot be measured by this technique, and asparagine 
and glutamine are converted to aspartic acid and glutamic acid, respectively, so 16 
values incorporating the abundance of 18 of the amino acids are reported from the 
analysis. We used an ordinary least squares optimization routine and the known 
amino acid sequences to find the most likely ratio of the different proteins in the 
sample. The optimized Gαs : Gβ1-Gγ2 : β2AR ratio from the measurement of three 
replicates was 0.75 : 1.45 : 1.00. In figure 2-10 below, the least squares error is 
shown as a surface function of the ratio of Gαs and Gβ1-Gγ2 to the β2AR, which is 
held at a relative concentration equal to 1.00.  
 
Figure 2-10. Ordinary least squares optimization of amino acid analysis on β2AR-Gs 
complex. The receptor is assumed to be at a stoichiometry = 1.00, and the error of the 
predicted amino acid composition versus the experimental measurement is plotted as a 
function of the stoichiometery of the Gαs and Gβ1-Gγ2 subunits.  
It can be seen that the amino acid analysis shows an excess of Gβ1-Gγ2 subunits in 
our preparations, but is not highly suggestive of having multiple receptors per 
complex. Taken together with the fluorescamine data, which indicated a slight deficit 
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of receptor, we determined that we probably did not have 2 receptors per complex 
molecule. However, both assays showed higher than expected levels of Gβγ 
subunits, so we added an additional M1 FLAG antibody affinity column to our 
evolving purification protocol for separating the FLAG-tagged receptor-G protein 
complex from unreacted G protein subunits. It was considered highly unlikely that 
the excess of Gβγ subunits was due to any true physiological reason, since it had 
long been known that the alpha and beta subunits associate in a 1:1 ratio using both 
biochemical and crystallographic methods.69, 84 
2.12 – Maltose neopentyl detergents enhance complex stability. 
After we had confirmation that we could trap the β2AR and Gs proteins together in a 
purifiable complex with reasonable stoichiometry, we started working to enhance the 
stability of our molecular complex while simultaneously attempting crystallography 
using the best protocol that we had developed at that point. One of the problems 
with our samples was that the β2AR-Gs complex in DDM detergent shows significant 
dissociation after 48 h at 4 °C, shown in figure 2-11A below. We screened and 
characterized existing detergents as well several new families of amphiphiles made 
by Samuel Gellman and identified the new MNG class85 of amphiphiles as 







Figure 2-11. MNG amphiphiles enhance receptor-G protein stability. A) Gel filtration of 
β2AR-Gs complex samples in various detergents after incubation at 4° for 48 hours. Notice 
there is significant amounts of dissociated receptor and G protein in the typically used DDM 
detergent, but less in the two MNG family detergents tested. Figure reprinted from 
Rasmussen et al.86 B) Structures of the three amphiphiles used in part A. Data was collected 
by Søren Rasmussen using samples prepared by Søren Rasmussen and Brian DeVree. 
MNG detergents were synthesized by Pil Seok Chae.  
In addition to keeping the β2AR-Gs complex together better than DDM during 
purification, the MNG detergents also had the beneficial property that they tended 
not to dissociate very well from the receptor when the solution was diluted below the 
detergent’s critical micelle concentration. However, free micelles containing only 
detergent and no receptors rapidly dissociated upon dilution, allowing us to prepare 
samples for electron microscopy that contained β2AR-Gs complexes with no free 
micelles to complicate particle identification.  
2.13 – Nanobody 35 enhances complex stability. 
We also worked with Jan Steyaert to develop camilid antibody fragments 
(nanobodies) to stabilize the complex. Work with our laboratories87, 88 and many 
other ones89-92 has shown that these nanobodies can bind proteins and protein 
complexes in ways that enhance the stability of particular conformations of the target 
protein. They often also promote crystallization, in most cases providing numerous 
crystal contacts. We immunized two llamas with crosslinked β2AR-Gs complex, 
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generated phage display libraries of nanobodies from cDNA libraries of their 
peripheral lymphocytes, and screened the library according to the method given in 
section 6.11. Several nanobodies were found that bound to the complex, including 
nanobody 35 (NB35) and 37 (NB37). NB35 prevented complex dissociation, shown 
below, and was eventually found to be particularly good at promoting high-quality 
crystal formation. 
 
Figure 2-12. Nanobody 35 prevents dissociation of receptor-G protein complex. A) Gel 
filtration of a non-nanobody bound β2AR-Gs complex. The complex can be very effectively 
dissociated into free receptor and G protein subunits by adding 100 μM of the non-
hydrolysable GTP analogue GTPγS. B) Gel filtration of a β2AR-Gs complex bound to NB35. 
The nanobody-bound complex is very slightly larger than the complex alone, and cannot be 
dissociated into components by 100 μM GTPγS. Data was collected by Søren Rasmussen 
using samples prepared by Søren Rasmussen and Brian DeVree. Figure reprinted from 
Rasmussen et al.86 
In part A) of figure 2-12 above, a sample of β2AR-Gs complex can be dissociated 
with GTPγS, but in part B) the same β2AR-Gs complex is resistant to dissociation 
when NB35 is added at a 1:1.2 complex:NB35 stoichiometry. The nanobody clearly 
helped the complex stay together, so we added it into our protocol for complex 
preparation for crystallography. 
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2.14 – High affinity agonists, lipidic cubic phase, and T4L fusion proteins 
promote crystallogenesis. 
Some other refinements we made to our protocol for making β2AR-Gs complex 
samples for crystallography was to use a very-high affinity agonist to stabilize the 
activated form of the receptor, using a specialized cubic-phase forming lipid, and to 
fuse a T4 lysozyme protein on the N-terminal (extracellular) side of the receptor. The 
agonist BI-167107, shown below in figure 2-13A, was identified in Dr. Kobilka’s lab 
using a receptor melting temperature screen of several dozen proprietary and non-
proprietary high-affinity agonists. It was one of a series of ligands provided by 
Boehringer Ingelheim and was previously used to crystallize the receptor bound to a 
G protein mimic nanobody, NB80.87  
In the past, we had also had good results incorporating the receptor into lipidic cubic 
phase (LCP) based matricies to promote crystallogenesis,87, 93, 94 so for our 
crystallography of the β2AR-Gs complex samples we also focused our efforts on 
using LCP matricies. However, the typical lipid used for forming LCP, 9.9 MAG, 
shown in figure 2-13B, formed a cubic phase with aqueous channels of 40 Å 
diameter.95 We thought such a small channel was likely to restrict diffusion of the 
soluble parts of the complex, which totaled about 120 kDa of protein. (For 
comparison, the Stokes diameter of carbonic anhydrase, a 29 kDa protein, is also 40 
Å.) Instead, we used the lipid 7.7 MAG, also shown below in figure 2-13B, to make a 
cubic phase which had larger channels of about 62 Å.95 These channels were 





Figure 2-13. Ligand, lipid matrix, and receptor construct used for crystallography. A) The 
high-affinity agonist BI-167107 used to stabilize the receptor-G protein complex. It has a KD 
of 84 pM for the receptor. B) Lipids used for making lipidic cubic phase. The 9.9 MAG 
(monoacylglycerol) lipid was initially used, but was replaced by the 7.7 MAG lipid in order to 
get larger aqueous pores in the cubic phase. C) Schematic of the receptor construct used 
for overexpression. Faded residues represent parts of the wild type receptor that were not 
included in the crystallization construct. Figure modified from Kashai et al.96 The G proteins 
were completely wild type, with the exception of 6 histidine residues added to the N-
terminus of the Gβ subunit.  
Dr. Kobilka also established the strategy of replacing the intercellular loop three of 
the receptor with a T4 lysozyme fusion protein to promote receptor 
crystallogenesis.87, 93, 94 However, for the β2AR-Gs complex we fused the lysozyme 
to the N-terminal extracellular portion of the receptor and we left the third loop 
unmodified in order to allow unhindered interaction of the receptor with the G 
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HA signal sequence
FLAG peptide
TEV protease recognition sequence
T4 lysozyme, catalytically dead
Point mutations:
M96T & M98T to increase expression
N187E to avoid glycosylation
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2.15 – Section summary. 
At this point in the project, we were able to routinely make and purify milligram 
quantities of β2AR-Gs complex. We regularly attempted crystallography screens with 
the best protocols we had available, but the process of getting well diffracting 
crystals took several years. During that time, we would also send small amounts of 
the β2AR-Gs complex samples to Dr. Virgil Woods and Dr. Georgios Skiniotis for 
analysis by deuterium exchange and electron microscopy, respectively, in order to 
determine what could be improved in our sample preparations. The data they 
collected with our samples were also useful on their own right aside from helping 
with the crystallography effort, and they are described in detail in section 3 along 







CHAPTER 3  
STRUCTURE AND DYNAMICS OF A RECEPTOR-G 
PROTEIN COMPLEX 
 
3.1 – Introduction. 
This section describes data that was collected as part of a large collaboration 
between 8 laboratories and published in a series of high-impact publications in 
2011.86, 88, 97 The completion of the project was a longstanding goal in the GPCR 
field and was cited as a major factor that led to the awarding of the 2012 Nobel Prize 
in Chemistry to Dr. Brian Kobilka along with Dr. Robert Lefkowitz.  
My own part in the work was to determine the initial conditions and strategy for 
coupling receptor and G protein, described in the previous chapter, and later on to 
produce G protein in large quantities for crystallography sample preparation. I also 
helped with crystallographic data collection and figure preparation. In lieu of detailing 
each collaborator's contribution in the text of the chapter, I have instead compiled a 
list of principal investigators and students/postdocs that were involved in the project. 
Also listed are the major contributions from each person.  
Principal Investigators: 
Martin Caffrey - Lipid synthesis and production for lipidic cubic phase 
crystallography. 
Samuel H. Gellman - Detergent synthesis and production. 
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Brian Kobilka - Project design, major funding, receptor-G protein biochemistry, 
receptor production, crystallography and crystallographic data collection, manuscript 
preparation. 
Georgios Skiniotis - Project design, funding, electron microscopy, manuscript 
preparation. 
Jan Steyaert - Nanobody screening and production. 
Roger Sunahara - Project design, major funding, receptor-G protein biochemistry, G 
protein production, crystallographic data collection and analysis, manuscript 
preparation. 
William Weis - Crystallographic data analysis. 
Virgil L. Woods Jr. - Deuterium exchange by mass spectrometry.  
Students/Postdocs: 
Diane Calinski - Sunahara lab; G protein production. 
Pil Seok Chae - Gellman lab; Detergent design and synthesis. 
Ka Young Chung - Kobilka lab; Deuterium exchange by mass spectrometry, 
receptor-G protein biochemistry .  
Brian T. DeVree - Sunahara  lab; G protein production, receptor-G protein 
complexation and purification,  receptor-G protein biochemistry, crystallographic 
data collection and analysis, figure preparation.  
Somnath Dutta - Skiniotis lab; electron microscopy data collection. 
Tong Sun Kobilka - Kobilka lab; receptor production. 
Andrew C. Kruse - Kobilka lab; crystallography, crystallographic data collection and 
analysis.  
Sheng Li - Woods lab;  Deuterium exchange by mass spectrometry. 
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Tong Liu - Woods lab;  Deuterium exchange by mass spectrometry. 
Joseph A. Lyons - Caffrey lab; lipid production for lipidic cubic phase 
crystallography. 
Jesper M. Mathiesen - Kobilka lab; receptor biochemistry. 
Austin N. Oleskie - Skiniotis lab; electron microscopy data collection. 
Els Pardon - Steyaert lab; nanobody screening and production. 
Søren G. F. Rasmussen - Kobilka lab; receptor production, receptor-G protein 
complexation and purification,  receptor-G protein biochemistry, crystallography, 
crystallographic data collection, manuscript and figure preparation.  
Syed T. A. Shah - Caffrey lab; lipid production for lipidic cubic phase crystallography. 
Min Su - Skiniotis lab; electron microscopy data collection. 
Foon Sun Thian - Kobilka lab; receptor production. 
Gisselle A. Vélez-Ruiz - Sunahara lab; receptor-G protein biochemistry. 
Gerwin H. Westfield - Skiniotis lab; electron microscopy data collection and data 
analysis, low-resolution structure reconstruction. 
Yaozhong Zou - Kobilka lab; receptor biochemistry, crystallographic data collection 
and analysis. 
3.2 – Crystallographic data collection, model solving, and statistics. 
The highly-stabilized T4L-β2AR-Gs-Nb35 complex samples crystallized in the 
primitive monoclinic space group P21 from a PEG 400 and potassium nitrate based 
crystallization buffer at pH 6.5, shown below in figure 3-1 (detailed methods given in 
section 6.13). Diffraction patterns from the crystal were collected at Argonne 
National Laboratory on the Advanced Photon Source beamline 23 ID-B. The 
beamline's microfocus capabilities (5 µm diameter beam) and ability to search for 
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diffraction spots by screening through the volume of the opaque lipidic cubic phase 
matrix that the crystals were embedded in were critical to successful data collection.  
 
Figure 3-1. T4L-β2AR-Gs-Nb35 complex crystals used for data collection. Scale bar 
represents 100 µm. Figure reprinted from Rasmussen et al.86 
Reflections from 20 different crystals were merged to create the final data set, and 
the electron density of the crystal was determined by molecular replacement with 
previously determined crystal structures of the individual proteins, followed with an 
iterative process of automatic atomic position refinement and manual model 
adjustment and residue building. The crystals were anisotropic, with reflections 
along one axis going out to 2.9 Å and the other two going out to only 3.2 Å. Although 
the structure is reported as a 3.2 Å structure, the extra 2.9 Å reflections were 
included in the solution and aided in defining the electron density more accurately 
than would normally be expected from a 3.2 Å data set. The crystallographic 
statistics are shown below in table 3-1, and full details about solving the structure 




Data collection   
  Number of crystals 20  
  Space group P 21 
Cell dimensions   
  a, b, c (Å) 119.3, 64.6, 131.2 
  a, b, g (°) 90.0, 91.7, 90.0 
  Resolution (Å) 41 – 3.2 (3.26 – 3.20) 
  Rmerge  (%) 15.6 (55.3) 
  <I>/<σI> 10.8 (1.8) 
  Completeness (%) 91.2 (53.9) 
  Redundancy 6.5 (5.0) 
    
Refinement   
  Resolution (Å) 41 – 3.2 
  No. reflections 31075 (1557 in test set) 
  Rwork/Rfree  (%) 22.6 / 27.8 
  No. atoms 10,275  
  No. protein residues 1,318  
  Anisotropic B tensor B11= -6.4 / B22= 3.8 / B33= 2.6 / B13= 1.9 
Unmodelled sequences   
  β2 adrenergic receptor 29, 176-178, 240-264, 342-365 
  Gs α 1-8, 60-88, 203-204, 256-262 
  Gs γ 1-4, 63-68 
  T4 lysozyme 161 
Average B-factors (Å2)   
  β2 adrenergic receptor 131.6  
  Gs α, ras domain 81.4  
  Gs α, helical domain 121.9  
  Gs β 63.0  
  Gs γ 83.6  
  Nanobody 35 59.5  
  T4 lysozyme 112.1  
R.m.s. deviation from ideality   
  Bond length  (Å) 0.007  
  Bond angles (°) 0.71  
Ramachandran statistics   
  Favored regions (%) 95.4  
  Allowed regions (%) 4.6  
  Outliers (%) 0  
 
Table 3-1. Crystallographic statistics for T4L-β2AR-Gs-Nb35 complex crystals. Highest shell 
statistics are in parentheses. All purification tags and the listed regions were omitted from 




The Rwork and Rfree factors for the refinement of the crystal structure are typical or 
slightly below average for a structure of 3.2 Å,98 indicating with a well optimized 
model and consistent with the fact that some reflections of higher resolution than 3.2 
Å were included in the final data set. It also help that the crystal contains many 
regions of well ordered and well packed domains, such as the lysozyme and 
nanobody that were added to promote crystallography and the very stable β-
propeller fold of the Gβ subunit. The quite low r.m.s. deviation from ideality statistics 
are a function of our conservative strategy while model building. We generally 
preferred to keep bond lengths and angles close the average values since there 
were no truly high-resolution structures available of the biologically interesting 
molecules in the crystal to accurately guide modeling of non-standard residue 
orientations.  
3.3 – Crystallographic packing. 
The β2AR-Gs complex packed into a crystal with alternating flat layers of lipid and 




Figure 3-2. Crystal packing lattice of the β2AR-Gs complex crystals. The receptor, shown in 
green, packs into the lipid layers, indicated as grey squares. All other proteins pack into the 
soluble layer of the crystal. Figure reprinted from Rasmussen et al.86 
In the aqueous domain the various proteins are packed very tightly, utilizing many 
crystal contacts that formed with residues from the nanobody and lysozyme proteins, 
as expected. Only the transmembrane part of the receptor packed into the lipid 
domain of the crystal, with the receptors spaced widely apart from each other. 
Absolutely no contacts are made between adjacent receptors in the crystal, which is 
consistent with previous findings from our lab that a single receptor is sufficient to 
activate a G protein.77, 80, 81 Also, the lack of crystal contacts between the receptor 
and the rest of the lattice results in relatively high B-factors for the receptor 





Figure 3-3. B-factor heatmaps of active-state β2AR crystal structures. Blue residues 
represent the lowest B-factors and red residues are the highest B-factors. A) B-factors of the 
β2AR-Gs complex structure (PDB 3SN6). B) B-factors of the β2AR-NB80 complex structure 
(PDB 3P0G). 
It can also be seen that the extracellular portion of the receptor has particularly high 
B-factors, which makes detailed conclusions about the side chain orientation in 
receptor’s ligand binding site difficult. However, comparison of this structure with the 
structure of the nanobody 80 bound receptor, with was crystallized with the exact 
same ligand, allows us to determine that the overall shape of the ligand binding site 
is very similar between the two structures and almost all the differences between 
them are in the G-protein binding intercellular half of the receptor. One can also see 
that the α-helical domain of the Gα subunit also has somewhat elevated B-factors 
relative to the rest of the G protein, which is possibly a reflection of its overall 
increased mobility after nucleotide loss, which is discussed more in the context of 




3.4 – Overview of structure.  
The overall structure is consistent with previously determined biochemical 
information about the GPCR-G protein complex. Techniques like electron 
paramagnetic resonance99 and fluorescence quenching100 have shown that that 
activation of the receptor causes large movements of the cytoplasmic side of  
transmembrane helix 6 (TM6) away from the core of the receptor. The complex 
structure also shows a 14 Å outward movement of TM6. This movement creates a 
large binding pocket on the intercellular face of the receptor, in which the C-terminus 
of the Gα subunit binds. Work with domain swapping of different Gα subunits,101, 102 
NMR and peptide binding,103 mutational analysis,104 and more recently 
crystallography105 has established that the C-terminus of the Gα subunit and the cleft 
opened by TM6 movement are the primary, though not the only, regions of 
interaction between the receptor and G protein. Both the Gα and Gβγ subunits are 
present in the structure, which we expected because both subunits were found in an 
approximately 1:1:1 ratio of Gα : Gβγ : receptor during our purification (section 2.11) 
and because activation of the Gα subunit has been shown to be quite in absence of 





Figure 3-4. Overview of the β2AR-Gs crystal structure. Figure modified from Rasmussen et 
al.86 Please see text for details. 
A genuine surprise in the structure was the extremely large movement of the Gsα α-
helical domain relative to the Ras-like domian. The center of the domain moves by 
about 45 Å, with the individual residues moving by 12 to 86 Å. The domain is rotated 
by 127° around the hinge region where it is attached to the Ras-like domain. The 
movement removes the sugar binding part of the GTP/GDP binding site on the Gα 
subunit, disrupting it in a manner consistent with the nucleotide-free nature of the 
β2AR-Gs complex.77 Previously, most proposed models of G protein activation 
assumed little or no movement of the α-helical domain, instead suggesting that 
nucleotide entered and exited the Gα subunit near the switch I and II domains after 
Gβγ-aided movement of the β3-α2 loop away from the nucleotide binding site.107 




domain are associated with GPCR-stimulated nucleotide exchange108, 109 and that 
the nucleotide-free receptor and G protein complex is quite conformationally 
flexible.110 Our data clearly support the latter findings.   
The complex structure also shows how nanobody 35 (NB35) binding enhances the 
stability of the complex and prevents dissociation. It binds at the interface of both the 
Gα and Gβ subunits, with the complementarity determining region (CDR) 1 
interacting primarily with Gβ and a long CDR3 loop interacting with both Gα and Gβ. 
These interactions help hold the two subunits together, keeping the complex intact 
for the several days that are needed for crystallization. The nanobody also prevents 
GTP binding (shown in section 2.13) by forcing the loop 2 region of the Gα subunit to 
remain bound to the β subunit, keeping it in the inactive conformation that cannot 
bind the third phosphate group of GTP.  
3.5 – Structural analysis of the receptor in the receptor-G protein complex. 
One of the most important questions that this structure helps answer is how the 
binding of the β2AR’s natural agonists, epinephrine and norepinephrine, in the 
extracellular part of the receptor leads to the opening of the G protein binding site in 
the intercellular part of the receptor. No single dataset can tell us everything, but the 
structure of the β2AR-Gs complex and the structure of the NB80 bound β2AR97 show 
the receptor’s fully activated G protein-stimulating conformation. That information, 
combined with a structure from the highly similar β1AR co-crystallized with 
isoproterenol,111 a synthetic epinephrine derivative, gives us a very detailed look into 
the structural changes that happen in response to epinephrine binding. Comparison 
of these activated or partially activated conformations with the inactive structure of 
the receptor bound to the inverse agonist carazolol52, 94 or antagonist alprenolol112 
shows a significant tightening of the binding pocket is associated with agonist 
binding. As shown in figure 3-5A below, binding of both alprenolol and the agonist 
BI-167107 involves interaction of the drugs’ hydroxyethylamine backbone to residue 
D133 on transmembrane domain 3 (TM3) and N312 on TM7. At the other end of the 
binding pocket, TM5 moves and rotates inward, allowing S203 and S207, which are 
both on the TM5 helix, to interact with the hydroxyl and amine of the BI-167107 
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benzoxazinone ring. For native agonists, the catechol hydroxyls would make a 
similar reaction, shortening the S207-D113 distance from 12.0 Å to 11.4 Å. In 
contrast, it can be seen that for alprenolol, there are neither any interactions to 
stabilize the TM5 movement, nor are there any steric hindrances to prevent it, true to 
the drug’s nature as a neutral antagonist. 
 
Figure 3-5. Hydrogen bonding of β2AR ligands. A) BI-167107 and the NB80-bound β2AR are 
drawn in green, and the antagonist alprenolol bound to an inactive β2AR structure is drawn 
in orange. B) BI-167107 and the NB80-bound β2AR are drawn in green, and the inverse 
agoinist carazolol bound to an inactive β2AR structure is drawn in cyan. 
The tightening of the receptor ligand binding pocket upon activation is slightly more 
evident when the BI-167107 bound active receptor is compared to the inactive 
carazolol bound receptor. The S207-D113 distance shortens by ≈0.8 Å, shown 
above in figure 3-5B. One of the major differences between the antagonist alprenolol 
and the inverse agonist carazolol is that while alprenolol has no hydrogen bonding 
interactions with S203, carazolol does hydrogen bond with the residue, but in the 
inactive position. This prevents the inward movement of the residue during receptor 
















The binding site for the adrenergic receptors (and many similar hormone binding 
GPCRs) is buried partway within the transmembrane region of the protein, so upon 
activation the tightening of the binding pocket restricts the ability of ligands to freely 
exchange between the pocket and the bulk solvent. This effect is explored in detail 
using traditional pharmacological methods in chapter 4, but the structures of the 
active and inactive receptor easily show why this phenomenon occurs. In figure 3-6 
below, the surface representation of the active and inactive receptors are shown. In 
the active structure (figure part A), the atoms that lie above the binding pocket move 
close enough together to prevent the agonist from leaving the binding site. They 
would likely also prevent ligands from entering the binding site if the receptor 
became activated through basal activity. In particular, the structure shows that the 
TM7 movement during activation breaks a salt bridge that between residues K305 
(on TM7) and D192 (on ECL2), and instead K305 forms a hydrogen bond with the 
backbone carbonyl of F193 (on ECL2) right above the binding site. This aids the 
movement of F193 and Y308 (on TM7) towards each other, further capping off the 
catechol binding-part of the ligand binding site from bulk solvent. The breaking of the 
K305-D192 salt bridge during activation is also corroborated with solution state NMR 
studies which demonstrated that an ionic bond involving K305 is broken in an 
agonist-dependent manner.113 In comparison, the inactive conformation of the ligand 
binding pocket (figure part B) has a much larger opening for the ligand to diffuse in 
and out of. Unlike the F193-K305 hydrogen bond, the D192-K305 salt bridge in the 
inactive receptor lies off to the right side of the view shown and is not expected to 




Figure 3-6. Tightening of the β2AR ligand binding pocket upon activation. A) Surface detail of 
activated receptor binding pocket. Shown is agonist BI-167107 in NB80-bound β2AR (PDB 
3P0G). B) Surface detail of inactive receptor binding pocket. Shown is inverse agonist 
carazolol in β2AR (PDB 2RH1).  
The tightening of the ligand binding pocket also promotes movements of the 
transmembrane helices that ultimately causes the G protein binding site to open on 
the intercellular face of the receptor, diagrammed below in figure 3-7. The rotation of 
the extracellular half of TM5 caused by agonist binding also pulls TM4 in slightly 
closer toward the ligand, allowing for the formation of a new hydrogen bonding 
contact between Y199 and the backbone carbonyl of T164. At the proline kink of 
TM5, the helix rotates around the mostly stable TM3 like the pivot of a cantilever, 
causing the intercellular half of the helix to move away from the receptor core by 
about 4 Å. This movement is followed and amplified by TM6, which packs along TM5 
and moves outward by about 12-14 Å at its intercellular end. The shifting positions of 
TM3, TM4, and TM5 allow the ICL2 loop to adopt a helical conformation, which is 
stabilized by a new hydrogen bond that forms between the aspartate of the DRY 
motif on TM3 and Y141 on the ICL2 helix. TM7 then moves in towards the core of 
the receptor by ≈1-2 Å along its length, a movement with is aided by agonist binding 
to N312. The tyrosine residue from the conserved NPxxY motif on TM7 also bulges 
into the upper part of the gap vacated by TM6 movement, helping to stabilize the 




Figure 3-7. Diagram of structural changes during receptor activation. The inactive β2AR is 
drawn in cyan (PDB 2RH1) and the active β2AR is drawn in green (PDB 3SN6). Receptors 
are aligned using residues 50-120, the most stable part of the receptor that includes TM2 
and parts of TM1 and TM3. Numbered features are as follows: 1) Rotation of TM4 and TM5 
caused by agonist binding. 2) Formation of hydrogen bond between Y199 and T164. 3) TM5 
pivots against TM3 at the helix’s proline kink. 4) Intercellular end of TM5 and TM6 moves 
outward to form G protein binding cleft. 5) ICL2 adopts a helical conformation stabilized by a 
hydrogen bond between D130 and Y141. 6) TM7 moves in towards the core of the receptor. 
7) Y326 of the NPxxY motif moves 7.0 Å into part of the gap created by TM6 movement. 
Please see text for additional details.  
The movement of TM5&6 is also helped by rearrangement of the hydrophobic 
residues near the proline kink of TM5. In the inactive receptor, I121 from TM3 packs 
side-by-side with F282, separating it from P211 on TM5. In the activated receptor, 
I121 moves up towards the ligand binding site and F282 packs underneath it, 
moving much closer to P211 and allowing TM6 to rotate along with TM5. These 




Figure 3-8. Hydrophobic core repacking during receptor activation. Inactive β2AR is drawn in 
blue (PDB 2RH1) on the left, and active β2AR is drawn in orange (PDB 3P0G). Figure taken 
from Rasmussen et al.87 
Overall, these TM domain rearrangements lead to an opening of a large cleft 
between TM5&6 and the core of the receptor, in which the C-terminus of the Gα 
subunit can bind. Both the NB80 and G protein bound structures show how 
activation involves many sections of the receptor that are highly conserved in the 
GPCR family, such as the DRY and NPxxY motifs, demonstrating the reason that 
these sequences are under evolutionary pressure to remain unchanged. 
3.6 – Structural analysis of the receptor-G protein interface. 
The interface where the β2AR and Gαs proteins interact has several structural 
features that show previously unknown aspects of how the receptor communicates 
an activation signal to the G protein. As expected, the G protein's C-terminal helix 
binds to the pocket formed from TM5&6 movement, but the structure also shows a 
2-turn extension of the TM5 helix that would not have been able to form in the 
inactive structures due to the presence of a T4 lysozyme domain fused between 
TM5 and TM6 that replaced residues in the receptor's intercellular loop 3 (IL3). The 
TM5 helix extends all the way over the Gα subunit C-terminal helix and terminates 
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very close to an L-shaped pocket formed by the α4 helix and part of the loop 
between the α4 and αG helices, shown below in figure 3-9. Although the shape of 
the pocket is closely contoured to fit the residues of the TM5 helix with many 
residues within 4 Å of one another, there are no obvious hydrogen bonding or ionic 
interactions that would enhance the binding of TM5 to the Gα subunit in this region. 
Instead, it could be that the most important structural aspect in this region is that 
there are not any steric clashes between the receptor and G protein surfaces. This is 
discussed more in the context of G protein subtype-specificity in section 5.7. 
 
Figure 3-9. Interface between TM5 of the receptor and the α4-αG region of the G protein. 
The receptor is drawn in green with a grey mesh indicating the Van der Waals surface of the 
residues. The Gαs subunit is drawn as an orange Van der Waals surface. 
The Gα subunit C-terminal helix interacts extensively with the activated receptor, 
contributing the majority of the 2,576 Å2 of total buried surface area of the β2AR-Gαs 
interface. There are two different regions and modes of interaction between the C-
terminus and the receptor, drawn below in figure 3-10. In the region shown in figure 
section A, the middle part of the C-terminal helix forms an extensive ionic and 
hydrogen-bonding network with residues along the receptor TM5 helix and the 
backbone amines of the TM3 helix. These interactions involve 4 side chains from the 





negative charges that would be expected to bind relatively strongly together, but 
would also have to be fully solvated when the two proteins are not interacting.  
 
Figure 3-10. Gαs C-terminal helix interactions with the activated β2AR. A) Network of 
charged and polar residues that interact via ionic and hydrogen bonds in the middle region 
of the C-terminal helix. B) Hydrophobic interactions that dominate the interaction between 
the extreme C-terminal end of the helix and the core of the receptor. Figure reprinted from 
Rasmussen et al.86 
At the end of the Gα C-terminus, the interaction between the receptor and the G 
protein is much more hydrophobic in character. The C-terminal helix extends until 
the last three residues, which wrap back around the helix as it nears the TM7-H8 
turn of the receptor to form a cap at the end of the helix. The binding pocket that 
surrounds this region of the C-terminus is formed by TM6, TM5, and TM3 and is 
lined with mostly alanine and leucine/isoleucine residues, which pack along a patch 
of three leucine residues on the C-terminal helix and cap. The interaction is shown 
above in figure 3-10B.  
Another very important interaction between the receptor and G protein shown below 
in figure 3-11 involves F139, which is located at the beginning of the ICL2 helix and 
sits in a hydrophobic pocket formed by Gαs H41 at the beginning of the β1-strand, 
V217 at the start of the β3-strand and F376, C379, R380 and I383 in the C-terminal 
helix. This interaction is likely to explain the finding that the β2AR mutant F139A has 
severely impaired coupling to Gs.114 Also of interest, the ICL2 helix is stabilized by 
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an interaction between D130 of the conserved DRY sequence and Tyr 141 in the 
middle of the ICL2 helix.  
 
Figure 3-11. Interactions of ICL2 that stabilize Gαs binding. Tyrosine 141 binds to the 
aspartate of residue of the receptor DRY motif to stabilize formation of the ICL2 helical 
conformation, and phenylalanine 139 binds a hydrophobic pocket on Gαs formed between 
the C-terminal helix and the β1-β3 strands. Figure reprinted from Rasmussen et al.86 
Overall, these interactions lead to stabilization of the activated conformational state 
of the receptor and a nucleotide-free Gα subunit. The interaction surface between 
the two proteins includes a large amount of buried surface area and numerous 
hydrogen and ionic bonds. All these interactions are not accessible on the inactive 
receptor or the nucleotide-bound G protein, so they serve to stabilize the 
conformational states of the proteins that pass the activation signal from the agonist 
binding site of the receptor to the nucleotide binding site of  the G protein.  
3.7 – Structural analysis of the G protein in the receptor-G protein complex. 
The extensive interactions between the β2AR and Gαs Ras-like domain cause 
several structural re-arrangements in the Gα subunit that ultimately lead to 
nucleotide loss. The most direct effect of receptor binding is a displacement of the C-
terminal helix by 6 Å towards the receptor as it projects into the transmembrane core 
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of the β2AR, accompanied by a rotation of the helix by about 30°, shown below in 
figure 3-12A.  
 
Figure 3-12. Structural re-arrangements of the Gαs C-terminal helix in the β2AR-Gs 
complex. A) The Gαs subunit from the β2AR–Gs complex is drawn in orange, and it is 
aligned with the GTPγS-bound Gαs drawn in grey,115 showing overall movement of the helix 
into the transmembrane core of the receptor. The helix moves by about 6 Å towards the 
receptor and rotates by about 30°. B) The loop between the C-terminal helix and the β6 
strand contains the G-box sequence 5 and forms part of the guanine base-binding portion of 
the nucleotide binding site. C) Movement of the helix disrupts the structure of loop, which 
destabilizes nucleotide binding. Figure reprinted from Rasmussen et al.86 
The movement of the C-terminal helix disrupts the position of the loop that links the 
beginning of the helix to the β6 strand. When GTP or GDP is bound to the Gα 
subunit, this loop interacts with the guanine ring of the nucleotide. Residues A366 
and V367 provide a hydrophobic surface that interacts with the π-cloud of the ring, 
and the backbone amide of A366 forms a hydrogen bonding interaction with the 
guanine nitrogen base carbonyl, shown above in figure 3-12B. Upon movement of 
the C-terminal helix, these two resides are forced to adopt new positions as shown 





helix, with the α-carbons of the alanine and valine residues moving 7.7 and 6.8 Å 
away from their nucleotide-binding positions, respectively.  
Another change in the Gα conformation is caused by the binding of F139 on the 
receptor ICL2 to the hydrophobic pocket on the Gα subunit formed by residues from 
the C-terminal helix and the β1 and β3 strands, shown in detail above in figure 3-11. 
The binding of this residue pulls the β1, β2, and β3 strands up towards the receptor 
by 2-3 Å, a motion that is helped along by the rotation of the c-terminal helix, shown 
below in figure 3-13A. 
 
Figure 3-13. Conformational changes involving the β1 strand of the Gαs subunit. Gαs bound 
to GTPγS is drawn in grey (PDB 1AZT), showing the position of the β1 strand and P-loop of 
the GTP or GDP bound state. Drawn in color is the nucleotide-free Gαs subunit from the 
β2AR-Gs structure (PDB 3SN6). The β1 strand is colored in cyan, the G-box consensus 
sequences are colored in magenta, and the P-loop residues are colored in bright green. A) 
The β1 strand and nearby β2 and β3 strands are all moved in towards the core of the fold 
upon receptor binding. B) The warping of the β1 strand pushes the position of the P-loop 
about 2.5 Å towards the nucleotide, disrupting binding of the GTP or GDP β-phosphate. 
Although the movement of the β1 strand is not large, it is enough to warp the 
positioning of the β1-α1 loop, shown in figure 3-13B. This loop, also known as the 
"P-loop," contains the G-box sequence 1 that binds the β-phosphate of the GTP or 
GDP molecule. The position of the loop is shifted towards the guanine-base end of 
the binding pocket by about 2.5Å. However, this change in position is probably not 
as important as the overall flexibility that is imparted on the region by the interaction 
A) B)  
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with receptor. As discussed below in section 3.8, we also observed a dramatic 
increase in deuterium exchange of the β1 strand peptide, indicating increased 
disorder and solvent accessibility. Our interpretation of these data is that the 
movement of the β1-β3 strands associated with F139 binding from the receptor ICL2 
domain is incompatible with the proper positioning of the P-loop relative to the rest of 
the nucleotide binding site, leading to a situation where the GTP/GDP β-phosphate 
binding and ICL2 binding to the Gα subunit are mutually exclusive. 
The final difference between the nucleotide-free Gαs structure in the β2AR-Gs 
complex and the GTPγS bound Gαs is the most dramatic change seen in the whole 
structure. The α-helical domain of the Gαs is normally positioned next to the Ras-like 
domain at the site of nucleotide binding, forming a loop that packs around the ribose 
group of the nucleotide and positioning the catalytic residue R201 next to the β- and 
γ-phosphates, shown below in figure 3-14A. However, in the complex structure the 
center of the α-helical domain moves away by 45 Å, rotating by 127° around the 





Figure 3-14. Movement of the Gαs α-helical domain in the β2AR-Gs complex. Gαs bound to 
GTPγS is drawn in grey (PDB 1AZT), and drawn in yellow is the nucleotide-free Gαs subunit 
from the β2AR-Gs structure (PDB 3SN6). When bound to GTP or GDP, the domain packs 
against the nucleotide’s ribose group, forming a portion of the binding site. The position of 
the α-helical domain in the nucleotide-free Gαs subunit of the β2AR-Gs complex structure is 
much different, far removed from the nucleotide binding site. Figure reprinted from 
Rasmussen et al.86 
The movement of the Gαs α-helical domain disrupts the nucleotide binding site and 
contributes to the loss of nucleotide caused by binding to the receptor. Based on 
electron microscopy work described below in section 3.9, We propose that the 
observed position of the α-helical domain in the β2AR-Gs complex crystal is only one 
of many positions relative to the Ras-like domain that it can take, and that in solution 
the domain is expected to sample the alternate positions rapidly. This view is 
supported by recent EPR data taken using transducin and rhodopsin, where the 
distance distribution between the tranducin α-helical domain and the Ras-like 
domain broadens out and increases on average when the transducin interacts with 





3.8 – Dynamics of the receptor-G protein complex determined by deuterium 
exchange. 
In addition to crystallizing the β2AR-Gs complex, we also performed studies on the 
samples using deuterium exchange by mass spectrometry (DXMS). The sample was 
incubated in deuterated buffer, quenched in acid, digested with an immobilized 
pepsin column, and finally analyzed by LC-MS/MS to determine the identity of each 
peptide as well as the number of incorporated deuterium atoms (full methods given 
in section 6.15). The technique can count the total number of deuteriums on each 
peptide, but cannot localize them to a specific residue. Very few peptides from the 
receptor were recoverable in the assay without greatly sacrificing the yield of G 
protein peptides, so we chose to optimize the assay to obtain good sequence 
coverage for G protein subunits. For the Gα subunit, 80% of the sequence was 
measured by at least one peptide, and for the Gβγ subunit, the coverage was 75%. 
The raw data was converted to % deuteration values based on the theoretical 
maximum number of exchangeable hydrogen atoms on each peptide. Data for three 
different time points of deuterium incubation are shown below as a ribbon diagram 
for the Gαs subunit in figure 3-15 and for the Gβγ subunits in figure 3-16. The DXMS 
measurements were repeated for samples of heterotrimer alone, the β2AR-Gs 
complex, and the complex treated under two conditions that are known to disrupt the 
receptor-G protein coupling. The addition of GDP plus AlF3 mimics the binding of 
GTP and fully dissociates both the G protein from the receptor and the Gα subunit 
from the Gβγ subunit.116 The addition of GDP by itself allows the coupling reaction 
between the receptor and the G protein to run in reverse, yielding free receptor and 





Figure 3-15. Ribbon diagram of the hydrogen-deuterium exchange levels of Gαs.  A) 
Exchange levels in heterotrimer alone. B) Exchange levels in the β2AR-Gs complex. C) 
Exchange levels in the β2AR-Gs complex treated with GDP/AlF3. D) Exchange levels in the 
β2AR-Gs complex treated with GDP. Indicated is the amino-acid sequence and secondary 
structure. Exchange levels are color-coded according to the indicated heat map. Residues 
not colored represent fragments where no mass information was obtained. Figure reprinted 




Figure 3-16. Ribbon diagram of the hydrogen-deuterium exchange levels of Gβγ.  A) 
Exchange levels in heterotrimer alone. B) Exchange levels in the β2AR-Gs complex. C) 
Exchange levels in the β2AR-Gs complex treated with GDP/AlF3. D) Exchange levels in the 
β2AR-Gs complex treated with GDP. Indicated is the amino-acid sequence and secondary 
structure. Exchange levels are color-coded according to the indicated heat map. Residues 
not colored represent fragments where no mass information was obtained. Figure reprinted 
from Chung et al.97 
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An overall visual survey of the data shows that there are only a few domains on 
either of the proteins that exchange over 50% of their available hydrogen atoms in 
the time frame of the study. These regions include domains that are known to be 
relatively flexible on the Gα subunit, such as the hinge region between the Ras and 
α-helical domain and the C-terminus. Interestingly, a large amount of exchange was 
found on the loop that contains the αG helix of the protein, one of the more variable 
regions for the different α subunits. On the Gβ subunit, a stretch of residues that 
form an extended random coil near the C-terminal region of the Gγ subunit are also 
rather flexible. Most curiously, two loop regions in the Gα α-helical domain and the 
Gβ subunit, shown below in figure 3-17, also showed completely unexpected high 
basal levels of exchange and a small increase in exchange when they were bound in 
the nucleotide-free receptor-G protein complex. The regions are in very close 
proximity to each other in the complex crystals, although they do not pack against 
one another. However, the DXMS data was obtained without NB35 bound, so the 
relative position of the Gα and Gβ domains may be more flexible in these samples 
compared to the nanobody-bound sample used for crystallography. It is tempting to 
speculate that the two domains may transiently interact or collide, and this might 
lead to the elevated deuterium exchange. However, we know of no studies where an 
interaction like such has been proposed, and so at this point we show these data 
only as an interesting finding and not as any basis for a particular interpretation of 




Figure 3-17. Regions on the Gα α-helical domain and the Gβ subunit that show 
unexpectedly high deuterium exchange values. The regions are drawn in red, with the Gα 
subunit in green and the Gβ subunit in cyan. 
There are also several other regions on the Gα subunit that do not exchange 
hydrogens with solvent much in a nucleotide-bound conformation, but do so when 
the protein is nucleotide-free in the β2AR-Gs complex. They are best seen in figure 
3-18 below, where the data from the 100 second timepoint are used to make a 
heatmap showing the difference in deuterium exchange levels between the Gα 




Figure 3-18. Pairwise comparisons of deutrium exchanged levels for Gαs under different 
conditions. A) Changes in DXMS measurements for Gαs in the β2AR-Gs complex compared 
to the Gs heterotrimer. B) Changes in DXMS measurements for Gαs in the β2AR-Gs 
complex caused by dissociation with GDP/AlF3. C) Changes in DXMS measurements for 
Gαs in the β2AR-Gs complex caused by dissociation with GDP alone. The changes in 
hydrogen-deuterium exchange (HDX) given as changes in the percentage of the theoretical 
maximum number of deuterons incorporated per peptide were mapped on to the crystal 
structure of Gαs based on the GTPγS bound form (PDB 1AZT) as indicated by included 
heatmap. Regions where no mass spectrometry data were obtained are indicated in grey. 
Figure reprinted from Chung et al.97 
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As expected, it can easily be seen in the figure part A that the residues next to the 
GDP/GTP binding site all increase their deuterium exchange levels when going from 
GDP bound heterotrimer to the nucleotide-free β2AR-Gs complex.  The opposite is 
true in figure parts B and C, where the β2AR-Gs complex is treated with GDP/AlF3 or 
GDP and the residues near the binding site all decrease their levels of deuterium 
exchange. These changes in the deuterium exchange levels of the nucleotide-
binding residues are consistent with a large increase in solvent accessibility and 
flexibility of the residues when the nucleotide is absent from the binding site.  
The DXMS data also show that the C-terminal region of the α-subunit is less flexible 
and solvent exposed in the β2AR-Gs complex, consistent with the position of the 
helix in the crystal structure, where is it bound in the transmembrane core of the 
receptor. When the complex is dissociated with GDP/AlF3, the opposite is true and 
the C-terminal residues return to the high basal rate of exchange. However, the 
addition of GDP alone is not as efficacious at enhancing the exchange rates on the 
helix, even though it is just as good at stabilizing the residues in the nucleotide 
binding pocket as GDP/AlF3 treatment. One possible explanation for this 
discrepancy is that there might be a transient, GDP-bound conformation of the G 
protein that can still interact with the receptor through its C-terminus. Several other 
labs have proposed such a pre-bound conformation,117, 118 and if it exists, it is likely 
to enhance response times for GPCR signaling by removing the need for G protein 
to diffuse to the receptor before it can interact. Nevertheless, it is likely that the GDP-
bound β2AR-Gαs complex is not very stable, because increased exchange at the C-
terminal helix could be observed following longer exchange durations or incubations 
at higher (but still physiological) temperatures. 
The most unexpected finding with the DXMS data was that the β1 strand of the Gα 
subunit, which links the N-terminal helix and the P-loop for the nucleotide-binding 
site, was found to undergo extremely rapid deuterium exchange in the β2AR-Gαs 
complex samples. Shown below in figure 3-19, the position of the β1 strand differs 
slightly from the GDP bound conformation, but by enough to disrupt the positioning 




Figure 3-19. Comparison of the structure and dynamics of Gαs in β2AR-Gαs complex with 
Gαi bound to GDP. The change in deuterium exchange levels from the Gs heterotrimer to 
the β2AR-Gαs complex is indicated according to the indicated heatmap. The structure of Gαi 
bound to GDP is shown in grey for comparison. Figure reprinted from Chung et al.97 
Given the extreme change in deuterium exchange levels, it seems likely that in 
solution the β1 strand is undergoing much more movement than is seen in the 
crystal structure. The β1 strand residues are very highly conserved in the Gα protein 
subtypes. For Gαs and Gαolf, the sequence is RLLLL, but in most receptors the 
arginine is substituted for a lysine residue. Evidently, this domain has evolved to be 
an important conformational link between the areas were the Gα subunit interacts 
with receptor and the phosphate binding loop of the nucleotide binding site. In this 
case, the DXMS data was crucial to determining this aspect of GPCR-mediated 
nucleotide exchange on the G protein, as the changes in the crystal structure were 
subtle and one would usually assume that a β-sheet would not normally be 
associated with such high flexibility.   
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3.9 – Analysis of the receptor-G protein complex by electron microscopy. 
The β2AR-Gs complex samples for crystallography were also studied by electron 
microscopy. For these studies, the sample was bound to a formvar-coated grid and 
negative stained with uranyl formate (full details given in section 6.16). The samples 
were all solubilized in MNG-3 detergent, which stays bound to the protein-detergent 
complex for very long periods of time after the detergent is diluted underneath its 
critical micelle concentration (cmc). Because of this, we can see significant density 
that corresponds to the MNG-3 micelle surrounding the receptor, making it look 
larger than its molecular weight would suggest. Unlike the receptor-bound micelles, 
the free micelles of MNG-3 rapidly dissociate when diluted underneath the cmc, 
which helped greatly to reduce the number of non-target particles in the EM images.  
Imaging of the complex shows a low-density electron map that agrees in general 
with the crystal structure of the complex. Shown below in figure 3-20, the 2D 
reprojections of the crystal structure appear very similar to the experimental EM 
data, with the exception that the EM data includes a large micelle of MNG-3 bond to 
the receptor. From the analysis of the class averages, we identified two major and 
distinct conformational subpopulations of the complex. One conformation, which 
accounted for about a third of the analyzed particles, includes clear density for the 
Gαs α-helical domain in an orientation similar to its position in GDP or GTP bound 
Gα subunits. For the other two-thirds of the particles, the density corresponding to 






Figure 3-20. Two-dimensional projection analysis of the T4L-β2AR-Gs complex in the 
nucleotide-free state. A) Raw EM image of detergent-solubilized T4L-β2AR-Gs complex 
embedded in negative stain (scale bar, 50 nm). B) Representative EM class averages of the 
nucleotide-free complex with the projection profile of the α-helical (AH) domain not visible 
(left), or visible on the Ras-like domain (right, AH indicated by arrow). Cartoon models that 
represent the conformations reflected by the EM averages are shown below the averaged 
images (scale bar, 10 nm). C) Reprojections (upper section) of the β2AR-Gs crystal structure 
(lower section) in the same overall orientation as figure part B reveal the identity of each EM 
density component. The crystal structure on the right shows the AH domain in the same 
position relative to the Ras-like domain as determined in the crystal structure of Gαs bound 
to GTPγS alone. Figure reprinted from Westfield et al.88  
The data were also used to construct a 3D map of the electron density of the two 
classes of particles. The maps are shown below in figure 3-21, with the ribbon 
representation of the constituent proteins superimposed in the density maps. Again, 
the maps are in good agreement with the crystal structure of the β2AR-Gs complex, 




Figure 3-21. Three-dimensional reconstructions of the T4L-β2AR-Gs complex in the 
nucleotide-free state. In the reconstruction to the left, the α-helical (AH) domain (orange 
ribbon) is shown in the same position as found in the docked crystal structure. Absence of 
sufficient density to accommodate this domain indicates that its position is highly variable in 
this particle population. In the reconstruction to the right, the AH domain is modeled within 
the available EM density right below the Ras-like domain of Gαs, as also suggested by the 
2D averages. Figure reprinted from Westfield et al.88  
In order to further determine what conformations the α-helical domain was taking in 
the two-thirds of the β2AR-Gs complex particles where it could not be localized, we 
incubated the samples with a nanobody that bound to the α-helical domain and 
increased its molecular weight. This nanobody, designated as nanobody 37 (NB37),  
was found to bind to the complex in the same screen that found NB35, but did not 
end up aiding the quality of the crystals significantly. However, it did prove to be 




Figure 3-22. 2D class averages of the T4L-β2AR-Gs complex bound to NB37. NB37 binds to 
the α-helical domain, indicated by an arrow, and allows identification and classification of 
several different positions of the domain. Figure reprinted from Westfield et al.88  
The relative location of the domain is variable, and can extend all the way from a 
position close to where it was found in the crystal structure to the position it adopts 
when a nucleotide is bound. We used these class averages to reconstruct a 3D map 
of the electron density for each of the variable α-helical domain positions. The maps 
are shown below in figure 3-23.  
 
Figure 3-23. Three-dimensional reconstructions of the T4L-β2AR-Gs complex with NB37 
bound to the α-helical (AH) domain. The Nb37-enhanced density of the AH domain (marked 
with an oval) shows variable positioning around the Ras-like domain of Gαs (scale bar, 5 
nm). Figure reprinted from Westfield et al.88  
With the aid of NB37 binding, the α-helical domain can be localized in the many 
different position shown. It is likely that the domain is actually fully flexible and can 
be found in all the positions along the trajectory of movement, but these particular 
structures are averages of similar conformations that were binned together because 
they were indistinguishable within the resolution limits of the technique. 
We also wanted to determine what factors stabilized the α-helical domain in its 
"normal" position packed against the Ras-like domain. To assess this, we subjected 
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a sample of the complex to several different treatments and measured how many of 
the imaged particles contained a stabilized α-helical domain, shown below in figure 
3-24.  
 
Figure 3-24. Nucleotide-dependent positioning of the Gαs AH domain. The distribution of 
particles with a distinct projection profile of the α-helical (AH) domain stabilized on the Ras-
like domain across different conditions is quantified (inset right, marked with a white dot. A 
class average of a particle with a nonvisible AH domain is shown for comparison, inset left). 
The presence of foscarnet and GDP significantly increases the number of particles with 
stabilized AH domain. Figure reprinted from Westfield et al.88  
Treatment with either NB35 or pyrophosphate did not seem to alter the distribution of 
α-helical domain positions significantly, but the addition of Foscarnet or GDP 
showed a clear increase in the number of particles with stabilized α-helical domains. 
GDP treatment caused partial dissociation of the complex, but enough particles were 
still intact to obtain the data shown. It is not surprising that GDP causes the α-helical 
domain to close, as the domain is normally positioned in that orientation when 
nucleotide is bound to the G protein. However, the most interesting finding is that 
Foscarnet also stabilized the domain. Foscarnet, or phosphonoformic acid, is a 
pyrophosphate mimic that is assumed to bind where the β-phosphate of GDP or 
GTP binds the P-loop of the Gαs subunit. We propose that the changes in the 
domain position distribution due to the drug is because it is stabilizing the phosphate 
binding part of the nucleotide-binding site without also requiring the guanine base-
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binding residues of the site to adopt their GDP or GTP bound position. This allows 
partial ordering of the nucleotide binding site without also requiring the Gαs C-
terminal helix to adopt its GDP/GTP bound position, thus allowing the extensive 
interaction between the receptor and the C-terminus to remain intact. However, it is 
unclear why pyrophosphate did not also show a similar effect the in experiment.  
We also imaged the complex after treatment with GTPγS, shown below in figure 3-
25. As expected, the complex rapidly dissociates. However, if the sample 
preparation was done quickly, the particles could be visualized in the various stages 
of disassembly. 
 
Figure 3-25. Dissociation of the β2AR-Gs complex with GTPγS. Representative class 
averages of the T4L-β2AR-Gs complex after rapid mixing with GTPγS (1 μM) and immediate 
stain embedding reveal both intact as well as partially or fully dissociated complexes (scale 
bars, 10 nm). Figure reprinted from Westfield et al.88  
Although this technique is not appropriate for detailed study of the dissociation 
pathway due to the difficulty of accurately identifying which particles belong to the 
various stages of dissociation, it does give us a general idea about the process. In 
particular, it can be seen that the Gαs and the Gβγ subunits dissociate from one 
another before the entire complex dissociates from the micelle. Unfortunately, it is 
not clear if the Gβγ subunit dissociates before the Gα-receptor interaction is broken, 
or if the entire G protein dissociates from the receptor before subsequently breaking 
apart as well. Such questions are likely best addressed by other techniques, such as 




3.10 – Section summary. 
 The data presented in the sections above give us a detailed view of how the 
activation signal carried by a GPCR agonist is transferred across the plasma 
membrane and causes the first step of the G protein activation reaction. As one of 
the main players of a large collaborative effort, my research has given the field much 
new information about the structure and dynamics of GPCR and G protein 
activation. We have shown the molecular interface between receptor and G protein, 
detailed the structural changes that happen during receptor-G protein interaction in 
atomic detail, and determined regions of the proteins that undergo changes in 
flexibility and position while the complex is in solution, free from artifacts of 
crystallization. The structural changes that we observed involved some domains of 
the proteins that have long been known to be involved in the interaction, but we also 
showed several previously unknown aspects of the activation process. Overall, this 
work is a major addition to the understanding of how GPCRs and G proteins function 








CHAPTER 4  
PHARMACOLOGY OF A RECEPTOR-G PROTEIN COMPLEX 
 
4.1 – Introduction. 
This section explores the nature of the activation signal that is passed during the 
interaction between receptor and G protein. We propose that the binding of the two 
proteins to one another in the manner described in chapters 2 and 3 is, in itself, this 
activation signal. This would imply that there is a negatively cooperative interaction 
between receptor ligand binding site and G protein nucleotide binding site in the 
receptor-G protein complex. If this is true, then not only would the G protein be 
forced to lose its bound GDP during interaction with the activated receptor, but the 
binding of a nucleotide-free G protein must also induce the receptor itself to adopt an 
activated conformation. As discussed in the main introduction, this relationship is 
classically seen as the appearance of a second, higher affinity binding site for 
agonists to receptors when their cognate G proteins are present in the samples. This 
capacity of G proteins to allosterically modulate agonist binding serves as the basis 
for the “ternary complex model” (TCM) between receptor, G protein, and agonist.119  
Shown in the following experiments, we find that formation of the G protein-receptor 
complex stabilizes a conformation of the receptor that restricts both access to and 
dissociation from the ligand binding site of the receptor for an antagonist, which we 
identify as the activated receptor conformation. We also show that GDP binding to 
the complex reverses this unique pharmacological signature of the activated 
receptor. Moreover, we show that a G-protein mimic, NB80, is able to force the 
receptor into this activated conformation and can use it to make significant progress 
towards finding a complete kinetic solution of how the activated receptor interacts 
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with ligands. These findings support the basic idea behind the TCM by linking the 
new structural information about receptor and G protein activation to both well 
known and underappreciated aspects of the receptor’s pharmacology.   
Most of the work shown in this chapter was produced by me, again with the 
exception that the receptor used throughout was made by Søren G. F. Rasmussen. 
Any other exceptions are noted in the text, including major contributions from 
Gisselle Vélez-Ruiz.  
4.2 – Nucleotide sensitivity of antagonist binding the β2AR-Gs complex. 
During the process of figuring out what we needed to do to get a sample of β2AR-Gs 
complex, described in chapter 2 above, we used the neutral antagonist 
[3H]-dihydroalprenolol ([3H]DHAP) to label our receptors. Initially, we expected the 
antagonist to bind fully to all samples no matter if they were complexed with the G 
protein or not, as it should not matter if the receptor is stabilized in the active 
conformation since antagonists should bind both active and inactive receptor states 
equally well. It became apparent, however, that this assumption was incorrect and 
that we were getting reduced levels of binding to the G protein-complexed receptor 
in our binding assays. To determine what was happing, a series of experiments were 
performed by Gisselle Vélez-Ruiz where a monomeric β2AR preparation in rHDL 
discs experiences G protein coupling and removal of free GDP through the addition 
of apyrase (full methods given is section 6.18), followed by re-addition of high 
concentrations of GDP. The capacity of [3H]DHAP to bind to the receptor was 




Figure 4-1. Binding of 2 nM [3H]DHAP to Gs-β2AR-rHDL samples. The samples were 
incubated with 100 nM GDP and then treated with apyrase for the indicated times. Following 
apyrase treatment, 100 μM GDP was added back to the samples. Data obtained by Gisselle 
Vélez-Ruiz with proteins purified by Søren G. F. Rasmussen and Brian DeVree. 
Counter to our initial expectations, removal of free GDP by apyrase decreases 
[3H]DHAP binding in a time-dependent manner. The release of nucleotide appears 
to be rate-limiting since apyrase is capable of completely hydrolyzing 100 μM GDP 
within 10 min under identical assay conditions, as determined by anion-exchange 
chromatography of the nucleotides (data not shown). Since no exogenous GDP is 
initially added, the GDP concentration before apyrase addition is equal to the 
concentration of G protein added to the mixture (~1-3 nM). If GDP is resupplied at 
high concentration (100 μM), the [3H]DHAP binding is partially restored, albeit not 
completely since apyrase will likely continue to degrade GDP during the entirety of 
the [3H]DHAP binding assay. To explore this effect further, Gisselle measured 
saturation isotherms (method given in section 6.22) on apyrase-treated Gs-β2AR 
complex samples that had been purified away from the remaining apyrase enzyme, 




Figure 4-2. The effect of apyrase treatment on [3H]DHAP binding to Gs and β2AR containing 
samples. A) Saturation binding analysis of [3H]DHAP to apyrase-treated, Gs-β2AR 
complexes in rHDL in the presence or absence of GTPγS. Data obtained by Gisselle Vélez-
Ruiz with proteins purifited by Søren G. F. Rasmussen and Brian DeVree. B) Binding of 2 
nM [3H]DHAP to β2AR and Gs reconstituted in vesicles, in membranes prepared from Sf9 
cells expressing β2AR and Gs, and in native membranes prepared from rat lung. Data 
obtained by Gisselle Vélez-Ruiz. 
The saturation curves suggest that [3H]DHAP binds with comparable affinities in the 
absence or presence of 10 μM GTPγS: 0.41 nM and 0.66 nM, respectively. 
However, uncoupling Gs from the β2AR with GTPγS results in a dramatic increase in 
the maximal number of [3H]DHAP binding sites (Bmax ≈ 16.6 fmol), compared to 
control (Bmax ≈ 5.5 fmol). A similar phenomenon can be seen in vesicle 
reconstitutions with model bilayers (prepared according to method 6.19), 
membranes prepared from β2AR and Gs-expressing Sf9 cells (prepared according 
to method 6.20), and even in native murine lung membranes (prepared according to 
method Sf9 cells growing in mid-log phase were infected at a multiplicity of infection 
of 0.5-1 with recombinant baculoviruses containing expression constructs for FLAG-
His10-mECFP-β2AR (CBAR) and Gs subunits. 48–60 hours later, the cells were 
pelleted by centrifugation for 10 min at 500 × g. They were resuspended in 1/10 the 
original culture volume of TBS buffer (25 mM Tris-Cl pH 7.4, 137 mM NaCl, and 3 
mM KCl ) + 1× PTT (35 μg ml−1 phenylmethanesulphonyl fluoride, 32 μg ml−1 tosyl 
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phenylalanyl chloromethyl ketone, 32 μg ml−1 tosyl lysyl chloromethyl ketone) and 1× 
LS (3.2 μg ml−1 leupeptin and 3.2 μg ml−1 soybean trypsin inhibitor). They were lysed 
by sonication and centrifuged at 500 × g for 10 min to pellet unlysed cells and nuclei. 
The supernatant was centrifuged at 35 min at 100,000 × g to pellet the membranes. 
The membranes were resuspended in 1/20 the original culture volume with low salt 
buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1× LS, 1× PTT), flash frozen with 
liquid nitrogen, and stored at −80°C until use. 
 6.21), shown above in figure 4-2B. The figure shows strong GTPγS-dependent 
increases in the number of [3H]DHAP binding sites, which provides support that the 
effect is not an artifact of the rHDL reconstitution but instead an intrinsic property of 
the β2AR and Gs proteins under nucleotide-depleted conditions. 
It is also well established that high-affinity agonist binding may be disrupted by 
guanine nucleotides binding to Gα subunits, and the triphosphate form is known to 
be more effective. Shown below in figure 4-3, we also found that GTPγS uncouples 
the nucleotide-free form of Gs from the receptor with lower apparent effective 
concentration than GDP (EC50 = 5.0 and 39 nM, respectively), as indicated by the 
capacity of the guanine nucleotides to increase [3H]DHAP binding. These values are 
slightly lower than previously reported ones for a somewhat similar experiment, 
where GTP and GDP were found to cause a β2AR-Gαs (the short isoform) fusion 
protein to uncouple with an EC50 of 50 and 80 nM, respectively.120 Although it is hard 
to directly compare the two experiments due to the different protein constructs used 
and the use of GTP instead of GTPγS, it seems clear that guanine nucleotides can 
start affecting nucleotide-free Gαs subunits in the mid to low nanomolar range of 




Figure 4-3. Concentration-dependent effect of nucleotides on 2 nM [3H]DHAP binding to 
nucleotide-free β2AR-Gs in rHDL particles. Samples were apyrase-treated and purified by 
gel filtration. Data obtained by Gisselle Vélez-Ruiz with proteins purified by Søren G. F. 
Rasmussen and Brian DeVree 
4.3 – Reduced antagonist binding the β2AR-Gs complex is a kinetic 
phenomenon. 
In principle, there are two ways that Gs might be able to affect the binding of ligands 
at the β2AR orthosteric binding site. One way is that the binding of the G protein 
stabilizes a conformation of the receptor that has a lower affinity for the ligand, in 
which case the ligand should act as an inverse agonist with regards to G protein 
activation. However, a large body of research shows that DHAP and its parent 
compound, alprenolol, are neutral antagonists121 or possibly weak partial agonists in 
some tissue systems,122 so such an explanation is unlikely to be the cause of our 
observed reduction in the number of [3H]DHAP binding sites. Instead, we 
investigated the second possibility, which is that the binding of the G protein does 
not cause any change in affinity for the ligand, but instead slows the kinetics of drug 
binding to timescales longer than the length of a typical binding assay itself.  
In order to test for kinetic phenomena as the basis of our observations of reduced 
[3H]DHAP binding, we used the nanobody NB80 which we had previously employed 
for crystallography purposes. NB80 behaves like a G protein mimic for the receptor 
and supports high affinity agonist binding.87 However, it is small, soluble, and has no   
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nucleotide binding activity, which makes it better for studying receptor activation than 
the much more complex G protein heterotrimer. Here, we use NB80 as a G protein 
surrogate to test whether forcing the receptor into the NB80-bound conformational 
state, with is very similar to the agonist bound, activated, and G protein bound state, 
also changes the kinetics of [3H]DHAP binding. Shown below, figure 4-4 and 4-5 are 
the association and disassociation, respectively, of [3H]DHAP from the β2AR in the 
presence of increasing amounts of NB80 (full methods given in section 6.24). 
 
Figure 4-4. Association of [3H]DHAP to β2AR-rHDL the presence of varying NB80 
concentrations. 5 nM [3H]DHAP was used and the data was fit to a biphasic association 
curve, given below in table 4-1. The data points shown are the averages of 3 replicates with 
the error bars indicating the SEM. 
 
Table 4-1. Rate constants and percent fast phase fitted values for figure 4-4. Rates 
constants are given in fM-1 min-1. 


































































Figure 4-5. Dissociation of [3H]DHAP to β2AR-rHDL the presence of varying NB80 
concentrations. 5 nM [3H]DHAP was used and the data was fit to a monophasic dissociation 
curve, given below in table 4-2. The data points shown are the averages of 3 replicates with 
the error bars indicating the SEM. 
 
Table 4-2. Rate constants and percent fast phase fitted values for figure 4-5. Rate constants 
are given in min-1. 
In the figure, the data are fit to a two phase association model and a single phase 
dissociation model. The fast phase of the association curves was constrained to be 
the same in all curves and is the rate of [3H]DHAP association to receptors that are 
unbound to NB80. At high concentrations of NB80, the kinetics of drug binding and 
release slows dramatically, suggesting that the activated conformation of the 
receptor does not allow drugs to enter or exit the orthosteric binding site. The effect 
is large. The sample with the highest nanobody concentration tested, 30 μM, would 
take about 14.5 hours to reach 95% of its equilibrium binding value, as compared to 
the sample without nanobody, which does so in only 10.5 minutes, or less than 
1/80th of the time.  
Although the crystal structures of NB80 and Gs bound β2AR both show very similar 
conformations, we wanted to be sure that the kinetic effect on ligand binding we 
obtained using NB80 was truly representative of the behavior of the Gs-β2AR 
complex. To do so, we prepared a sample of pure, nucleotide-free, and ligand-free 









































































































































Gs-β2AR complex in rHDL and tested the association kinetics of [3H]DHAP binding 
after the addition of guanine nucleotides, shown in figure 4-6 below (full methods 
given in sections 6.18 and 6.25).  
 
Figure 4-6. Association of 5 nM [3H]DHAP to β2AR-Gs complex in the presence of varying 
guanine nucleotide concentrations. Fitted rate constants are given below in table 4-3. The 
data points shown are the averages of 3 replicates with the error bars indicating the SEM.  
 
 
Table 4-3. Rate constants and percent fast phase fitted values for figure 4-6. Rate constants 
are given in min-1. 
It is clear that for [3H]DHAP association, the same general trend is evident for both G 
protein and NB80 binding. When either protein is bound to the receptor, it forces it 
into the activated conformation, which greatly restricts diffusion of the into the 
orthosteric binding site. However, when GDP or GTP is present, the G protein is 
able to dissociate from the receptor, leading to quick ligand exchange as the 
receptor has access to its full ensemble of conformational states. 
4.4 – Cooperativity of nanobody 80 and agonist binding.  
We also measured the extent of cooperativity between nanobody 80 and agonist 
binding using competition binding with [3H]DHAP as a radiolabel. An assay was 
performed where the full agonist (-)-epinephrine (EPI) added at increasing 































concentrations to samples of 15 fmol β2AR in rHDL in the presence of 2 nM 
[3H]DHAP and varying concentrations of NB80 (full methods given in section 6.23). 
This experiment was incubated for an extended amount of time (6 hours) in order to 
minimize the effect of the slow drug binding kinetics due to NB80 binding, described 
in section 4.3 above. The data are graphed below in figure 4-7. As expected, the 
presence of the NB80 dramatically increases the affinity of epinephrine by over 2 
orders of magnitude.  
EPI-NB80 binding cooperativity




























Figure 4-7. Competition binding of 2 nM [3H]DHAP and epinephrine (EPI) in the presence of 
NB80. The fitted Ki estimate values are given below in table 4-4.The data points shown are 
the averages of 3 replicates with the error bars indicating the SEM.  
 
Table 4-4. Ki estimate values for figure 4-7. Equilibrium constants are given in molar units. 
4.5 – Agonist enhancement of nanobody 80 affinity is primarily due to faster 
on rates. 
Despite our best efforts, we were unable to directly measure the binding of tritiated 
agonists (either epinephrine or 4-methoxyfenotrol) to the receptor in the presence of 




















interferometry, to measure the binding of NB80 in the presence of an agonist. We 
used a Blitz instrument (FortéBio) to determine how NB80 binds to receptors in rHDL 
discs. While the operation of the Blitz is not the focus of this section, a summary of 
its operation is appropriate given the novelty of the instrument and technique. Bio-
layer interferometry relies on using a specialized glass rod which is coated with a 
partially reflective reference surface and an immobilized layer of proteins. When 
white light is sent down the glass rod, the beam hits either the reference or protein 
layer, and is reflected back to the detector. Using inferometery, slight differences 
between the two reflected light beams are compared, and in this way changes in the 
optical density of the protein layer can be detected. In our setup, biotin-labeled rHDL 
discs are bound to a streptavadin layer immobilized on the glass rods, and the 
binding of NB80 to receptor incorporated into the discs is followed as a function of 
time. 
Previous work done by Jacob Mahoney from the lab has established that the 
association rate of NB80 to receptor increases dramatically when the agonist 
isoproterenol is bound to the receptor.123 For example, when no ligand is bound, the 
G protein mimicking nanobody binds with a rate constant of about 3.1 ˣ104. In 
contrast, when the receptor is bound to saturating amounts of isoproterenol, NB80 
binds much quicker, with a rate constant of 1.1 ˣ106. Overall, the affinity of NB80 for 
the receptor increases from 760 nM for binding to the unliganded receptor to 2.9 nM 
for binding an isoproterenol-saturated receptor. In other experiments, he also 
noticed when the receptor is bound to the inverse agonist ICI-118,551, negligible 
binding is detected.  
We wanted to confirm that the natural hormone agonist epinephrine (EPI) would also 
increase the rate of NB80 binding. Although we were unable to run full sets of 
experiments to optimize the assay for epinephrine and obtain a full characterization 
of NB80 binding, we were able to perform some initial trials that appear to confirm 




Figure 4-8. Kinetic binding assay of NB80 to β2AR in rHDL discs. A) Association of 1 or 10 
µM NB80 to receptor in the presence or absence of a saturating concentration of 
epinephrine. Differences in the maximal signal are due to non-specific binding of the 
nanobody to the glass rod, which finishes in the first 2 seconds of the traces. B) Dissociation 
of NB80 from receptor in the in the presence or absence of a saturating concentration of 
epinephrine. 
This data shows that the bound agonist causes 1 µM NB80 to be able to bind 
receptor at a rate faster than even 10 µM NB80 can bind to the unliganded recpetor. 
The effect of the ligand bound to the receptor on the dissociation rate of NB80, 
shown above in figure 4-8B, is much smaller compared to changes in the 
association.  
4.6 – Global modeling of receptor binding with agonist, antagonist, and 
nanobody. 
The data presented in the previous sections can tell us several qualitative aspects 
about the activated conformation of the receptor and how it interacts with G proteins 
and NB80, listed below: 
• Antagonist associates with the receptor very slowly when it is bound to either 
NB80 or nucleotide-free Gs.  
• Antagonist dissociates very slowly from the receptor when it is bound to 
NB80. 
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• The slow antagonist binding to the receptor due to interaction with nucleotide-
free Gs can be reversed with by re-addition of GDP or GTP. 
• NB80 binding cooperatively enhances the affinity of agonist (or possibly 
decreases the antagonist affinity). 
• Agonist binding cooperatively enhances the affinity of NB80. 
•  Most of the NB80 affinity enhancement is due to an increased rate of 
association. 
• The dissociation rates of NB80 from agonist bound receptor and non-ligand 
bound receptor are similar. 
We wanted to use these clues to build a full kinetic model of how the receptor 
interacts with antagonists, agonists, and NB80. At this point, we know the model 
cannot be fully optimized because we are not able to get direct binding data of an 
agonist to the receptor and because we need a fuller set of curves to define NB80 
binding in the presence of both agonist and antagonist. However, we do have 
enough data to prototype the overall strategy of the data analysis. In addition to 
giving us some partial indications of the validity of the model, starting on the 
modeling and analysis was also a way for me to learn the programming and 
numerical computation skills that are necessary for completion of such a project. 
This model takes advantage of our ability to use NB80 binding to manipulate the 
conformational state of the receptor in a way that simply is not possible with a 
heterotrimeric G protein. The model we used is identical in form to the extended 
ternary complex model (eTCM) of GPCR action, except that NB80 binds to the 
receptor instead of G protein. We chose to use a model based on the eTCM instead 
of the more thermodynamically complete cubic TCM model because we could find 
no indication that NB80 could actually bind to the inactive receptor. In this model, 
designated as model #1, we did not constrain any parameters to be identical to one 
another as we wanted to avoid making assumptions about the nature of the 




Figure 4-9. Model #1 used for global fitting of data. The bound agonist is represented by the 
symbol “Ag”, the bound antagonist is represented by the symbol “Ant”, the inactive and 
active conformations of the receptor are represented by the symbols “R” and “R*”, 
respectively, and the bound NB80 is represented by the symbol “Nb”.    
The set of rate equations that the model describes can be represented as the matrix 
equation d/dt (S) = MS where M is a 9×9 matrix of the rate constants and S is a 
vertical vector of the concentration of the states. The matrices are shown below in 
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Equation 4-1. M, the model matrix. The matrix describes the mass transfer relationship 






















































Equation 4-2. S, the state matrix. The matrix describes the concentrations of the different 




Because all our experiments were performed under pseudo-first-order conditions, 
we could solve any equilibrium binding problem by finding the eigenvectors of the 
model matrix. Full details about the equilibrium solving method are given in section 
6.29. Kinetic binding problems were solved by first calculating the initial distribution 
of states by assuming full equilibration with the given conditions before the reaction 
was started, followed by numerical integration of the rate equations given by d/dt (S) 
= MS. Full details about the kinetic solving method are given in section 6.30. Initial 
estimates for rate constants and other experimental variables were determined by 
analysis of the individual experiments and knowledge of several equilibrium 
constants. The initial estimates used for optimizing this model are given below, in 
table 4-5. 
k1 1.0 ˣ108 k-1 1.0 ˣ101 
k2 1.4 ˣ108 k-2 7.0 ˣ10-2 
k3 3.0 ˣ106 k-3 3.0 ˣ105 
k4 3.0 ˣ106 k-4 3.0 ˣ107 
k5 3.0 ˣ106 k-5 3.0 ˣ107 
k6 1.0 ˣ106 k-6 5.0 ˣ10-4 
k7 1.0 ˣ106 k-7 5.0 ˣ10-4 
k8 1.0 ˣ105 k-8 2.0 ˣ10-2 
k9 1.0 ˣ105 k-9 2.0 ˣ10-2 
k10 1.0 ˣ105 k-10 2.0 ˣ10-2 
k11 1.0 ˣ106 k-11 5.0 ˣ10-4 
k12 1.0 ˣ106 k-12 5.0 ˣ10-4 
 
Table 4-5. Initial estimates for the optimization of model #1.   
A custom Python program was designed to perform the data fitting and global 
optimization. The program weighted each curve to a similar extent, so that there was 
information from as many experimental conditions and measurements as possible 
incorporated in the final goodness-of-fit value. Full details on the program are given 
in section 6.28. The data shown in figures 4-4 through 4-8 were fitted to the model 
and used to optimize the values for the 24 rate constants, determined with repeated 
rounds of simulated annealing. The best solution found so far is given below in table 
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4-6. Also shown are the calculated microequlibrium constants for each binding or 
conformational change step in the model. 
k1 8.33 ˣ106 k-1 2.73 ˣ101 K1 3.28 ˣ10-6 
k2 7.87 ˣ107 k-2 4.97 ˣ10-2 K2 6.31 ˣ10-10 
k3 6.08 ˣ104 k-3 8.61 ˣ102 K3 1.42 ˣ10-2 
k4 1.53 ˣ105 k-4 1.91 ˣ105 K4 1.25 
k5 9.61 ˣ104 k-5 3.95 ˣ105 K5 4.11 
k6 3.08 ˣ105 k-6 4.99 ˣ10-6 K6 1.62 ˣ10-11 
k7 2.30 ˣ103 k-7 2.19 ˣ10-6 K7 9.52 ˣ10-10 
k8 1.14 ˣ107 k-8 1.35 ˣ10-1 K8 1.18 ˣ10-8 
k9 1.20 ˣ106 k-9 1.76 ˣ10-1 K9 1.47 ˣ10-7 
k10 5.53 ˣ106 k-10 4.30 ˣ10-1 K10 7.78 ˣ10-8 
k11 3.83 ˣ105 k-11 7.89 ˣ10-6 K11 2.06 ˣ10-11 
k12 3.41 ˣ103 k-12 2.91 ˣ10-5 K12 8.51 ˣ10-9 
 
Table 4-6. Rate constants and the associated microequlibrium constants for the NB80 
binding model #1 obtained by global fitting. Please refer to figure 4-9 for a diagram of the 
model. 
A graph of simulated vs. real data using the best values we obtained for model #1 is 




Figure 4-10. Graph of the best global fit obtained. Please see figures 4-4 through 4-8 for full 
descriptions of the experiments.   
Several important aspects about the solution are apparent from the fitted rate 
constants and the data. In general, the NB80 modification of the eTCM model 
appears to be sufficient to explain the general pattern of the data. Although the fit is 
not perfect, the overall pattern of curves matches the data very well. Also, all of the 
rate constants that describe binding to an activated receptor are slower than the 
corresponding constants for the inactive receptor. This difference is more 
pronounced for the antagonist than the agonist, with may be a reflection of the larger 
molecular weight of the antagonist compared to the agonist used.  
There also seems to be an indication of a partially active state for non-drug-bound 
receptor. Both agonist and antagonist bound receptors transitioned to the active 
state at slower rates than the unbound receptor. The agonist bound receptor showed 
a very slow transition back to the inactive state as well as binding the nanobody at 
very fast rates. Once formed, the antagonist-bound active receptor showed fast 
transition to either the inactive or nanobody-bound states, indicating that it is likely 
not a preferred conformation. However, the receptor adopts an approximately equal 
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distribution of active and inactive conformations, but binds nanobody about 10 fold 
slower than the agonist bound receptors. This indicates that the unliganded "active" 
conformation and the agonist-bound "active" conformation may not have exactly the 
same degree of active character. 
After seeing how model #1 tended towards having partially activated states for 
unliganded and antagonist bound receptor, we wanted to see how well a model that 
required all the “active” receptor states to be conformationally equivalent. This could 
be accomplished by modifying model #1 so that the nanobody was forced to bind the 
antagonist-bound, agonist-bound, and unliganded receptor at exactly the same rate. 
To do so, all that was required was to replace the rate constants k9 and k10 with k8 
and k-9 and k-10 with k-8, giving us a new model, designated as model #2, drawn 
below in figure 4-11. 
 
Figure 4-11. Model #2 used for global fitting of data. The bound agonist is represented by 
the symbol “Ag”, the bound antagonist is represented by the symbol “Ant”, the inactive and 
active conformations of the receptor are represented by the symbols “R” and “R*”, 
respectively, and the bound NB80 is represented by the symbol “Nb”.  This model forces the 

























Model #2 was optimized in the same manner as model #1, using the best estimates 
for the rate constants of model #1 as the initial guesses, with the exception that the 
initial guesses for k8 and k-8 were set at 6.0 x106 and 0.2, respectively. The best 
estimate of the model #2 parameters are given below in table 4-7. 
k1 2.91 ˣ107 k-1 1.47 ˣ101 K1 5.04 ˣ10-7 
k2 2.86 ˣ108 k-2 8.23 ˣ10-2 K2 2.88 ˣ10-10 
k3 1.36 ˣ105 k-3 3.22 ˣ103 K3 2.37 ˣ10-2 
k4 6.58 ˣ104 k-4 2.01 ˣ105 K4 3.05 
k5 2.77 ˣ104 k-5 2.62 ˣ105 K5 9.44 
k6 9.92 ˣ105 k-6 2.86 ˣ10-6 K6 2.89 ˣ10-12 
k7 1.12 ˣ104 k-7 3.11 ˣ10-6 K7 2.78 ˣ10-10 
k8 5.03 ˣ106 k-8 1.40 ˣ10-1 K8 2.79 ˣ10-8 
k11 2.87 ˣ105 k-11 4.06 ˣ10-6 K11 1.42 ˣ10-11 
k12 4.25 ˣ103 k-12 5.56 ˣ10-5 K12 1.31 ˣ10-8 
 
Table 4-7. Rate constants and the associated microequlibrium constants for the NB80 
binding model #2 obtained by global fitting. Please refer to figure 4-11 for a diagram of the 
model. 
A graph of simulated vs. real data using the best values we obtained for model #2 is 




Figure 4-12. Graph of the best global fit obtained. Please see figures 4-4 through 4-8 for full 
descriptions of the experiments. 
Model #2 gave a slightly worse fit to the data, but not terribly so. One way to 
measure this is to look at the final goodness-of-fit parameter for the given solution, 
the value of which is smaller for better fits. For model 1 this parameter was 180, and 
for model 2 this parameter was 268 (for comparison, the absolute minimum for the 
goodness-of-fit parameter is 30). One of the places where model 2 seems to be 
unable to accommodate the data well is where the on-rate of NB80 is measured 
using the Blitz instrument. This is not terribly surprising, as this is exactly where we 
constrained model 2 relative to model 1. In general, it appears that model 2 forces 
NB80 to bind to the unliganded receptor too quickly and to the agonist bound 
receptor too slowly. Again, this is suggestive that there is probably is a real 
difference between the active, agonist-bound conformation of the receptor and the 
“active” conformation that the receptor is able to reach without any ligand bound. 
The other experiment that model #2 seems to have trouble predicting is the 
equilibrium competition binding assay where NB80 causes an increase in agonist 
affinity for the receptor. In particular, it appears that forcing nanobody to bind 
Time (min) Time (min)
































































identically to all the different activated receptor conformations limits the amount of 
cooperativity that can be simulated between the nanobody and agonist. However, 
the overall difference between the models does not seem to be terribly large. Better 
quality and more data are needed before we would be confident in choosing 
between them or determining that neither is sufficient to describe the system.  
It is worthwhile to look at how well defined each parameter is in the two models 
presented. A full estimation of the error in each measurement is beyond the scope of 
this study, but one can get a general idea of what the relative errors of the different 
parameters are by perfuming a simple sensitivity analysis. For this analysis, one 
simply increases or decreases the value of each optimized parameter one at a time 
and records the overall goodness-of-fit parameter. In general, the more well-defined 
a value is, the greater the increase of the goodness-of-fit parameter will be when the 
value is changed from its optimized value. Given in figure 4-13 below is the 
sensitivity analysis for increasing or decreasing each fitted parameter in the two 






Figure 4-13. Sensitivity analysis of global model parameters for model #1 and #2. The 
goodness-of-fit value was recorded when the value of each parameter was changed an 
order of magnitude higher (blue) and lower (red) of the optimized value.  
It can be seen in the sensitivity analysis that not all values for the parameters are 
likely to be well fitted. In particular, the rate constants for drug association and 
dissociation from the activated conformations of the receptor are not well determined 
by these models. This is related to the fact that these rate constants are expected to 
be quite slow in general, as access to the ligand binding site should be obscured 
when the receptor is in an activated conformation, as discussed earlier in this 
chapter and in chapter 3. Most likely, the best one will ever be able to do even with 
more extensive data is to get an upper limit for these values. It can also be seen that 
the most well estimated parameters are the rates of nanobody binding and 
dissociation, and in particular that of dissociation. 
4.7 – Section summary. 
In this chapter, we complemented our crystallographic evidence with 













































receptor activation is the tightening of the ligand binding pocket. This tightening is 
stabilized by agonists and promoted by binding of nucleotide-free G proteins or a G 
protein mimic nanobody. The tightening of the ligand binding pocket that is promoted 
by nucleotide-free G protein can be reversed by the addition of GDP as well as GTP, 
which is evidence that the G protein cannot bind both the receptor and GDP at the 
same time.  
In an effort towards determining the full kinetic model of how a receptor and G 
protein interact, we collected data and started modeling the interaction of the 
receptor and a much simpler G-protein mimicking nanobody. There is still more work 
to be done before even the simplified nanobody system can be confidently solved in 
full kinetic detail, but so far the results are consistent with our overall hypothesis that 
the binding of G protein to the activated receptor is coupled the loss of GDP from the 








EXTENDED DISCUSSION AND CONCLUSIONS  
 
5.1 – Overview of discussion. 
This section extends the analysis of the data presented in chapters 2-4 above. There 
are three general themes that are discussed. The first theme, found in sections 5.2 
and 5.3, concerns the practical advances in scientific techniques that this work 
demonstrates, as well as some of the direct questions that they raise. The second 
theme, sections 5.4 and 5.5, is a thorough analysis of the major findings in chapters 
3 and 4 from a more holistic viewpoint. The third theme, found in sections 5.6, 5.7, 
and 5.8, is speculative in nature and regards some new avenues of research that 
this work suggests might be productive.  
5.2 – Advances in G protein purification. 
One of the major technical achievements in this body of work is the re-working of our 
Gs heterotrimer purification scheme. Originally, we started with a protocol based off 
of the work of Tohru Kozasa,73 but we required that the protein to be in the detergent 
DDM instead of Tohru’s Lubrol detergent. This was a surprisingly difficult change to 
make. In our first iterations of making the detergent switch, we simply substituted 
DDM for C12E10 (the very close relative of Lubrol we had been using), but the switch 
ended up causing the final samples to be significantly dirtier. Eventually, we figured 
out two details that were probably causing the problem and how to compensate for 






Figure 5-1. Purity of Gs heterotrimer samples. Shown are the SDS-PAGE analyses of the 
final gel filtration step for several different Gs purification runs. A) Purification with cholate-
CHAPS-Lubrol detergent sequence as in Kozasa et al.73 Notice how the remaining 
impurities are mostly at higher molecular weights than the G protein and can easily be 
excluded from the final sample. B) Purification with cholate-DDM detergent sequence as 
initially attempted. Notice how the G protein sample is no longer easily separable from the 
remaining impurities. C) Purification with optimized cholate-Anzergent-DDM detergent 
sequence as given in section 6.1. The increase in purity is mainly due to overall reduction of 
the level of impurities in the sample before gel filtration.  
One reason why we were getting reduced purity was due to the nature of the 
detergents themselves. Both C12E10 and DDM are nonionic detergents with low 
critical micelle concentration (cmc) values (0.013% and 0.0087%,74 respectively) and 
rather large micelle sizes ( the micelle size for C12E10 is not known but would be 






















Load     6   9  12  15  18  21 24  27 30  33  36  39 42    
Load    4   6    8   10  12 14  16 18  20  22  24  26  28     












alternating hydrophobic-hydrophilic nature of the C12E10 polyoxyethylene head group 
allows the C12E10 micelles to fuse and split easily, since the headgroups neither 
attract nor repel their neighbors strongly. In contrast, detergents with extremely 
hydrophilic sugar-headgroups like DDM create a large hydration shell and resist 
being too close to neighboring headgroups, so their micelles tend to avoid fusion 
and splitting, favoring instead association and dissociation of single molecules from 
the micelle.124 A similar phenomenon can also occur with ionic detergents where the 
headgroups repel one another based on like charges.125 Consequently, when our Gs 
heterotrimer was solubilized in DDM, the only way for any contaminating membrane 
proteins embedded in the same micelle as a G protein to move to a new micelle 
would be for either the contaminant or the G protein to dissociate into aqueous 
solution and back into a different micelle, an inherently slow process. In contrast, 
when the Gs was solubilized in C12E10, the micelle could split and fuse with empty 
micelles, separating contaminating proteins without ever forcing them to dissociate 
into aqueous solution.  
Another reason why we saw increased contamination was due to the abrupt 
exchange into DDM that the sample underwent during purification. In the purification 
scheme for Gs heterotrimer, the protein is solublized from membranes with sodium 
cholate as the detergent. This detergent is cheap and highly effective at solublizing 
phospholipid membranes. However, it is neither compatible with anion exchange 
columns nor does it support ligand binding of β2AR or most other GPCRs. In order to 
exchange the cholate for another detergent that is more compatible with the columns 
and receptors, the solublized, clarified membranes are diluted underneath the cmc 
of cholate using buffers with the new detergent. When we initially diluted the 
membranes directly in DDM, we did so by simple mixing. Eventually, we figured out 
that this was a mistake. The quick dilution caused the cholate micelles to rapidly 
disperse, but the previously solublized membrane proteins seemed not to be able to 
transfer to the DDM micelles very effectively, with the samples becoming somewhat 
cloudy upon dilution (this observation was not immediately identified because 
solutions with DDM inherently tend to be somewhat cloudy to begin with). If the 
dilution solution was slowly added to the solublized membranes over about 20-30 
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minutes on ice, the turbidity of the resulting solution was markedly reduced. 
Chromatrography of the G protein was also improved after using the slow dilution 
method.  
While it was effective to dilute the soluble membrane samples directly into DDM, the 
large volumes of buffer needed for the dilution step made the direct use of DDM 
prohibitively expensive for routine purifications. Instead, we used an intermediate 
detergent, anzergent 3-12, for the dilution and then exchanged our sample into DDM 
on-column during the Ni-NTA purification step. Anzergent 3-12 was an ideal choice 
because it is relatively inexpensive, and has a cmc that is intermediate between 
cholate and DDM, which promotes good detergent exchange of samples from 
cholate but does not inhibit later exchange of the sample into DDM. We also made 
sure to wash the Ni-NTA column free of diluted, solublized membrane after the 
loading step. We used buffer that contained the exact same concentrations of 
Anzergent, cholate (now under its cmc but likely still interacting somewhat with the 
micellar phase), and ionic strength (which is known to effect both micelle size and 
cmc for many detergents). Only after we knew that as much contaminant protein as 
possible was washed through the column did we then exchange the sample into 
DDM, which appeared to prevent most of the co-localization of contaminant and 
target protein into the same DDM micelle.  
After switching to buffers with rationally designed detergent sequences, the 
variability in the purity of the final protein sample was markedly reduced. 
Unfortunately, the yield of the purifications was still quite variable. From the analysis 
of SDS-PAGE gels, it appeared that all the protein that was extractable from the 
membranes with cholate was also being successfully purified, with minimal losses 
after extraction. However, large amounts of protein were left in the insoluble fraction 
after cholate solubilization of the membranes, and extended extraction at a variety of 
temperatures and in several detergents could not enhance the solublization (data 
not shown). This led us to conclude that this insoluble protein was denatured. In this 
case, enhancing the yield of G protein beyond the average of 0.75 mg/liter culture 
volume is primarily dependent on finding a way to improve the ability of insect cells 
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to successfully fold the Gα and Gβ subunits of the G protein. Luckily, the path 
forward to higher expression levels has probably already been shown.  
Folding of the Gβ subunit, and of β-propeller protein in general, is difficult and 
generally requires the cellular chaperone machinery. Specific chaperone proteins for 
both Gβ and a Gγ subunits have been identified as phosducin-like protein (PhLP),67 
and dopamine receptor interacting protein 78 (DRiP78),68 respectively. It is quite 
likely that coexpession of these proteins during overexpression of the Gβγ subunit 
would increase the yield dramatically. A similar finding has also been made with Gα 
subunits. There are two chaperone proteins that help fold Gα; Ric8B helps Gαs to 
fold, and Ric8A helps most of the other Gα subunits. Specifically, it has been found 
that the Ric8 proteins bind to the nucleotide-free Gα proteins and are released upon 
GTP or GDP binding.126  
Currently, we use three high-quality baculoviruses to express G protein in Hi5 insect 
cells. There is one virus that carries each gene for the Gα, Gβ, or Gγ subunit that we 
wish to express, and the appropriate combination is used to co-infect the cells all at 
the same time. However, advances in commercially available baculovirus transfer 
vectors now allow one to insert two genes for overexpression in each virus. It is 
highly likely that if each of our subunit viruses were remade so that their specific 
chaperone protein was co-expressed, we could increase yields of the heterotrimer. 
Of course, there are many other possible ways to improve G protein yields, but the 
proposed change would not require any other modifications of the overall procedure 
which we already know produces high-quality protein. 
5.3 – Technological advances for membrane-protein crystallography. 
The ability to crystallize the β2AR and other GPCRs has so far required the use of 
varied stabilization techniques with the exception of only two receptors; bovine 
rhodopsin and squid rhodopsin. While it is unfortunate that as of yet nobody can get 
structural information with wild type receptors that are not rhodopsins, the 
information gained by analysis of even imperfect structures has proven invaluable to 
our understanding of GPCR function. Hopefully, within the near future less invasive 
strategies to obtain membrane protein structural information will be discovered. For 
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example, crystallographic data collection with the recently developed free-electron 
laser127 might be able to compensate for the general small size and high sensitivity 
to radiation damage characteristic to GPCR crystals. Alternatively, recent work with 
patterned nanoarrays has yielded some that hold small molecules in crystal-like 
arrays that are capable of producing Bragg reflections for X-ray analysis, but do not 
require actual crystallization of the compound.128 Similar arrays may soon be able to 
hold proteins as well; a leading candidate for making such an array are folded DNA 
scaffolds because of the rapid progress in the field and the compatible length scales 
of the arrays with typical protein dimensions.129 However, it is our laboratory’s 
opinion that the pressing need for structural information of GPCRs, and membrane 
proteins in general, necessitates the application of the proven but imperfect 
technologies described below to an ever widening circle of biologically important 
proteins.  
One of most important techniques for getting GPCRs to form crystals is genetic 
fusion of the receptor with easily crystallizable protein domains. The first example of 
this strategy was in 2007, when Brian Kobilka and Ray Stevens replaced the flexible 
ICL3 region of the β2AR with a catalytically dead but well-folded mutant of T4 
lysozyme (T4L). A very similar strategy uses a receptor fusion construct with a 
thermostabilized apocytochrome (b562RIL, or BRIL) domain in the same position. So 
far, these two IL3 fusion protein replacement strategies have been used to 
successfully crystallize 15 other GPCRs.94, 130-143 In addition, this work and a more 
recent structure by Yaozhong Zou et al144 also show that simply fusing the T4L to 
the N-terminus of the GPCR can be sufficient to promote crystallogenesis, avoiding 
the structural perturbations caused by ICL3 replacement.  
Another strategy that promotes crystallization of difficult targets and rare 
conformations is antibody stabilization, in particular using nanobodies derived from 
camelids. The use of traditional antibody Fab fragments for promoting crystallization 
is well known,145 and they have even been used for successful GPCR crystallization 
as well.52 However, the small size of nanobody fragments appears to make them 
particularly adept at stabilizing various 3-dimensional conformations of the target 
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protein, as opposed to the linear peptide epitopes that are often recognized in the 
binding cleft of traditional antibodies.146 In addition, the single-polypeptide, single-
domain nature of these fragments allows for efficient selection of clones by 
screening of phage display libraries as well as fast expression and purification of the 
selected clones.  
The use of bicelles and lipidic cubic phase (LCP) based matrices for membrane 
protein crystallography has also been helpful for GPCRs. Traditional membrane 
protein crystallization techniques are pretty much identical to those used for soluble 
proteins, but performed in the presence of detergent. As discussed above in section 
5.2, the maltose-based headgroups on the detergents that have been the most 
successful for GPCR purification generally make micelles that are resistant to fusion 
and splitting. This includes the new MNG class of detergents used in this study. It is 
expected that this property would typically be detrimental to the process of 
crystallization, as the receptor molecules in solution must fuse their associated 
micelle with the growing crystal's detergent layer in order to pack in any orientations 
that have contacts between the receptor transmembrane regions. In contrast, the 
bilayer-like nature of both bicelles and LCP easily allow for receptors to contact the 
growing crystal in a parallel or antiparallel orientation to the receptors already 
incorporated in the crystal. Additionally, this bilayer-like character is more similar to 
the receptor's native environment of a phospholipid membrane, which should protect 
the receptor against denaturation during the crystallization process.  
LCP in particular has proven to be very useful for crystallization of transmembrane 
proteins.147 Likely, this is related to the 3-dimenionsal nature of the matrix, which 
enhances diffusion and stacking of these proteins, which are typically restricted to 2-
dimentional movement in their native lamellar bilayers. However, the narrow 
aqueous channels in the typical monoolein-based matrix appear to be inhibitory 
when the transmembrane protein of interest also has large soluble domains, as was 
the case for our work with the large Gs heterotrimer in complex with the receptor. 
For this situation, the use of different lipids that form a cubic phase with larger 
aqueous channels was critical to successfully using the method for crystallography. 
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In general, this also seems to be the case for other transmembrane proteins with 
large soluble domains as well.147 Even with this improvement, though, the LCP 
method suffers from a serious drawback. The crystals grow surrounded by the 
extremely viscous cubic phase, and no amount of careful washing can remove the 
crystal from the surrounding matrix without destroying the crystal. Instead, one must 
simply scoop the lipid matrix and embedded crystals into a crystallography loop and 
freeze it as is. The lipid matrix is both optically dense and highly birefringent, making 
it impossible to see the embedded crystals in typical X-ray crystallography beamline 
setups. This is a formidable challenge, as is it pretty much impossible to obtain high-
quality data when the crystals cannot be accurately positioned in the X-ray beam.  
For this work, that challenge was overcome by the use of the GM/CA-CAT beamline 
at Argonne National Lab. The work of the beamline staff on the controlling software 
package, JBluce, allowed us to efficiently screen through the entire volume of the 
frozen LCP blob with a low-power X-ray beam, looking for places where the invisible 
crystals produced Bragg peaks in the diffraction pattern. Because the target protein 
was so difficult to crystallize in general, we needed to locate the few good crystals in 
a very large pool of poor quality crystals. The GM/CA-CAT beamline is also one of 
the few microfocus beamlines available for protein crystallography. At the time we 
collected data for the β2AR-Gs complex, beam diameters down 5 µm were available 
for use, which allowed us to focus on individual regions of our small crystals. This 
allowed us to take diffraction patterns at very high beam intensity, which promotes 
high-resolution diffraction, on one region of the crystal until it was too damaged to 
continue, then move to a different region of the same crystal and continue. Using 
judicious selection of crystal rotation as we consumed the different regions of each 
crystal, we were able to obtain a complete dataset with the highest possible 
resolution for the crystals, even though we were very limited on the amount of good 
quality crystals. The same challenges will most likely exist for many other GPCR 
crystallization projects, so the technological advancements made by GM/CA-CAT 
and similar facilities to lower the barrier of what quality of crystals can practically 
yield useful data will allow increasingly challenging target proteins to finally be 
structurally characterized.  
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5.4 – Structural basis for GPCR-mediated G protein activation. 
One of the most important parts of this work is its contribution to our understanding 
of how the structures of a GPCR and a G protein change during the process of 
activation. Some aspects of the findings, like the movement of TM6 during activation 
and the interaction of the Gα C-terminal helix, have been well characterized in the 
past and are confirmed again here. However, several new findings can also been 
seen from the structure, such as the exact orientation of the G protein to the receptor 
and the wide separation between Gα subunit domains. Shown below in figure 5-2 is 
a summary of the structural changes that allow the agonist binding to the β2AR to 
cause the nucleotide loss on the Gαs subunit of the Gs heterotrimer. 
 
Figure 5-2. Overview of structural changes involved in activation of β2AR and Gs to the 
β2AR-Gs nucleotide-free intermediate complex. Numbered features are as follows: 1) 
Agonist causes ligand binding site to contract by 1-2 Å, mainly by pulling TM5 and TM7 
towards the stable TM3. 2) The ligand binding site contraction on the extracellular side of 
the receptor causes TM5 and TM6 to be pushed outward on the intercellular side, similar to 
the working of a lever. 3) TM7 moves in and the NPxxY motif bulges in order to stabilize the 
outward movement of TM6. 4) The cleft opened by TM6 movement binds the Gα C-terminal 
helix and the ICL2 helix binds next to the Gα N-terminal helix. 5) The binding mode of the 
Gα to the receptor causes major disruption of the guanine nucleotide binding residues, 
leading to the loss of GDP. 6) Loss of nucleotide also disrupts the interface between the 
Ras-like domain and the α-helical domain of Gα, causing the α-helical domain to disengage 





































There are many more details about the structural changes during β2AR-Gs complex 
formation in sections 3.5 through 3.9, but here we summarize some more general 
structural aspects of the interaction between β2AR and Gs. One issue that this 
structure does not fully answer but instead leads to more questions is that of the role 
of Gβγ subunits in G protein activation. In all our work, Gβγ was required for the 
interaction between the β2AR and Gs and it did not dissociate after Gα nucleotide 
loss, but in the complex structure Gβγ doesn’t actually contact the receptor. As far 
as we can tell, its primary role seems to be binding the Gα N-terminal helix and 
helping to present it on the membrane in the correct orientation for receptor 
interaction. This is consistent with several Gαi structures that show the N-terminus 
folding up into a microdomain that also binds the end of the C-terminal helix. This 
microdomain covers up most of the surfaces on the C-terminal helix that interact with 
the receptor as well as the binding site for ICL2 binding to Gα, but in the heterotrimer 
the microdomain does not form and instead the N-terminus binds to Gβγ, shown 
below in figure 5-3. 
 
Figure 5-3. N-terminal microdomain formation on Gαi. The structure of Gαi1 bound to GDP 
and Mg++ (PDB 1BOF)148 is drawn in green with a blue N-terminal domain. The structure of 
the Gαi1 heterotrimer (PDB 1GP2)69 is drawn in tan with a purple N-terminal domain.  
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Even if a Gα subunit does not form an N-terminal microdomain similar to the one 
observed for Gαi1, it could likely still benefit from being displayed in the correct 
conformation for receptor interaction next to the membrane by a Gβγ subunit. It also 
seems likely that Gβγ-binding of the N-terminus would aid in putting strain on the β1 
strand of the Ras-like domain, since it severely limits the ability of the N-terminus to 
adopt alternate positions that would accommodate the binding of the receptor ICL2 
domain. However, most of these proposed roles for Gβγ are still quite speculative 
and more work is needed to determine why it is generally so difficult to get Gα 
subunits to interact with receptors without its presence. 
The receptor and G protein complex structure also shows why several regions of 
both proteins are so highly conserved. Most of these conserved residues are ones 
that participate directly in the movements of the proteins. In order to help visualize 
this relationship, shown below in figure 5-4 is a map of the relative entropy of each 
position in the 7TM receptor or the Gα family, as determined by the Pfam hidden 
markov model for each family, onto the β2AR-Gs complex structure. Relative entropy 
is basically a measure of sequence conservation, except that it takes into account 
how likely one is to see a particular type of residue in the first place given its overall 




Figure 5-4. Relative entropy of the 7TM receptor or the Gα family. Places with low relative 
entropy (low sequence conservation) are white, changing to red and then blue as the 
residues is more conserved.  
The figure above shows the region with the most conserved residues includes the 
G-box domains, which make up the nucleotide-binding site and nearby residues in 
the Gα subunit. On the receptor, the NPxxY and DRY motifs also have very low 
relative entropy, as expected. It can be seen that other residues in the receptor are 
also fairly conserved, mainly those that are involved in packing interfaces with other 
TM helices. Similar analyses have determined that the residues that pack in the 
central part of the receptor tend to make contacts with one another that do not 
require the residues to be completely conserved, but instead have a more 
generalized pattern,40, 149 which is consistent with the observed intermediate relative 
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entropies that suggest partial conservation. Another observation that can be made 
with this type of analysis is that unlike the residues involved in the conformational 
changes that happen during activation, the actual protein-protein interaction surface 
of the G protein and the receptor is not terribly well conserved within the protein 
families. This suggests that the identity of the interacting residues is likely less 
important than the overall topology of the surfaces.  
5.5 – Allosteric communication between agonists and guanine nucleotides. 
Consistent with the tighter ligand binding pocket on the receptor shown by 
crystallography, we saw slower association and dissociation of ligands into the 
receptor when it was forced into the active conformation by binding the G protein 
mimic NB80. The same behavior was seen when heterotrimeric G protein was used 
instead of NB80, but the G protein had to be nucleotide-free in order to interact with 
the receptor in a manner that closes the ligand binding site. Both GTP and GDP can 
bind to the nucleotide-free G protein and allow it to be released from the receptor, 
but GTP (and GTPγS) will cause the G protein subunits to split from each other, 
which prevents reengagement of the G protein with the receptor. However, GDP 
binds reversibly, allowing G protein and receptor to periodically disengage, but then 
come back together as the G protein-receptor nucleotide-free complex, which 
releases the GDP back into solution. These observations lead us to propose that the 
model needed to describe the relationship between the GPCR and G protein is at 
least as complicated as a version of the eTCM model modified to include the binding 






Figure 5-5. Minimum possible model of GPCR and G protein interaction. The G protein is 
assumed to be nucleotide-free, and the loss of GDP and the binding of receptor are 
modeled as a concerted reaction.  
This model of GPCR function can include reduced diffusion of ligands into activated 
receptors and can also account for all features of our observed competition binding 
curves between radiolabled antagonist and unlabeled agonist of samples that 
contain Gs-β2AR nucleotide-free complexes in figure 4-6. When there is no 
nucleotide present in the assay, only one low affinity site exists for the agonist which 
corresponds to any receptor in the sample that is not interacting with G protein. 
Receptors that are complexed to nucleotide-free G protein and assayed without any 
nucleotide present are stuck in an activated, closed conformation and thus cannot 
bind the drug in the time frames that are typically used for such assays. Under 
conditions where GDP is added in concentrations approaching its apparent affinity 
for Gs, radiolabeled antagonist can bind to the receptor when the G protein binds 
GDP, allowing the receptor to access its open, inactive conformation before being 
forced back into the closed, active conformation when GDP is lost from the G 
























invisible to the assay because they were locked in the active conformation in a 
nucleotide-free receptor-G protein complex. The receptors are then able to bind 
competing radiolabeled antagonist and unlabeled agonist concentrations, and the 
positive cooperativity between agonist and G protein binding causes the appearance 
of a high-affinity binding site in the competition assay. However, very large amounts 
of GDP would increase the off-rate of the G protein and eventually reduce the affinity 
of the high-affinity state so that it would become indistinguishable from the low-
affinity state.  
The sensitivity of the high-affinity agonist binding site to GDP in compeitition assays 
needs to be characterized for other receptor systems and in more detail than 
reported here.  A major prediction of the model presented above would be that in a 
true equilibrium assay, the Kd value of the high-affinity state should vary with the 
GDP concentration, becoming lower affinity with higher amounts of GDP present. If 
this cannot be found, it is likely that a model akin to the cubic ternary complex model 
would be needed to explain the results. This type of model would allow the G protein 
to remain bound to the receptor and GDP at the same time. Most likely, this receptor 
and GDP-bound G protein would be in a conformation that is much different than our 
nucleotide-free receptor-G protein complex structure. It is also probable that new 
biophysical assays will have to be developed in order to test these hypotheses, as 
the ligand binding assays used extensively in this work offer only an indirect 
measurement about what is happening on the G-protein binding side of the GPCR. 
5.6 – Flexible α-helical domains and the mechanism RGS protein activity. 
The surprising finding that the Gα α-helical domain moves so dramatically during the 
activation process suggests the interesting possibility that the domain may also be 
flexible in the GDP or GTP bound states as well. Although at first glance it seems 
that the Gα α-helical domain must contribute significant surface area to the 
nucleotide binding site, the only contacts made between the domain and the 
GDP/GTP are in a small area on the ribose portion of the nucleotide. Most other 
contacts which define the binding site, including 4 of the 5 highly conserved G-box 
sequences, are completely located on the Ras-like domain. Since Ras is able to bind 
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GDP at nanomolar concentrations and it is also known that the α-helical domain can 
be removed from Gαs and the Ras-like domain expressed separately as a functional 
domain,150 it seems clear that the α-helical domain and the nucleotide ribose group 
need not be in constant interaction in order to maintain the integrity of the protein.  
This hypothesis that the α-helical domain can move away from the Ras-like domain 
while in a “normal” GDP or GTP bound state could have physiological implications. It 
is known that in the typical cell, most G proteins do not become deactivated by 
hydrolysis of GTP to GDP by their own intrinsic GTPase activity, but instead by 
hydrolysis stimulated by the binding of an RGS protein. Based on structural analysis 
of GDP, [AlF4]-, and RGS bound Gα structures, the consensus explanation of how 
RGS proteins stimulate GTPase activity has been that the RGS binding protein 
subtly pushes the catalytic residues into optimal positions for enhancing the 
reaction.151 However, it is possible that an additional job that RGS binding does to 
the Gα subunit is simply to force the α-helical domain to remain in close proximity to 
the Ras-like domain, allowing the catalytic arginine to stay near the γ-phosphate of 
the GTP. Structures of several RGS-Gα complexes show residues of RGS and the 
Gα α-helical domain in close proximity (≤ 4 Å) to each other, and the nature of these 
interactions varies with the specific pair of proteins used.152 An addition, a recent 
structure of RGS2 and Gαq shows extensive contact between the α-helical domain 
and the RGS protein, and mutations in the interface are associated with large 
changes in GTPase activating activity (both in positive and negative directions).153    
In many ways, a mechanism that works this way is more consistent with the 
hydrolysis method of the Ras family of small GTPases. When GTP binds to the Ras 
protein, it cannot be hydrolyzed quickly without the binding of another protein that 
carries the catalytic arginine residue, known as RasGAP. RasGAP accelerates the 
GTPase activity partly by simply putting the missing catalytic arginine near the rest 
of the enzyme’s active site, but also by stabilizing the switch II region of the Ras 
protein into a conformation that favors the transition state for hydrolysis.154 For 
heterotrimeric Gα subunits, these two jobs are separated so that the α-helical 
domain supplies the catalytic arginine and the RGS protein provides the switch 
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domain stabilization. However, if the α-helical domain is normally not positioned 
correctly for catalysis and is instead moving around, having RGS bind the α-helical 
domain to keep it in place would achieve the same end as the RasGAP protein. 
5.7 – Subtype specificity of G protein binding to GPCRs. 
One of the outstanding unresolved questions about GPCR-mediated activation of G 
proteins is how the ~800 human GPCRs are able to signal through the appropriate 
combination of the 27 isoforms of the 16 G proteins. For some pairs of receptor and 
G protein, the specificity seems to be accounted for by highly restricted expression 
patterns, as in the case for the olfactory G protein, Golf. Golf is typically expressed 
exclusively in olfactory sensory neurons and is very similar to Gs. When the Gαolf 
subunit is artificially expressed in S49 cyc- cells which naturally lack the Gαs 
subunit, it can substitute for Gαs in order to stimulate cAMP production.155 Thus, it is 
likely that if Golf was expressed widely in tissues, it would interact with many 
receptors that it normally would not interact with solely due to its very specific 
expression patter. However, for most cell types, there are at least several different of 
subtypes of G proteins and hundreds of different GPCRs that are expressed in the 
same cell. The cell maintains the correct signaling network of receptors and G 
proteins by using both the intrinsic affinity of specific GPCR-G protein pairs for each 
other and by subcellular localization processes.156   
Our work does not offer any insight to how localization contributes to the specificity 
of G protein signaling in vivo, but it does give us a better idea about where to look for 
structural determinants that determine the intrinsic ability of any particular receptor to 
activate a G protein subtype. Many of these regions have been previously identified 
as important for coupling using various techniques on different receptor families,107 
but our structure now allows us to link specific receptor and G protein regions as 
places of contact. In order to aid in the interpretation of the role for each of the 
contact regions, we generated a structure-based alignment of the Gαs (PDB 1AZT), 
Gαi1 (PDB 1AS0), and Gαq (PDB 4EKD) proteins with 3D-Coffee,157 shown below in 
figure 5-6. Also labeled on the sequence are 10 main regions of interest on the G 




Figure 5-6. Structure based alignment of Gαs, Gαi1, and Gαq. The coloring of the residues 
indicates the degree of structural homology between the different proteins and the “cons” 
column in the alignment indicates the degree of sequence similarity. 
The areas of interest are generally those on the G protein that are close the receptor 
in the β2AR-Gs crystal structure. They are listed below in table 5-1, along with the 










Number Region of G protein Region of Receptor 
1 Turn between N-terminal helix 
and β1 strand 
Intercellular loop 2, F139 on β2AR 
2 1st hinge region between Ras 
and α-helical domain  
None, but should effect region 3 due to the 
general mobility of the α-helical domain 
3 Loop between αB and αC helices  Intercellular loop 2, also could affect region 
4 of G protein 
4 Turn between β2 and β3 strand Intercellular loop 2, F139 on β2AR 
5 αG helix and associated region Extensions of TM5 helix and proximal 
region of intercellular loop 3 
6 α4 helix TM5 helix 
7 α4 helix and α4-β6 turn Possibly TM6 and proximal region of 
intercellular loop 3 
8 β6 strand TM5 helix 
9 C-terminal helix TM5 helix, Intercellular loop 2, F139 on 
β2AR 
10 C-terminal helix TM5, TM6, and TM3 helices 
 
Table 5-1. Regions of interest on G proteins for the determination of specificity of interaction 
with GPCRs. 
In the β2AR-Gs crystal structure, regions 1, 4, and 9 are all involved in forming the 
binding pocket for F139 from the ICL2 domain on the receptor (described in section 
3.6). The location of the regions can be seen in figure 5-7, below. A bulky 
hydrophobic residue (I, L, V, M, or F) is typically found on most GPCRs in the same 
position. Substitution of one bulky hydrophobic residue for another has much less of 
an effect on receptor-G protein coupling than substituting a small, polar, or charged 
residue.114 This suggests that these regions may tend to be more important for the 
conserved mechanism of G protein activation than for selection between different G 
protein subtypes, which is also supported by the regions’ involvement in the 





Figure 5-7. Location of domains involved in G protein signaling specificity. The domains are 
numbered as in table 5-1 and mapped onto the β2AR-Gs crystal structure in varying colors, 
given as follows: 1 – yellow, 2 – teal, 3 – periwinkle, 4 – orange, 5 – salmon, 6 – blue, 7 – 
magenta, 8 – cyan, 9 – purple, 10 – tan.  
Regions 2 and 3 might be involved in interactions between the α-helical domain and 
the IL2 region of the receptor. Region 2 is one of the hinge regions between the α-
helical domain and the Ras-like domain. This is the region on Gs where the “short” 
and “long” isoforms differ, where the “long” isoform has 15 extra amino acids 
inserted at this position. The long isoform promotes the constitutive activation of the 
G protein, presumably by promoting the flexibility of the α-helical domain.120 The 
region 3 domain contains parts of the αB and αC helices of the α-helical domain as 
well as the loop connecting them. The large movement of the α-helical domain in the 
β2AR-Gs crystal structure brings this region up to close proximity to the ICL 2 
domain of the receptor and the β2-β3 loop region of the Ras-like domain. This region 
on the α-helical domain is one of the more structurally divergent parts of the Gα 














Figure 5-8. Alignment of Gα α-helical domains in a possible ICL2-interacting conformation. 
Gαs (PDB 3SN6) is shown in green (Ras domain) and blue (α-helical domain), Gαi1 (PDB 
1AS0) α-helical domain is shown in pink, and Gαq (PDB 4EKD) α-helical domain is shown in 
yellow. β2AR (PDB 3SN6) is shown in purple.  
In the figure above, one can see that this variable domain on the α-helical domain is 
positioned quite close to the receptor, about 6-8 Å. Given the general flexibility of the 
α-helical domain when the G protein is nucleotide-free, one would imagine that 
contact could easily be made in this region when the receptor-G protein complex is 
in solution and not trapped in a crystal.  
Regions 6, 8, and 9 all contribute to large contact surfaces between the G protein 
and the TM5 helix of the receptor. These regions have previously been linked with G 
protein specificity, especially region 6.107 While the different G protein subtypes 
show very high structural conservation in this region, the sequence conservation is 
strongly maintained only on the side of the helix that is buried in the core protein 
fold.  As noted in chapter 3, the surface between the two proteins in the β2AR-Gs 
crystal structure does not contain any obviously strong interactions that would likely 
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dominate the nature of the interaction, but that certainly does not mean that other 
receptor-G protein pairs would not have such an interaction. 
Region 5 is near the end of the TM5 helix in the β2AR-Gs crystal structure. For the 
Gαs protein, there are about a dozen extra residues in this region, known as the αG 
helix region. These residues form a large loop structure that sits on top of the α4 
helix which is not present in most other Gα subunits. Alignment of the Gαi and Gαq 
proteins in the same position suggests that these G protein subtypes could tolerate 
at least one or two more helix turns on TM5 before it would cause a steric hindrance 
with their smaller αG helix region. This region would also be in a prime position to 
interact with any residues in the TM5 proximal region of the receptor ICL3 domain. 
Region 7 is structurally divergent between the G proteins studied, and is positioned 
right below the TM6 region of the receptor. While there are no contacts between this 
region and the receptor in the β2AR-Gs crystal structure, it would be in an obvious 
place to look for interactions with the TM6 proximal region of the ICL3 loop on other 
receptor-G protein pairs. Also, if the proposed receptor-G protein “pre-coupled” 
complex with the receptor in a more inactive conformation does exist, it seems very 
likely that this region would be a likely site of interaction between the G-protein and 
the receptor TM6. 
Region 10 is the C-terminus that forms extensive interactions between the receptor 
TM5, TM6, and TM3 helices and the G protein. The region has long been known to 
drive much, though certainly not all, of the specificity in G protein interaction and has 
been studied extensively. The interaction is formed by helices packed against each 
other in perpendicular fashion, so without structural data or high-quality homology 
models, it would be hard to predict exactly which residues contact each other.  
The β2AR-Gs complex structure has allowed us to determine these aforementioned 
contact regions and other structurally linked domains that should be involved in the 
process of GPCR signaling specificity. It is out of the scope of this analysis to 
attempt to derive rules governing why a particular receptor signals through one G 
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protein or another, as it is clearly a complex process that involves at least several 
non-adjacent domains on both proteins.  
5.8 – Existence of a GDP-liganded pre-coupled state between receptor and G 
protein. 
There have been several reports that suggest the receptor and G protein and 
interact even when the G protein is in a GDP-bound conformation. This GDP-bound 
G protein would almost certainly interact with the receptor in a different manner than 
what we observe in our nucleotide-free complex structure. From a physiological 
standpoint, this type of interaction would make a lot of sense. If the G protein was 
always literally right next to the receptor, it would be able to convey the activation 
signal more quickly because it would avoid the delay caused by diffusing to the 
receptor before it could interact. A relatively stable interaction between receptor and 
GDP-bound G proteins could also contribute to subtype-specific G protein signaling, 
especially for receptors with a large receptor reserve. If a particular subtype of G 
protein interacted with the receptor in the GDP-bound state, it would sterically hinder 
the interaction of the receptor with other G proteins until it was forced to leave the 
site following activation and GTP binding. If certain ligands promoted this interaction 
more so than others, it could also explain many cases of ligand-biased signaling 
through GPCRs without requiring that the evolutionarily conserved receptor and 
nucleotide-free G protein complex transmit any of the biased-ligand signal. A similar 
mechanism could also exist for preventing receptor binding with other types of 
proteins, such as arrestins and GRKs, that in general should not interact with the 
receptor until after an agonist binds to it. For all these reasons and more, it is 
sensible to entertain the idea that the GDP-bound G protein and receptor might be 
able to interact.  
Although our data does not go far in proving or disproving such a hypothesis, we are 
still able to shed some light on several aspects of the issue. From the data given in 
sections 4-3 and 4-6, we know that if an interaction between the receptor and the 
GDP bound state of the G protein exists, it does not restrict access to the receptor’s 
ligand binding site like the interaction of the nucleotide-free G protein or NB80 does. 
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This is suggestive that the receptor is likely to in a conformation that is most similar 
to its inactive state. The same conclusion was also arrived at with a photobleaching 
recovery study of  muscarinic receptors and Gq.117  
We also saw an indication that there might be a weak interaction between the GDP-
bound heterotrimer and the receptor in our DSMS data, shown in section 3.8. When 
our samples of nucleotide-free receptor-G protein complex were treated with GDP, 
the 100 second timepoint sample indicated that the GDP was able to fully stabilize 
the nucleotide-binding site, but it also still showed partial stabilization of the Gα 
C-terminus. In contrast, treatment of the same samples with GDP and AlF3 caused 
the C-terminus to be completely flexible and solvent exposed.  
5.9 – Conclusion. 
In the work presented in this dissertation, significant progress has been made in 
elucidating the mechanism for the first, key step of G protein activation by a GPCR. I 
have detailed the process and rationale behind the production of the G protein 
heterotrimer, as well as the strategy we used for making the receptor-G protein 
complex signaling intermediate. With a large, multi-lab collaboration, we were also 
able to obtain both structural and dynamic information about this complex. This has 
allowed us to form a plausible qualative model about the molecular nature of G 
protein activation that incorporates both previously known and new aspects of the 
process.  
I have used this model to study the pharmacology of the receptor while incorporated 
into the receptor-G protein complex and a similar receptor-nanobody complex. Both 
equlibirum and kinetic data were used to create quantative models of drug and 
binding and receptor activation. These models are consistant with the qualitative 
model inferred from structural analysis, but they represent only the beginning of the 
process of getting a full mathematical understanding of the activation process.  
There are two areas of future work that should naturally follow this effort. More 
structures of GPCR-G protein complexes need to be obtained, so that one can 
compare and contrast them to get a better idea what aspects of the activation we 
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have seen in this structure are general to all GPCRs and which ones are specific to 
our particular proteins. The methods developed here should guide and aid this effort 
considerably. Additionally, new biophysical assays that probe the binding and 
conformational changes of the G protein during activation need to be developed in 
order to complete the full mathematical model of the activation process. When such 
a model is obtained, it can be used to unambiguously predict the G protein’s 
contribution to such complex processes like biased signaling and downregulation of 








MATERIALS AND METHODS 
 
6.1 – Gs heterotrimer expression and purification.  
Bovine Gαs short, His6-rat Gβ1 and bovine Gγ2 were expressed in HighFive insect 
cells (Invitrogen) grown in Insect Xpress serum-free media (Lonza). Cultures were 
grown to a density of 1.5 million cells per ml and then infected with three separate 
Autographa californica nuclear polyhedrosis viruses each containing the gene for 
one of the G protein subunits at a 1:1 multiplicity of infection (the viruses were a gift 
from A. Gilman). After 40–48 h of incubation the infected cells were harvested by 
centrifugation and resuspended in 75 ml lysis buffer (50 mM HEPES, pH 8.0, 65 mM 
NaCl, 1.1 mM MgCl2, 1 mM EDTA, 1× PTT (35 μg ml−1 phenylmethanesulphonyl 
fluoride, 32 μg ml−1 tosyl phenylalanyl chloromethyl ketone, 32 μg ml−1 tosyl lysyl 
chloromethyl ketone), 1× LS (3.2 μg ml−1 leupeptin and 3.2 μg ml−1 soybean trypsin 
inhibitor), 5 mM β-mercaptoethanol (β-ME), and 10 µM GDP) per liter of culture 
volume. The suspension was pressurized with 600 p.s.i. N2 for 40 min in a nitrogen 
cavitation bomb (Parr Instrument Company). After depressurization, the lysate was 
centrifuged to remove nuclei and unlysed cells, and then ultracentrifuged at 
180,000g for 40 min. The pelleted membranes were resuspended in 30 ml wash 
buffer (50 mM HEPES, pH 8.0, 50 mM NaCl, 100 µM MgCl2, 1× PTT, 1× LS, 5 mM β-
ME, 10 µM GDP) per liter culture volume using a Dounce homogenizer and 
centrifuged again at 180,000g for 40 min. The washed pellet was resuspended in a 
minimal volume of wash buffer and flash-frozen with liquid nitrogen. 
The frozen membranes were thawed and diluted to a total protein concentration of 
5 mg ml−1 with fresh wash buffer. Sodium cholate detergent was added to the 
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suspension at a final concentration of 1.0%. The sample was stirred on ice for 
40 min, and then centrifuged at 180,000g for 40 min to remove insoluble debris. The 
supernatant was diluted fivefold with Ni-NTA load buffer (20 mM HEPES, pH 8.0, 
363 mM NaCl, 1.25 mM MgCl2, 6.25 mM imidazole, 0.2% Anzergent 3-12, 1× PTT, 
1× LS, 5 mM β-ME, 10 μM GDP), taking care to add the buffer slowly to avoid 
dropping the cholate concentration below its critical micelle concentration too 
quickly. Ni-NTA resin (3 ml; Qiagen) pre-equilibrated in Ni-NTA wash buffer 1 
(20 mM HEPES, pH 8.0, 300 mM NaCl, 2 mM MgCl2, 5 mM imidazole, 0.2% cholate, 
0.15% Anzergent 3-12, 1× PTT, 1× LS, 5 mM β-ME, 10 μM GDP) per liter culture 
volume was added and the sample was stirred on ice for 20 min. The resin was 
collected into a gravity column and washed with 4× column volumes of Ni-NTA wash 
buffer 1, Ni-NTA wash buffer 2 (20 mM HEPES, pH 8.0, 50 mM NaCl, 1 mM MgCl2, 
10 mM imidazole, 0.15% Anzergent 3-12, 0.1% DDM, 1× PTT, 1× LS, 5 mM β-ME, 
10 µM GDP), and Ni-NTA wash buffer 3 (20 mM HEPES, pH 8.0, 50 mM NaCl, 1 mM 
MgCl2, 5 mM imidazole, 0.1% DDM, 1× PTT, 1× LS, 5 mM β-ME, 10 µM GDP). The 
protein was eluted with Ni-NTA elution buffer (20 mM HEPES, pH 8.0, 40 mM NaCl, 
1 mM MgCl2, 200 mM imidazole, 0.1% DDM, 1× PTT, 1× LS, 5 mM β-ME, 10 µM 
GDP). Protein-containing fractions were pooled and MnCl2 was added to a final 
concentration of 100 μM. Purified lambda protein phosphatase (5 units or about 
50 μg; prepared according to method 6.3) was added per liter of culture volume and 
the eluate was incubated on ice with stirring for 30 min. The eluate was passed 
through a 0.22-μm filter and loaded directly onto a MonoQ HR 16/10 column (GE 
Healthcare) equilibrated in MonoQ buffer A (20 mM HEPES, pH 8.0, 50 mM NaCl, 
100 µM MgCl2, 0.1% DDM, 5 mM β-ME, 1× PTT). The column was washed with 
150 ml buffer A at 5 ml min−1 and bound proteins were eluted over 350 ml with a 
linear gradient up to 28% MonoQ buffer B (same as buffer A except with 1 M NaCl). 
Fractions were collected in tubes spotted with enough GDP to make a final 
concentration of 10 μM. The Gs-containing fractions were concentrated to 2 ml using 
a stirred ultrafiltration cell (Amicon) with a 10-kDa nominal molecular weight cut-off 
(NWCO) regenerated cellulose membrane (Millipore). The concentrated sample was 
run on a Superdex 200 prep grade XK 16/70 column (GE Healthcare) equilibrated in 
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S200 buffer (20 mM HEPES, pH 8.0, 100 mM NaCl, 1.1 mM MgCl2, 1 mM EDTA, 
0.012% DDM, 100 μM TCEP, 2 μM GDP). The fractions containing pure Gs were 
pooled, glycerol was added to 10% final concentration, and then the protein was 
concentrated to at least 10 mg ml−1 using a 30 kDa MWCO centrifugal ultrafiltration 
device (Millipore). The concentrated sample was then aliquoted, flash frozen, and 
stored at −80 °C.  
6.2 – Expression and purification of β2-adrenergic receptor constructs. 
Note: This protocol was developed by Kobilka lab, and is based primarily off of the 
method given in Zao et al.144 as well as optimizations by Søren G. F. Rasmussen. 
Recombinant baculovirus for expressing the β2AR receptor for bimane labeling was 
made using the Bac-to-Bac system with the transfer vector pFastbac1 (Invitrogen). 
Baculovirus for expressing the T4L-β2AR receptor constructs for crystallography was 
made using the Best-Bac system with the transfer pvl1393 (Expression Systems). All 
β2AR constructs start with an overexpression and purification tag which begins with 
the HA signal sequence (MKTIIALSYIFCLVFA) followed the FLAG tag antibody 
binding epitope (DYKDDDDA). During overxpression, the signal sequence, which 
was originally derived from human influenza hemagglutinin protein, directs the 
protein to the plasma membrane with high efficiency and is cleaved off during the 
process. This leaves the FLAG-tag at the extreme N-terminus of the receptor for 
only the proteins that were successfully trafficked to the plasma membrane. 
Subsequent purification with M1 anti-FLAG antibody affinity columns selects against 
any receptor that did not reach the plasma membrane because it can only bind the 
epitope when it is displayed on the N-terminus.158  
The β2AR protein was expressed by infecting Sf9 cells at a density of 4 million ml-1 in 
ESF 921 Insect Cell Culture Medium (Expression Systems) with a second passage 
baculovirus stock using 1 ml of virus stock per 50 ml of cell culture. 1 µM alprenolol 
was included to enhance the receptor stability and yield. The infected cells were 
harvested after 48 hours of incubation at 27°C and frozen. 
129 
 
Cell pellets were thawed and lysed by vigorous stirring in lysis buffer (10 mM Tris-Cl 
pH 7.5, 2 mM EDTA, 10 ml of buffer per gram of cell pellet) supplemented with 
protease inhibitor leupeptin (2.5 µg/ml final concentration, Sigma) and benzamindine 
(160 µg/ml final concentration, Sigma) for 15 minutes. The β2AR was extracted from 
the cell membrane by dounce homogenization in solubilization buffer (100 mM NaCl, 
20 mM Tris-Cl, pH 7.5, 1% DDM) supplemented with leupeptin and benzamindine. 
10 ml of solubilization buffer was used for each gram of cell pellet. The DDM-
solubilized receptor was then purified by M1 anti-FLAG antibody affinity 
chromatography (Sigma). Extensive washing using HLS buffer (100 mM NaCl, 20 
mM HEPES pH 7.5, 0.1%DDM) was performed to remove alprenolol. The protein 
was then eluted with HLS buffer containing a saturating concentration of cholesterol 
hemisuccinate (CHS) and supplemented with 5 mM EDTA and 200 µg ml-1 FLAG 
peptide. Fractions containing the protein were pooled, and 100 µM TCEP was 
added, which is a concentration that is sufficient to reduce any inter-molecular 
disulfide bonds without breaking the intra-molecular disulfide bridges in the 
receptor's extracellular loops.  
The receptor was further purified by affinity chromatography using alprenolol-
sepharose resin (ALP-resin). NaCl was added at a final of 350 mM, and the sample 
was loaded onto ALP resin (≈1 ml resin per 10 nMol of soluble receptor) at room 
temperature in a gravity column. The column was washed with ample HHS buffer 
(350 mM NaCl, 20 mM HEPES pH 7.5, 0.1%DDM) + CHS for 1 hour at room 
temperature, followed by HHS buffer + CHS + 2 mM CaCl2 1 hour at room 
temperature. The ALP column was eluted directly onto M1 anti-FLAG resin using 
approximately 3× the column volume of HHS buffer + CHS + 300 µM Alprenolol + 2 
mM CaCl2. The elution buffer was cycled through the columns for 3 hours at room 
temperature, and then the column was washed with HLS buffer + CHS + 2 mM 
CaCl2 (+ ligand of choice, if desired) 1 hour at room temperature. The sample was 
eluted with HLS buffer + CHS (+ ligand of choice) + 5 mM EDTA + 0.2 mg/ml FLAG 
peptide at room temperature and collected fractions were stored on ice. The sample 
was dialyzed against HLS buffer (+ ligand of choice) overnight at 4 °C to remove 
EDTA and FLAG peptide. Optionally, PNGaseF (New England Biosciences) can be 
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added to the sample to remove glycosylation and/or the FLAG tag can be removed 
by treatment with tobacco etch virus (TEV) protease (Invitrogen) during this step.  
Finally, the purified protein is concentrated using a 100 kDa molecular weight cut-off 
Vivaspin concentrator (Vivascience), exchanged into SEC buffer (10 mM HEPES pH 
7.5, 100 mM NaCl, 0.1% DDM, + desired ligand) using size-exclusion 
chromatography (SEC) on a Superdex 200 HR 30/100 column (GE healthcare) 
equilibrated in SEC buffer. The final sample is concentrated to >5 mg/ml using a 100 
kDa molecular weight cut-off Vivaspin concentrator, aliquoted, flash frozen with 
liquid nitrogen, and stored at -80 °C until use. 
6.3 – Expression and purification of lambda protein phosphatase.  
Note: This protocol was derived from work by Zuho et al.,159 but was not optimized 
much. In particular, we avoided eluting the protein with 50% glycerol as suggested 
because we thought we could not get such a viscous buffer to work properly on our 
FPLC columns. However, the protein interacts extremely well with the phenyl 
sepharose column even with 10% glycerol buffers, possibly indicating that it is 
binding the phenyl groups in a similar manner as it would a phosphotyrosine residue, 
using the resin as a ligand-affinity column. It is suggested for any future purifications, 
one might investigate if a phosphotyrosine mimic like benzoic acid or phenylacetic 
acid might be more effective at protein elution.  
Lambda phage protein phosphatase (λPPase, ORF221) was cloned from a 
commercial lambda DNA preparation (New England Biolabs) and heterologously 
expressed in Escherichia coli strain BL21 using the pET15b vector modified to 
remove the hexahistidine tag. Cell cultures in LB medium supplemented with 50 
μg/ml ampicillin were grown to an optical density at 600 nm of 0.7 at 37°. Expression 
was induced with 400 μM IPTG and the media was supplemented with 2 mM MnCl2. 
The cultures were incubated overnight at 23°. The following morning, the cells were 
harvested by centrifugation at 4500g for 15 minutes and resuspended in 30 ml lysis 
buffer (50 mM Tris pH 8.0, 30 mM NaCl, 2 mM EDTA, 3 mM MnCl2, 1 mM MgCl2, 4 
μg/ml DNAse I (Roche Diagnostics), 2 mM DTT, 0.4 mM phenylmethanesulfonyl 
fluoride, 10% glycerol) per liter of culture volume. Cells were lysed by passage twice 
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through a French press at 10,000 psi. Insoluble derbies were removed by 
ultracentrifugation at 180,000 g for 40 minutes. NaCl was added to the supernatant 
to a final concentration of 500 mM and then loaded onto a Phenyl Sepharose XK 
26/40 column (GE Healthcare) pre-equlibrated in buffer A (20 mM Tris pH 8.0, 500 
mM NaCl, 1 mM EDTA, 2 mM MnCl2, 1 mM DTT, 0.4 mM phenylmethanesulfonyl 
fluoride, 10% glycerol) The sample was then washed with 100 ml buffer A and 
bound proteins were eluted over 1200 ml with a linear gradient up to 100% Q buffer 
B (same as buffer A except with 30 mM NaCl). Fractions that contained λPPase 
were concentrated to 10 ml using using a stirred ultrafiltration cell with a 10 kDa 
MWCO regenerated cellulose membrane (Millipore). The concentrated protein was 
run in 2 ml injections on a Superdex 200 prep grade XK 16/70 column (GE 
Healthcare) equilibrated in S200 buffer (36 mM HEPES pH 8.0, 90 mM NaCl, 0.9 
mM EDTA, 1.8 mM MnCl2, 9 mM β-ME, 10% glycerol). Fractions containing the 
λPPase were collected and concentrated to ≈10 mg/ml, glycerol was added to a final 
concentration of 50%, and the sample was then aliquoted, flash frozen, and stored 
at -80°. Throughout the purification, the enzyme activity was assayed using the 
protocol given below in section 6.4. 
6.4 – Lambda protein phosphatase enzyme assay. 
The activity of the λ protein phosphatase was determined by measuring the 
hydrolysis of the substrate para-nitrophenylphosphate (pNPP) into inorganic 
phosphate and para-nitrophenol (pNP) in a manner similar to Zhuo et al.159 The 
appearance of the intensely yellow pNP molecule was quantified by absorbance 
measurements at 410 nM in a 96 well plate reader. For the assay, the enzyme 
sample dilutions were added to the bottom of the assay plate in 2 μl of assay buffer 
(50 mM Tris pH 8.0, 50 mM NaCl, 2 mM MnCl2, 2 mM DTT). 200 μl of assay buffer 
plus 20 mM pNPP was rapidly added to the samples and the plate was measured 
every 15 seconds for 10 minutes at room temperature. The rate of the reaction was 
calculated using the initial linear portion of the curve. Assuming an extinction 
coefficient at 410 nm for pNPP of 16.2 cm-1 mM-1 and that the definition of a unit to 
be μmol of pNPP hydrolyzed per minute, typical preps had a specific activities 
between 70 and 250 units per mg. 
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6.5 – Bimane-β2AR activation assay in rHDL particles. 
A β2AR construct with 4 reactive cysteines mutated to non-reactive residues (C77V, 
C327S, C378A, and C406A) was expressed, purified, and labeled with mono-
bromobimane on C365 according to protocols in Yao et al 2006.76 The labeled 
receptor (mbb-β2AR) was incorporated into rHDL discs according to method 6.7. 
Purified, concentrated Gs heterotrimer in DDM prepared method according to 
method 6.1 was added directly to the discs at a ratio of 10 Gs proteins to 1 receptor 
so that the detergent was below its critical micelle concentration and did not disrupt 
the discs. The samples were diluted to 100 nM mbb-β2AR and excited with light at 
370 nm with a bandpass of 4 nm. The fluorescence emission spectrum was 
recorded from 435 to 485 nM with a bandpass of 4 nm.  
6.6 – Bimane-β2AR activation assay in detergent 
A β2AR construct with 4 reactive cysteines mutated to non-reactive residues (C77V, 
C327S, C378A, and C406A) was expressed, purified, and labeled with mono-
bromobimane on C365 according to protocols in Yao et al 2006.76 Gs heterotrimer 
was expressed and purified according to method 6.1. Both the labeled receptor and 
Gs heterotrimer were solubilized in DDM detergent and the assay was run in a final 
detergent concentration of 0.05-0.2% plus 0.01% cholesteryl hemisuccinate (CHS) 
and HN buffer (20 mM HEPES pH 7.5, 100 mM NaCl). The proteins were mixed 
along with the indicated reagents in a BD Falcon 384-well small-volume black 
microplate to a total volume of 25 μl. The fluorescence spectra were read in a 
SpectraMax M5 plate reader (Molecular Devices) using an excitation wavelength of 
370 nM and emission range from 435 to 470 nm.  
6.7 – Incorporation of β2AR into rHDL particles 
To incorporate the β2AR into rHDL particles, we followed almost exactly the method 
given in Whorton et al 200780 and Kuszak et al 2009.160 The synthetic lipids 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, Avanti Polar Lipids) and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG, Avanti Polar 
Lipids) were mixed in a 3:2 POPC:POPG ratio, dried completely, and solubilized in 
HNEC50 buffer (20 mM HEPES pH 8.0, 100 mM NaCl, 1 mM EDTA, 50 mM sodium 
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cholate). The lipid mixture, HNE buffer (20 mM HEPES pH 8.0, 100 mM NaCl, 1 mM 
EDTA), ApoAI protein, and receptor were mixed together to yield final concentrations 
of 24 mM sodium cholate, 8 mM lipid, 100 μM ApoAI, and 5 μM receptor. The mix 
was incubated on ice for 1 hour. The cholate was removed by addition of 50 mg per 
100 μl of mix of Bio-Beads SM-2 (Bio-Rad Laboratories) washed extensively in HNE 
buffer followed by incubation overnight with shaking at 4°. The Bio-Beads were 
removed after the incubation and the rHDL samples containing 50 μM HDL discs 
and 5 μM receptor were stored on ice.  
6.8 – Expression and purification of Apolipoprotein A-I. 
Note: This protocol is adapted from Kuszak et al. 2009.160 Improvements to the 
protocol were developed with the aid of Sanna-Paula Pehkonen. 
A pET15 bacterial expression plasmid was created that expressed a fusion protein 
with an N-terminal hexahistidine tag, TEV protease cleavage site, and residues 44-
267 of the human Apolipoprotein A-I (ApoAI) gene. The plasmid was transformed 
into BL21(DE3) Escherichia coli cells and several liters of cells were grown from a 
single colony in Luria broth (LB) media at 37° with shaking at 250 rpm. When the 
cultures reached an optical density of 0.6 at 600 nm, protein expression was induced 
with 1 mM IPTG for 4 hours. After induction, the cells were harvested by 
centrifugation and resuspended in buffer A (100 mM NaH2PO4, 10 mM Tris, 6M 
GuHCl, pH 8.0). The cells were lysed by the addition of 1% final concentration Triton 
X-100 and treatment with a polytron homogenizer. Insoluble derbies were removed 
by ultracentrifugation at 180,000 g for 40 minutes, and the lysate was loaded onto 
1.25 ml of Ni-NTA resin (Qiagen) per gram of per gram wet weight of pellet, pre-
equlibrated in buffer a plus 1% Triton X-100. The column was washed with 10 
column volumes of buffer B (100 mM NaH2PO4, 10 mM Tris, 6M GuHCl, pH 7.0) 
plus 0.2% Triton X-100 followed by 10 column volumes of buffer C (50 mM 
NaH2PO4, 300 mM NaCl, pH 8.0) plus 0.2% Triton X-100. The protein was eluted 
from the column with 10 ½ column volumes of buffer D (50 mM NaH2PO4, 300 mM 
NaCl, 250 mM imidazole, pH 8.0) plus 0.2% Triton X-100. Elution fractions that 
contained significant amounts of protein were pooled together and the sample was 
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heated for 70° for an hour. After the heat treatment, the precipitated contaminant 
proteins were removed by centrifugation and the sample was concentrated to 2-4 ml 
using a positive pressure ultrafiltration cell (Amicon) with a 10 kDa MWCO 
regenerated cellulose membrane. The concentrated sample was again heated at 70° 
for an hour and the additional precipitated contaminant proteins were removed by 
centrifugation. Sodium cholate was added to a final concentration of 20 mM to the 
concentrated, clarified sample and it was loaded onto a Superdex 200 XK 16/70 gel 
filtration column (GE Healthcare) equilibrated in HNEC20 buffer (20 mM HEPES pH 
8.0, 100 mM NaCl, 1 mM EDTA, 20 mM sodium cholate). The ApoAI eluted from the 
column as a dimer and was well separated from the Triton X-100 peak. The fractions 
containing ApoAI were pooled and dialyzed 1× against HNEC20 buffer and then 
twice against HNEC5 buffer (same as HNEC20, but with 5 mM sodium cholate). After 
dialysis, the sample was concentrated to 10-15 mg/ml, snap frozen in liquid nitrogen, 
and stored at -80°. 
6.9 – Initial receptor and G protein complex coupling and purification method. 
For the initial preparation of milligram quantities of β2AR and Gs complex, we used 
the following protocol. It was slowly changed and refined over several years in order 
to arrive at the final complexing reaction given in method  6.12. β2AR (prepared 
according to method 6.2), Gs heterotrimer (prepard according to method 6.1), and 
buffer were added together to make a solution with final concentrations of  50 μM 
β2AR, 25 μM Gs, 20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA, 2 mM MgCl2, 
0.1% DDM, and 0.01% CHS. 100 μM agonist and 25 mU/ml apyrase (purchased 
from NEB) were added and the sample was incubated overnight at 18°.  
After incubation the receptor-G protein complex was diluted 10× with IEC Buffer A 
(20 mM HEPES pH 7.2, 20 mM NaCl, 1 mM EDTA, 1.1 mM MgCl2, 0.05% DDM) 
and loaded onto a MonoQ HR 5/5 column. The sample was eluted with a linear 
gradient from 0% to 25% IEC Buffer B (same as IEC Buffer A except with 1000 mM 
NaCl) at a flow rate of 0.6 ml/min. Fractions with the purified receptor-G protein 
complex were collected and concentrated to at least 10 mg ml−1 using a 30 kDa 
MWCO centrifugal ultrafiltration device (Millipore). 
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6.10 – Fluorescamine labeling for SDS-PAGE analysis. 
For labeling protein with fluorescamine, the sample was put into HEPES or Tris 
buffer at pH 8.0 and incubated with 1% SDS for 5 minutes at room temperature. An 
equal volume of freshly prepared 0.5 mg/ml fluorescamine dissolved in acetone was 
added to the protein sample and it was immediately mixed by vortexing. The sample 
was allowed to react for another 5 minutes before proceeding with SDS-PAGE 
analysis. To detect the fluorescent bands in the gel, a UV transilluminator was used 
for excitation and no cutoff filter was used for the detection of emitted blue light. 
Bands were quantified using the ImageJ software package provided by the NIH.   
6.11 – Nanobody generation against the receptor and G protein complex. 
Two llamas were immunized (Lama glama) with the bis(sulphosuccinimidyl)glutarate 
(BS2G, Pierce) cross-linked β2AR-Gs-BI-167107 ternary complex. Peripheral blood 
lymphocytes were isolated from the immunized animals to extract total RNA, prepare 
cDNA, and construct a nanobody phage display library according to published 
methods.90 Nb35 and Nb37 were enriched by two rounds of biopanning on the 
β2AR-Gs-BI-167107 ternary complex embedded in biotinylated high-density 
lipoprotein particles.80 Nb35 and Nb37 were selected for further characterization 
because they bind the β2AR-Gs-BI-167107 ternary complex but not the free receptor 
in an ELISA assay.  
6.12 – Receptor and G protein complex coupling and purification for 
crystallography.  
Approximately 100 µM Gs heterotrimer and 130 µM BI-167107-bound T4L–β2AR 
was mixed together in incubation buffer (10 mM HEPES, pH 7.5, 100 mM NaCl, 
0.1% DDM, 1 mM EDTA, 3 mM MgCl2, 10 μM BI-167107) and incubated for 3 hourr 
at room temperature. After the first 90 minutes of the incubation, apyrase 
(25 mU ml−1, NEB) was added to hydrolyse residual GDP released from Gαs upon 
binding to the receptor. The sample was the exchanged into the detergent MNG-3 
by adding the β2AR-Gs mixture to 4× the sample volume of MNG buffer (20 mM 
HEPES, pH 7.5, 100 mM NaCl, 10 μM BI-167107, 1% MNG-3) and further incubating 
for 1 hour at room temperature. To complete the detergent exchange, the β2AR-Gs 
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complex was immobilized on M1 FLAG resin and washed in MNG-FLAG buffer 
(20 mM HEPES, pH 7.5, 100 mM NaCl, 10 μM BI-167107, and 3 mM CaCl2, 0.2% 
MNG-3). To prevent cysteine bridge-mediated aggregation of β2AR-Gs complexes, 
100 μM TCEP was added to the eluted protein before concentrating it with a 50 kDa 
MWCO Millipore concentrator. The final size exclusion chromatography procedure to 
separate excess free receptor from the β2AR-Gs complex was performed on a 
Superdex 200 10/300 GL column (GE Healthcare) equilibrated with buffer containing 
0.02% MNG-3, 10 mM HEPES, pH 7.5, 100 mM NaCl, 10 μM BI-167107 and 100 μM 
TCEP. Peak fractions were pooled and concentrated to approximately 90 mg ml−1 
with a 100 kDa MWCO Viva-spin concentrator. 
6.13 – NB35 stabilization and lipidic cubic phase based crystallography of 
receptor-G protein complex. 
BI-167107 bound T4L-β2AR-Gs complex and Nb35 were mixed in 1:1.2 molar ratio. 
The mixture was incubated for 1 hr at room temperature before mixing with 7.7 MAG 
(1-(7Z-tetradecenoyl)-rac-glycerol) containing 10% cholesterol in a 1:1 protein 
solution to lipid ratio (w/w) using the twin-syringe mixing method reported 
previously.161 The concentration of T4L-β2AR-Gs-Nb35 complex in 7.7 MAG was 
approximately 25 mg ml-1. The protein-lipid mixture was delivered through an LCP 
dispensing robot (Gryphon, Art Robbins Instruments) in 40 nl drops to either 24-well 
or 96-well glass sandwich plates and overlaid en-bloc with 0.8 μl precipitant solution. 
Multiple crystallization leads were initially identified using in-house screens partly 
based on reagents from the StockOptions Salt kit (Hampton Research). Crystals for 
data collection were grown in 18 to 22% PEG 400, 100 mM MES, pH 6.5, 350 to 
450 mM potassium nitrate, 10 mM foscarnet, 1 mM TCEP, and 10 μM BI-167107. 
Crystals reached full size within 3–4 days at 20 °C and were picked from a sponge-
like mesophase and flash-frozen in liquid nitrogen without additional cryoprotectant. 
6.14 – Crystallographic data collection and model solving.  
The structure was solved by molecular replacement using Phaser.162, 163 The order 
of the molecular replacement search was found to be critical in solving the structure. 
In order, the search models used were: the β and γ subunits from a Gi heterotrimer 
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(PDB ID: 1GP2), the Gs α Ras-like domain (PDB ID: 1AZT), the active-state β2AR 
(PDB ID: 3P0G), a β2AR binding nanobody (PDB ID: 3P0G), T4 lysozyme (PDB ID: 
2RH1), and the Gs α-helical domain (PDB ID: 1AZT). Regions that were expected to 
differ in the complex structure compared to the reference models were removed 
from the models and manually re-built during refinement. Such regions included the 
complementarity determining regions of the nanobody, several residues in the hinge 
region between the Gα Ras-like and α-helical domains as well as the N-terminal 
helix, the C-terminal region of the Gγ subunit, and residues on the receptor 
intercellular loop 3 (IL3) that were in contact with the lysozyme fusion on that 
structure. Following the determination of the initial structure by molecular 
replacement, rigid body refinement and simulated annealing were performed in 
Phenix164 and BUSTER,165 followed by restrained refinement and manual rebuilding 
in Coot.166 After iterative refinement and manual adjustments, the structure was 
refined in CNS167 using the deformable elastic network (DEN) method.168 Although 
the resolution of this structure exceeds that for which DEN is typically most useful, 
the presence of several poorly resolved regions indicated that the incorporation of 
additional information to guide refinement could provide better results. The DEN 
reference models used were those used for molecular replacement, with the 
exception of NB35, which was well ordered and for which no higher resolution 
structure is available. 
6.15 – Analysis of the receptor-G protein complex with deuterium exchange by 
mass spectrometry analysis. 
1.5 ml of β2AR-Gs complex (10 mg ml-1) or 1.5 ml of Gs heterotrimer (7 mg ml-1) was 
mixed with 4.5 ml of D2O buffer (20mM HEPES, pH 7.5, 100mM NaCl, 10 mM BI-
167107, 100 mM TCEP, 0.0015% MNG-3 in D2O) and incubated for 100, 1,000 and 
10,000 seconds on ice. At the indicated times, the sample was quenched by 15 ml of 
ice-cold quench solution (0.1M NaH2PO4, 20mM TCEP, 16.6% glycerol, pH 2.4), 
immediately frozen on dry ice, and stored at -80 °C. Non-deuterated control was 
prepared in H2O buffer (20mM HEPES, pH 7.5, 100mM NaCl, 10 mM BI-167107, 
100mM TCEP, 0.0015% MNG-3 in H2O), mixed with quench solution, and snap-
frozen on dry ice. Samples were thawed and immediately passed through an 
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immobilized porcine pepsin column (16 ml bed volume) at a flow rate of 20 ml min-1 
of 0.05% trifluoroacetic acid. Peptide fragments were collected on a C18 trap column 
for desalting and separated by a Magic C18AQ column (Michrom BioResources Inc.) 
using a linear gradient of acetonitrile from 6.4% to 38.4% over 30 min. Mass 
spectrometric analysis was performed using LCQ Classic mass spectrometer 
(Thermo Finnigan), with capillary temperature of 200 °C. Deuterium quantification 
data were collected in MS1 profile mode, and peptide identification data were 
collected in data dependent MS/MS mode. Recovered peptide identification and 
analysis were carried out using DXMS Explorer (Sierra Analytics Inc.), specialized 
software for processing DXMS data.169  
6.16 – Analysis of the receptor-G protein complex by negative-stain electron 
microscopy. 
Samples of T4L-β2AR-Gs complex prepared for crystallography (method given in 
section 6.12) were also used for electron microcroscopy. For experiments where the 
complex was labeled with nanobody, the T4L-β2AR-Gs complex was incubated for 
15 min at room temperature with approximately equimolar concentrations of Nb35 or 
Nb37 and subsequently prepared by negative staining. For samples that were 
treated with  nucleotide (GDP or GTPγS) or nucleotide mimicking fragments (PPi or 
foscarnet), these compounds were rapidly mixed with the complex and the sample 
was immediately fixed by negative stain.  
For staining and visualization, several microliters of a sample solution was adsorbed 
to a glow-discharged carbon-coated copper grid, washed with two drops of 
deionized water, and stained with two drops of freshly prepared 0.75% uranyl 
formate.  Dried grids were imaged at room temperature with a Tecnai T12 electron 
microscope operated at 120 kV using low-dose procedures. Images were recorded 
at a magnification of 71,138× and a defocus value of ∼1.5 μm on a Gatan US4000 
CCD camera. All images were binned (2 × 2 pixels) to obtain a pixel size of 4.16 Å 
on the specimen level. Tilt-pair particles from 60° and 0° images were selected using 
WEB.170 Particles for only 2D classification of 0° projections were excised using 
Boxer (part of the EMAN 1.9 software suite).171 
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6.17 – Image processing and low-resolution 3D reconstruction for electron 
microscopy. 
The 2D reference-free alignment and classification of particle projections were 
performed using SPIDER.170 For all conditions, the 0° particle projections were 
iteratively classified into multiple classes for 10 cycles. For AH conformation 
assignments,.we used the first classification to select only the particles from 
averages clearly displaying the profiles of Ras-like, Gβγ, β2AR, and T4L domain 
densities in the same position, thereby restricting the range of particle projection 
orientations. These projections were pulled together and subjected to a second 
iterative classification (referred to as the “secondary” classification). For counting the 
numbers of particles with and without stabilized ΑΗ domain on the Ras-like domain, 
three different operators examined each secondary classification and assigned each 
class average according to the projection profile of the specific region. The 
assignment from the different operators was in good agreement, and the particle 
numbers belonging to individual classes were added to calculate percentages for 
each conformation. Assignments for each full individual dataset were done in 
addition to the secondary classification, and the results were in agreement.  
To test any bias, the particles from nucleotide-free, 1 mM PPi, 10 mM PPi, and 
foscarnet conditions were combined into a single dataset of 15,753 particles and 
were classified into 200 classes. The individual class averages were assigned as 
before according to the visibility of the AH domain, and the percentage of projections 
from each condition was determined according to the number of projections 
contributing to the assigned class averages. The results of this “blind” test showed 
very good agreement with our assignments from individual classifications. For 3D 
reconstructions, in a first step we used the random conical tilt technique172 to 
determine initial 3D maps by back-projection of tilted particle images belonging to 
individual classes. After a first round of angular refinement, corresponding particles 
from the images of the untilted specimen were added, and the images were 
subjected to another cycle of refinement. We thus generated reliable initial models 
for complexes with variability in the positioning of the ΑΗ domain of Gαs. After 
contrast transfer function (CTF) correction according to local defocus values 
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obtained by CTFTILT,173 the full dataset from each condition was subjected to 
multiple reference-supervised alignment 174, 175 with the “multirefine” routine in EMAN 
(1.9) by using our initial models as reference maps. This approach allowed us to 
separate particles from the entire dataset (of each condition) according to the 
positioning of the ΑΗ domain of Gαs. For final maps, we used the separated 
datasets, as provided by the multiple reference-supervised alignment, and used 
FREALIGN176 for further refinement of the orientation parameters and 
reconstruction. The resolution for each map was determined at FSC = 0.5. 
6.18 – Preparation of receptor-G protein complex in rHDL particles. 
Purified Gs heterotrimer was added to the pre-formed β2AR-rHDL particles (method 
6.7), incubated for 2 hours at 4°, and BioBeads were added to remove the excess 
detergent. Nucleotide-free Gs-β2AR complex was prepared by incubating β2AR-Gs-
rHDL particles with apyrase in the presence of 1 mM MgCl2 for 30 minutes at room 
temperature, or alternately, 2 hours at 4°. If needed, the sample was passed through 
a Superdex 200 HR 30/100 gel filtration column to remove free nucleotide and 
apyrase. 
6.19 – Reconstitution of β2AR and Gs in vesicles.  
Lipid stock mixtures of DOPC (3 mg/ml) and CHS (0.3 mg/ml) were prepared in 20 
mM HEPES pH 7.5, 100 mM NaCl including 1% β-OG, as previously described.177, 
178 Breifly, the lipid stocks were removed from storage, vortexed, and sonicated for 
30 min in an ice bath. The reconstitution mixture was prepared in 20 mM HEPES pH 
7.5, 100 mM NaCl + 0.1% DDM containing a 10-fold dilution of the lipid stock and 
β2AR +/- Gs. The final DOPC and CHS concentrations in this mixture were 0.3 and 
0.03 mg/ml, respectively. The reconstitution mixture was inverted several times and 
incubated for 2 h on ice. Detergent removal and formation of vesicles were attained 
by gel filtration chromatography on a Sephadex G-50 Fine column.177, 178 
6.20 – Preparation of β2AR and Gs containing membranes from Sf9 cells. 
Sf9 cells growing in mid-log phase were infected at a multiplicity of infection of 0.5-1 
with recombinant baculoviruses containing expression constructs for FLAG-His10-
mECFP-β2AR (CBAR) and Gs subunits. 48–60 hours later, the cells were pelleted 
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by centrifugation for 10 min at 500 × g. They were resuspended in 1/10 the original 
culture volume of TBS buffer (25 mM Tris-Cl pH 7.4, 137 mM NaCl, and 3 mM KCl ) 
+ 1× PTT (35 μg ml−1 phenylmethanesulphonyl fluoride, 32 μg ml−1 tosyl phenylalanyl 
chloromethyl ketone, 32 μg ml−1 tosyl lysyl chloromethyl ketone) and 1× LS 
(3.2 μg ml−1 leupeptin and 3.2 μg ml−1 soybean trypsin inhibitor). They were lysed by 
sonication and centrifuged at 500 × g for 10 min to pellet unlysed cells and nuclei. 
The supernatant was centrifuged at 35 min at 100,000 × g to pellet the membranes. 
The membranes were resuspended in 1/20 the original culture volume with low salt 
buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1× LS, 1× PTT), flash frozen with 
liquid nitrogen, and stored at −80°C until use. 
 6.21 – Preparation of β2AR and Gs containing membranes from rat lung. 
Lungs from freshly sacrificed rats (Rattus norvegicus) was homogenized in TBS 
buffer (25 mM Tris-Cl pH 7.4, 137 mM NaCl, and 3 mM KCl ) + 1× PTT (35 μg ml−1 
phenylmethanesulphonyl fluoride, 32 μg ml−1 tosyl phenylalanyl chloromethyl ketone, 
32 μg ml−1 tosyl lysyl chloromethyl ketone) and 1× LS (3.2 μg ml−1 leupeptin and 
3.2 μg ml−1 soybean trypsin inhibitor) using a Tissue-Tearor homogenizer (Biospec). 
The sample was centrifuged at 500 × g for 10 min to pellet large debris and the 
supernatant was centrifuged again at 35 min at 100,000 × g to pellet the 
membranes. The membranes were resuspended in 1/20 the original culture volume 
with low salt buffer (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 1× LS, 1× PTT), flash 
frozen with liquid nitrogen, and stored at −80°C until use. 
6.22 – Saturation binding of radioligand to β2AR in rHDL particles. 
Saturation binding assays were performed with [3H]-dihydroalprenolol ([3H]DHAP). 
Assays were carried-out in a volume of 100 µl in a 96-well format. Samples were 
incubated for 90 minutes (standard time) or longer (as indicated) at room 
temperature with or without GTPγS and the specified concentrations of [3H]DHAP in 
TBS buffer (25 mM Tris-Cl pH 7.4, 137 mM NaCl, and 3 mM KCl ). Reactions were 
terminated and free [3H]DHAP was removed by rapid filtration through Whatman 
GF/B filters pre-treated with 0.3% polyethylamine in TBS and washed with 3× 200 µl 
ice-cold TBS buffer. Non-specific binding was determined in the presence of 10 μM 
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(+/-)-propranolol.  Data were fit to a one-site binding model by using Prism 5.0 
(GraphPad) to determine Kd and Bmax. For single point binding assays, a 
concentration of 2 nM [3H]DHAP was used and the points were measured in 
triplicate. 
6.23 – Competition binding of radioligand with β2AR in rHDL particles. 
Competition experiments were performed with 2 nM [3H]DHAP as the radiolabel 
tracer. Assays were run at a concentration of 200 µl in ME-TK8 buffer (2 mM MgCl2, 
1 mM EDTA, 20 mM Tris-Cl pH 8.0, and 135 mM KCl) + 0.02 % sodium ascorbate + 
100 µM TCEP + 0.05% BSA. Increasing concentrations of the competing agonist, 
(-)-epinephrine (EPI) were added along with the specified amount of NB80. Samples 
were incubated for 6 hours at room temperature and filtered through Whatman GF/B 
filters pre-treated with 0.3% polyethylamine in TBS and washed with 3× 200 µl ice-
cold TBS buffer. Data were fit to a one or two-site competition binding model with 
Prism, using the Cheng-Prusoff correction for estimation of Ki values (assuming the 
Kd of [3H]DHAP = 0.5 nM).   
6.24 – Kinetic binding of radioligand to β2AR in rHDL with NB80. 
For association binding experiments with [3H]DHAP and NB80, β2AR-rHDL (20 fmol 
per timepoint, 20 pM final concentration) was pre-incubated with varying 
concentrations of NB80 for 30 minutes at room temperature in TBS buffer (25 mM 
Tris-Cl pH 7.4, 137 mM NaCl, and 3 mM KCl) + 0.05% BSA. 5 nM [3H]DHAP was 
then added and timepoints were taken by filtering the samples on Whatman GF/B 
filters pre-treated with 0.3% polyethylamine and washed with 3× 200 µl ice-cold TBS 
buffer. Dissociation experiments were done in a similar manner, except that first the 
samples were incubated with 5 nM [3H]DHAP for 30 minutes, then incubated with 
varying NB80 concentrations for 30 minutes. After the incubations, a zero timepoint 




6.25 – Kinetic binding of radioligand to β2AR-Gs complex in rHDL with guanine 
nucleotides. 
For association binding experiments with [3H]DHAP and β2AR-Gs nucleotide-free 
complexes, a gel-filtered sample of apyrase-treated β2AR-Gs-rHDL particles was 
incubated with 5 nM [3H]DHAP in TBS buffer (25 mM Tris-Cl pH 7.4, 137 mM NaCl, 
and 3 mM KCl) + 0.05% BSA for 30 minutes to bind any receptor that was not 
complexed with Gs. After the incubation, a zero timepoint was taken and the 
association experiment was started immediately afterward by adding varying 
amounts of either GDP or GTPγS. Timepoints were taken by filtering the samples on 
Whatman GF/B filters pre-treated with 0.3% polyethylamine and washed with 3× 200 
µl ice-cold TBS buffer. 
6.26 – Preperation of biotinyated apolipoprotein A-I.  
Purified apolipoprotein A-I in HNEC5 buffer (20 mM HEPES pH 8.0, 100 mM NaCl, 1 
mM EDTA, 5 mM sodium cholate) was biotinylated via amine coupling with 
N-hydroxysuccinimide-biotin (NHS-biotin). A 10× molar excess of dry NHS-biotin 
was weighed and dissolved in a volume of dry DMSO equal to that of the ApoAI 
sample. The freshly prepared NHS-biotin in DMSO and the apoAI were mixed, 
allowed to react for an hour at room temperature, and then quenched with 
ethanolamine. The sample was gel filtered on a Superdex 200 HR10/30 column in 
HNEC20 buffer (20 mM HEPES pH 8.0, 100 mM NaCl, 1 mM EDTA, 20 mM sodium 
cholate) to remove free biotin and DMSO. Fractions containing apoAI protein were 
collected, dialized 2x against HNEC5 buffer, and concentrated to a protein 
concentration equal to or greater than 10 mg/ml. 
6.27 – Kinetic binding of NB80 to β2AR in rHDL.  
Samples of β2AR were prepared in biotinylated rHDL discs following the method 
given in section 6.7, except that the apoA-I used was biotinylated according to the 
method given in section 6.26. The biotinylated discs were loaded onto biosensor tips 
(FortéBio) by incubation of the tip with the stock solution of discs for 5-10 minutes at 
room temperature. The tips were placed on the Blitz machine (FortéBio) and washed 
in excess buffer that included any drugs that bound to the receptor. The NB80 
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association reaction was started by incubating the appropriate concentration of 
nanobody with the tip while observing the interferometry signal. The dissociation 
reaction was started by incubation of the NB80 bound tip into an excess of non-
nanobody containing buffer while observing the interferometry signal. 
6.28 – Global optimization of NB80 binding model. 
An object-oriented program was created in Python to run the optimization. The 
program is organized around the requirements of fitting a globally shared theoretical 
model to the data from each individual experiment. The experimental data is 
supplied to the program in a multi-dimensional array that is attached to lists of 
experimental conditions and independent variable values as metadata along each 
array axis.179 The program is also given an object that contains the theoretical model 
that is used to simulate the different states of the system and other objects that 
provide methods to convert the collection of predicted states for each type of 
experiment into simulated data. The simulated and real data are subtracted to 
calculate residuals for the optimization routine to minimize. 
The general structure of the optimization software divides the variables needed for 
data fitting into two categories. For each experiment, there is a set of variables that 
is specific to that particular experiment, such as the level of non-specific binding, the 
maximal amount of ligand binding, etc. These variables are called “level 2” variables 
and are optimized for each experiment separately. Level 2 variables are not 
interesting from a theoretical standpoint, but they must still be estimated in order to 
successfully fit the data. There is also a single set of “level 1” variables, which are 
shared between all experiments and describe the behavior of the underlying physical 
model used to simulate the data. In this case, the level 1 variables are the 24 rate 
constants that describe the model shown in figure 4-9. To perform optimization of 
the level 2 variables, of which there were typically only a few per experiment, we 
used a simple least-squares optimization routine based on the Newton-Raphson 
method supplied by the software package Scipy.180  
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The global optimization of the level 1 variables was more complicated. One of the 
challenges of doing a global optimization with both the radioligand binding and Blitz 
data sets was that each type of data gave very different values for the sum of 
squares (ssq) on the calculated residuals, and each experiment also contained 
variable numbers of data points. In order to correct for this and make each 
experiment contribute an appropriate fraction of the total ssq value, we used two 
separate normalizations for each experiment. The first normalization divided the 
calculated ssq for each experiment by the minimum possible ssq for that dataset. 
For radioligand binding data, this was calculated by setting the fitted data as the 
mean of replicates for each data point. For Blitz data, we calculated the minimal ssq 
value using smoothed curve generated with a LOWESS routine provided by the 
Biopython software package.181 This normalized the raw ssq values to a number that 
represented the goodness of fit as a fold-over-minimum for each experiment which 
could, in theory, be compared with each other. However, some experiments 
contained more information about the system than others, and we wanted these to 
contribute proportionally more to the final goodness-of-fit value in the optimization. 
We did this by multiplying the fold-over-minimum value obtained with the first 
normalization by the number of “curves” that each experiment contained. For 
example, a competition assay run in the presence of 6 different NB80 concentrations 
would typically be graphed as 6 different curves, one for each NB80 condition, so its 
fold-over-minimum value was multiplied by 6. In contrast, a typical Blitz curve only 
gave information about a single experimental condition, so its fold-over-minimum 
value was multiplied by 1. In this way, we were able to combine multiple experiments 
with diverse types of data into a single goodness-of-fit parameter for use in an 
optimization routine. 
Initial estimates for the level 1 rate constant variables were determined by analysis 
of the individual experiments and knowledge of several equilibrium constants. The 
estimates were then used as a starting point for optimization of the level 1 values 
using the simulated annealing optimization routine provided by Scipy. The range that 
the values were allowed to change over for each optimization run was small, about 
1/3 of a base 10 logarithm unit in each direction. However, the routine was run many 
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times, with periodic re-optimizations of the level 2 parameters in-between the level 1 
optimization runs.  
6.29 – Simulation of equilibrium binding problems. 
The model we used to for fitting the data was composed solely of elementary steps 
and all data was taken under pseudo-first order conditions, so this allowed us to 
solve any equilibrium binding problems as an eigenvector problem. What we are 
seeking are the concentrations of each state in the vector S that gives us a net rate 
of change equal to zero for all states, consistent with the definition of chemical 
equilibrium. Mathematically, we are searching for the eigenvector corresponding to 
the eigenvalue = λ = 0 for this equation where M = the model matrix and S = a 
column vector of the model states: 
MS = λS 
Equation 6-1. Eigenvalue and eigenvector equation that must be solved to determine the 
equilibrium state of the model. 
The solutions to this equation are calculated numerically for each experimental 
condition using the linalg package given in Scipy, which uses the Fortran-based 
LAPACK library. Theoretically, the equilibrium solution to the problem should be the 
eigenvector associated with the eigenvalue λ = 0, but in practice we determine the 
desired eigenvector differently. Because of the numerical nature of the calculation, it 
can sometimes be difficult to determine the difference between a small eigenvalue 
and one that is truly equal to zero. In some cases, it is also possible that the matrix 
has multiple eigenvectors for the same eigenvalue, a situation that is also made 
worse by numerical instability in the returned eigenvectors. To overcome these 
issues, we instead had the program simply sort through the entire set of returned 
eigenvectors, looking for the one that implied exclusively positive or zero values for 
all concentrations of the vector S.  
6.30 – Simulation of kinetic binding problems. 
The simulation of kinetic data was performed by numerical integration of the rate 
equations using the odeint function supplied in Scipy, which is based on the fortran 
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library ODEPACK. The initial concentrations of each state were calculated by solving 
the system for equilibrium with the experimental conditions given. The conditions 
were then changed to their values at the beginning of the experiment and the 
predicted concentrations of the model states were determined by odeint to a relative 
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